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The principal aim of this study was to examine the feasibility of the 
production of oral controlled drug delivery systems by the direct compression of 
tablets from physical mixes of powders.
In the introduction to the work, the rationale for the controlled delivery of 
drugs to the body is discussed, and the routes by which this might be achieved are 
examined. The oral route is considered in detail, and the systems which have been 
proposed in the literature for use in this capacity are reviewed. The experimental 
work is divided into four chapters: the first dealing with an investigation of the 
feasibility of the use of hydrogenated vegetable oil as a tableting excipient for 
the production of oral controlled drug delivery systems by direct compression; the 
second and third with attempts to determine independently of drug release data a 
factor, tortuosity, which is included in the Higuchi equation describing drug 
release from the systems; and the fourth with the production of systems which 
release drug with zero-order kinetics.
Powder mixes of model drugs with hydrogenated vegetable oil and other 
tableting excipients were prepared and tableted. Drug release studies were 
performed in vitro and drug release from the tablets was found to be controlled by 
diffusion of drug through water-filled tortuous pores within the tablets. Drug 
release rates were found to be affected by various factors such as drug loading, 
hydrogenated vegetable oil concentration and particle size, drug solubility and 
excipient type and proportion, thus potentially providing several means of 
achieving desired drug release profiles.
The determination of tortuosity factors of matrix tablets was attempted in two 
ways. Firstly, air flow rate and pressure drop through matrices were studied using 
a permeametry technique, and pore surface area was determined using mercury 
intrusion porosimetry. An attempt was made to apply the Carman -  Kozeny equation to 
the data, but meaningless tortuosity factors were obtained, and this was
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postulated to be due to the heterogeneity of the pore size distribution within the 
matrix tablets. Secondly, a gaseous diffusion technique, based on Graham’s law of 
diffusion, was used to determine the effective diffusion coefficients through the 
tablets of helium in air. This method yielded tortuosity factors which were found 
to be comparable with those obtained from drug release studies, but only after a 
modification which was proposed had been applied to the Higuchi equation.
The feasibility of the production of zero-order releasing oral controlled drug 
delivery systems was investigated by adapting the hemispherical matrix principle to 
tablets. Hemispherical tablets were prepared and coated with a water-impermeable 
material. A delivery orifice was made in the coat on the planar surface of the 
tablets, and In vitro drug release studies were performed. Zero-order drug release 
was observed, and the effect of reduction of hydrogenated vegetable oil content was 
found to increase drug release rate, with zero-order release maintained at low 
concentrations of hydrogenated vegetable oil. These concentrations would not be 
expected to be sufficient to form matrices, and a combined dissolution -  diffusion 
mechanism was proposed to explain the drug release kinetics.
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1.1 Drug Delivery Systems
Drugs can be administered to patients in many types of dosage form and by 
several different routes. The aim common to all dosage forms has been to ultimately 
deliver the drug to its site of action in the body, and this has been achieved with 
varying degrees of success. The historical development of dosage forms reflects an 
increasing awareness of the importance of their contribution to the overall 
therapeutic effect of the drug. Conventional dosage forms of the single dose or 
bolus type include the most popular present day dosage form, the tablet, which 
accounts for approximately 50% of all medicines and together with capsules accounts 
for 65% (1). Other examples of conventional medicines available include oral liquid 
dosage forms, suppositories, pessaries, injections, inhalations, creams, ointments 
and eye, ear and nose drops. A second group of dosage forms has been the subject of 
great interest in recent years. This group of medicines is designed to prolong the 
delivery of drug to the body, preferably at a pre-determined rate. These systems 
have been described in a variety of ways, depending on their individual 
characteristics, but widely used generic terms are sustained or controlled drug 
delivery systems. Much research and development effort has been directed towards 
designing devices to be administered by the oral route either as tablets or 
capsules, although other novel approaches such as the transdermal route, 
intrauterine delivery and surgical implantation have yielded useful controlled 
release systems.
12. Rationale for Controlled Delivery of Drugs *
In order to provide a rationale for the controlled delivery of drugs to the 
body, conventional methods of delivery will be considered first The tablet can be 
taken as a typical example of a common conventional dosage form. Following 
administration, a tablet Is designed to disintegrate rapidly In the stomach, 
releasing drug which dissolves and is then absorbed into the bloodstream where it 
is carried to its site of action in the body. However, depending on its particular
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properties, the drug inevitably thus reaches most of the tissues which may require 
a large dose of the drug in order for it to be present at the therapeutic 
concentration at its site of action. Apart from being wasteful, this increases the 
potential for toxicity and is one of the principal reasons for interest in 
targeting drugs, especially highly toxic ones, to specific sites. Again, depending 
on the drug’s individual properties, it may be metabolised and finally the drug 
and/or its metabolite(s) are eliminated from the body. The rates at which these 
processes occur will obviously be drug dependent, but can also be influenced by the 
performance of the dosage form e.g. the rate of disintegration of the tablet.
The ratio of the concentration of drug in blood at which serious toxicity 
occurs to the minimum effective concentration is termed the therapeutic index of 
the drug, and its magnitude varies widely between drugs. Some drugs have an 
extremely small therapeutic index and in such cases it is critically important that 
the concentration of drug does not fluctuate greatly over the desired period of 
activity. The concentration of drug in the bloodstream following administration in 
a conventional tablet formulation generally increases to a peak and then gradually 
falls off with time. Such a dosage form can only achieve the aim of keeping the 
drug concentration within the therapeutic index by delivering the correct dose at 
suitable intervals. This results in a "peak and trough" effect in drug
concentration, which can result in both toxicity and ineffectiveness with 
inappropriate dosage form design. For some drugs with a small therapeutic index, 
this potential for serious toxicity can prevent their clinical use (2). An 
additional disadvantage occurs if the drug is rapidly eliminated from the body, and 
as a result will require administration at short time intervals if its 
concentration is to remain within the therapeutic index. This can be inconvenient 
for the patient and may lead to treatment adherence being compromised (3).
It will be apparent that a less variable and preferably constant concentration 
of drug in the bloodstream, which was within the therapeutic index, would be 
desirable and advantageous. These are the principal aims of the majority of
- 15 -
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controlled or sustained release delivery systems, and depending on the specific 
characteristics of the delivery system are achieved with varying degrees of 
success. It has been shown that using controlled drug delivery can reduce toxicity; 
for example, a controlled delivery formulation containing the antiparkinsonian drug 
levodopa was found to eliminate drug-induced dyskinesia (4). A controlled delivery 
formulation of procainamide has been shown to eliminate the need for dosing with 
this drug every three hours (5). Also, more efficient use of drug can lead to a 
decreased overall dose, for example a controlled delivery formulation of 
tetracycline has been shown to be equally as effective as a conventional dosage 
form in the treatment of acne vulgaris, but using only half the dose (6). Some 
other advantages of controlled delivery of drugs are more difficult to quantify, 
but are considered to contribute to an overall improvement of disease management 
It is considered that Improvements In drug delivery should result in more rapid 
cure or control of clinical conditions, and thus might be expected to result in
| less time spent In hospital or consulting doctors. It is thus feasible that cost
savings may be possible compared to treatment with conventional dosage forms.
One of the potential disadvantages of controlled delivery is also related to 
cost of treatment. A controlled delivery device is often more expensive to produce 
than a conventional dosage form, because it may be complex to manufacture and 
require investment in new technology. A second disadvantage is that "dose-dumping" 
may occur, that is, the entire drug load carried in the dosage form may be released 
rapidly If the device fails; for example, If the rate-controlling membrane 
surrounding a reservoir device (section 1.4.5.1 below) is ruptured. This would 
result in high initial concentrations of drug and, if the therapeutic index Is 
narrow, possibly cause serious toxicity (7). This problem could also occur if the 
patient was not aware of the nature of the dosage form, and crushed or chewed an 
oral delivery system prior to ingestion. A further potential problem is concerned,
with accidental or intentional overdoses of oral controlled delivery products,
where the slow release of drug may cause a delay before symptoms are recognised,
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making it impossible to retrieve the dosage forms from the stomach (8). The oral 
route also poses potential problems with devices fabricated with non-biodegradable 
materials. A case has been reported where 98 controlled delivery tablets of ferrous 
sulphate became trapped proximal to a neoplastic stricture in the colon of a 
patient (9). The patient had discontinued taking the tablets two months before the 
problem was discovered. Further disadvantages of the oral delivery route will be 
discussed below (section 1.3.1).
1.3 Routes of Administration of Controlled Drug Delivery Devices
Several of the conventional routes of administration of drugs have also been 
used to deliver drugs at controlled rates. Controlled delivery has also opened up 
possibilities of new routes of administration e.g the transdermal route. Li et al 
(10) have discussed the influence of route of administration on the design of 
controlled release systems. The routes which have generated the most research 
interest in recent years will be discussed briefly below, with particular emphasis 
on the oral route.
1.3.1 The Oral Route of Controlled Drug Delivery
Controlled drug delivery via the oral route has been the subject of several 
reviews (e.g. 11 -  13). The advantages of the oral route make it overwhelmingly the 
most popular route of conventional drug administration, and this is also reflected 
in the numbers of oral controlled release devices in clinical use. It is widely 
used due to its cost, simplicity of administration and potential for the use of a 
variety of both solid and liquid presentations e.g. tablets, soft and hard gelatin 
capsules, powders, liquids, solutions, suspensions and emulsions. Solid dosage 
forms such as tablets in particular are relatively straightforward to manufacture 
in large quantities, they allow accurate and reproducible dosing, and are 
convenient for the patient. The convenience of the oral route for both conventional 
and controlled delivery dosage forms is gained at the expense of the constraints
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imposed by the physiology of the gastrointestinal tract itself. Factors such as the 
varying pH along the tract, with particularly acidic conditions in the stomach; 
gastric emptying rate; intestinal motility; mucosal surface area and membrane 
permeability are all constraints which must be taken into account when designing 
oral controlled drug delivery systems. Further complications arise from the 
considerable inter- and intrasubject variation in these factors, in particular 
gastric emptying and intestinal motility, which are further affected by the absence 
or presence of food and/or liquid and their quantities and constituents. Some 
pathological conditions and many drugs (e.g. antacids) may also modify the 
conditions in the tract
Recently, the technique of gamma scintigraphy has yielded much valuable 
information regarding the gastrointestinal transit of various types of oral 
controlled delivery devices. The technique and some of the results obtained using 
it have been reviewed by Davis (14). Differences were found between the transit 
times of multiparticulate devices and non -  disintegrating single unit devices (15).
The gastric emptying times associated with both types of device were found to be 
affected by the presence and quantity of food (16). The transit time of both types 
of device through the small intestine was found to be independent of content and 
shorter than was previously thought at approximately 3 hours, with little 
intersubject variability compared to the other regions of the tract (17). Colonic 
transit was found to be widely variable, but some drugs were found to be well 
absorbed from the colon (18). This was not previously thought to be the case -  it 
had been thought that drugs were absorbed largely from the small intestine.
These findings have relevance in the design and administration of oral 
controlled delivery devices, and some general conclusions can be drawn i.e. single -  
unit non -  disintegrating systems may be retained in the stomach for several hours by 
being administered after a meal; twice or even once daily dosing might be possible 
if the drug is well absorbed in the colon; variability in total transit time is 
wide and can limit the usefulness of some controlled oral delivery systems. In
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recognition of the conclusion regarding the short transit time of the small 
intestine, several approaches have been proposed which attempt to prolong the 
residence time in the stomach of oral controlled delivery devices, thus extending 
the useful time of drug release. These will be discussed in more detail below
(section 1.4.4).
A further disadvantage of the oral route is termed the "first-pass" effect 
This phenomenon results from drugs which are absorbed from the gastrointestinal 
tract into the bloodstream being carried first into the portal circulation to the
liver where they may be metabolised before reaching other tissues. In some cases
the effect may result in virtually complete elimination of the drug from the
circulation, but an active metabolite may be formed from some drugs. With some 
drugs, first-pass metabolism is less significant or does not occur at all. 
Variability in the extent of first-pass metabolism has also been postulated as a 
reason for intersubject differences in bioavailability (18).
1.3.2 Other Routes of Controlled Drug Delivery
Alternative routes of drug administration which have also been used include 
the parenteral, transdermal, intraocular, intrauterine, and intravaginal routes and 
surgical implantation. A parenteral route of administration is correctly defined as 
any route other than the oral route, but it is generally accepted as meaning 
administration by some form of injection e.g. intravenous, intramuscular, or 
subcutaneous. Some advantages of the parenteral route are its easy access to the 
systemic circulation, lack of first-pass metabolism and the rapid achievement of 
effective drug concentrations, with virtually instantaneous action when the 
intravenous route is used. This may however be accompanied by a rapid decline in 
blood concentrations, and several attempts have been made to prolong the release of 
drugs from depot-type formulations which are usually given by intramuscular 
injection. Various approaches have been used, including the use of polymers to 
complex or adsorb drug molecules in solution and/or to increase the viscosity of
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the vehicle, aqueous and oil suspensions, oil solutions and emulsions of the drug 
(19). Further disadvantages of this route result from its invasiveness, the
requirement for sterile dosage forms and usually the requirement for skilled staff 
to administer the preparations used.
The transdermal route of drug administration is a relatively new route for 
controlled drug administration and it has been reviewed recently (20 -  22). Some of 
its advantages include the avoidance of first-pass metabolism, a possible
improvement in patient compliance and the ease of termination of treatment. Its 
principal limitation is the effectiveness of the skin as a barrier to drug 
transport, which to date has caused its application to be limited to potent drugs. 
Research has been conducted into ways of enhancing penetration through the skin, 
using both chemical (23, 24) and iontophoretic (25) methods.
The intrauterine route has been the subject of much research interest,
principally because of the potential of the route for local delivery of 
contraceptive drugs. Intrauterine devices have been manufactured to contain either 
copper (26) or a steroidal hormone (27), which are released at nearly constant 
rates. They have been shown to have the advantages and disadvantages associated 
with the use of conventional intrauterine devices but combined with increased 
contraceptive efficacy (28).
An attempt to improve the treatment of glaucoma using drugs such as 
pilocarpine, has been one of the reasons for the development of intraocular 
controlled delivery systems. Conventional eye drops suffer from the disadvantage 
that drug is rapidly removed from the eye by drainage in lachrimal secretions, with 
only approximately 1% of the instilled dose being available for effective use (29).
Also, subsequent systemic absorption of drug drained from the eye can result in 
toxicity (30). Polymeric ocular inserts have been developed and have been shown to 
be effective whilst only using one-quarter to one-eighth of the conventional dose 
(31). Nanoparticles with incorporated pilocarpine are another approach to ocular 
drug delivery which has been studied (32).
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The production of systems for surgical implantation has aroused much recent 
research interest, with particular emphasis being placed on the production of 
biodegradable polymers which obviate the need for removal of the spent device when 
drug delivery is complete. Such systems suffer from the disadvantages that 
implantation is invasive and that treatment alteration or cessation is difficult.
However, a significant advantage of using implants is that drug can be delivered 
for periods of many months (33, 34), overcoming the problem of patient compliance. 
Attention has therefore focused on the use of implants for example for long-term  
contraception (35, 36) and for the delivery of narcotic antagonists in the 
treatment of opiate addiction (37). Good tissue compatibility is an obvious 
requirement, and many polymeric substances have been investigated with regard to 
their toxicity when used as implants. Some examples of such classes of 
biodegradable polymers include polyamides, polyesters, polyorthoesters and 
polyanhydrides (38).
1.4 Types of Device used for Oral Controlled Drug Delivery
Many of the basic systems which have been developed for the controlled 
delivery of drugs have been used or adapted to deliver drugs by the oral route. 
Systems such as reservoir (section 1.4.5.1 below) and matrix devices (section
c
1.4.5.2 below) which have been used orally have also been used to deliver drugs by 
some of the routes discussed above. Since the studies described in later chapters 
are concerned with oral drug delivery, however, the systems described in the 
literature for use via this route will be reviewed. There are several possible ways 
to classify the various systems which have been developed, and a classification 
based upon the principal rate-controlling mechanism of the device will be used 
here, since several different types of system effectively utilise the same rate- 
controlling mechanism.
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1.4.1 Dissolution Controlled Systems
Controlled delivery systems employing dissolution as the rate -  controlling 
mechanism are in principle among the simplest to prepare. A drug which has a low 
intrinsic dissolution rate can have this property exploited in order to prepare a 
delivery system which has an inherent sustained release action but which contains 
only drug and which does not require any modification. For drugs with higher water 
solubilities and therefore higher dissolution rates, salts, other chemical 
derivatives or polymorphic forms can be prepared which are less soluble (11). If 
this approach is not possible or is unacceptable, the drug can be incorporated into 
a tablet containing a relatively insoluble material, and which does not contain any 
disintegrating agent. Several refinements to this more basic approach have been 
made, including development of encapsulated and matrix systems. Dissolution -  
controlled drug release has been used in oral controlled delivery systems, but it 
has been applied much more widely in systems administered via the parenteral route, 
where biocompatible polymeric materials which dissolve very slowly can be used as 
the basis for implantable systems. All dissolution controlled systems are based on 
the following theoretical principles.
The basic concept underlying dissolution controlled release is that the 
dissolution process is controlled by the rate of diffusion of drug molecules from 
the dissolving surface through an unstirred solvent layer to the bulk solution 
(39). The flux J under steady state conditions across a plane of unit area is given 
by the following differential equation:-
J = - D i (dC/dx)  equation 1.1
where Di = diffusion coefficient of species i
dC/dx = concentration gradient from the solid surface to the bulk 
solution
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This equation represents Fick’s first law of diffusion. Flux is defined as the 
flow of material with time (dM/dt) across a plane of area a :-
j  = (1/a ) (dM/dt)  equation 1.2
If it is assumed that the concentration gradient is linear and the thickness 
of the diffusion layer is hd then the concentration gradient is given by the 
equation: -
dC/dx = (Cb -  Cs)/h d  equation 1.3
where Cs = concentration at the solid surface i.e. drug solubility
Cb = concentration in the bulk solution
Combining equations 1.1, 1.2 and 1.3 results in the following equation: -
dM/dt = -(D ia/hdK C b -  Cs) = kda(Cs -  Cb)  equation 1.4
where kd = intrinsic dissolution rate constant
Equation 1.4 predicts that dissolution rate will be maintained constant, 
provided that surface area, diffusion coefficient concentration difference and 
diffusion layer thickness remain constant However, as dissolution of a solid 
surface proceeds, these terms may change, with surface area generally decreasing as 
the intact dosage form becomes depleted of drug.
The Hixson -  Crowell cube-root equation (40) can be used to describe the 
dissolution of particles where surface area decreases during dissolution but wherW 
there is no change in overall geometrical shape. This equation arises from an 
integration of Fick’s first law of diffusion (equation 1.1), and from the knowledge
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that the surface area of a regular geometrical shape varies with the two-thirds 
power of its volume. It expresses this change in volume in terms of the change in
mass of the particles as dissolution progresses: -
M01/3 -  M1/3 = kDt  equation 1.5
where M0 = initial mass of particle
M = mass of particle remaining at time t 
kD = cube-root dissolution rate constant
An equation describing drug release from dissolution controlled systems which 
can be applied to dosage forms with various geometrical shapes has been derived by 
Hopfenberg (41). This equation arises from consideration of shape changes with time 
during dissolution and integration of the differential equations obtained:- 6
M t/M *  =  1 -  (1 -  k0t/C 0ad)n  equation 1.6
where Mt = mass of drug released at time t
Me = mass of drug released at infinite time 
k0 = constant
C0 = concentration of drug in the device at time 0
ad = radius of sphere or cylinder, or half-thickness of a slab
n = 1 for a slab, 2 for a cylinder, 3 for a sphere
1.4.1.1 Encapsulated Systems
Coated granules and microcapsules release drug via dissolution control. The 
"Spansule" type of dosage form, which was the first controlled delivery product to 
reach the market in the early 1950s (11), consists of individual particles or 
granules of drug which are coated with a slowly dissolving material, usually ca
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polymer. A different thickness of coat is applied separately to several individual c 
batches of particles, and capsules containing granules from these batches having a 
range of thicknesses are prepared. This system exhibits a pulsed type of release 
pattern, with the particles having the thinnest coat dissolving first and so on, 
providing a fairly coarse control of release. Another way of achieving the same 
effect is to coat inert "seeds" with drug and then further coat them with different 
thicknesses of slowly dissolving substance. There have been numerous studies of the 
drug release characteristics of such systems (e.g. 42 -  45). As an alternative to 
filling capsules with the granules, compressed tablets also have been prepared, but 
other excipients and compaction pressure have been found to affect drug release 
rates, the latter sometimes causing rates to increase unpredictably due to granule 
fracture during the compaction process (46). Some examples of materials used in the 
preparation of dissolution controlled systems include beeswax, glyceryl
monostearate, ethylcellulose, polyamides and acrylic resin (47).
An alternative method of achieving encapsulated dissolution controlled drug 
delivery is to use the process of microencapsulation. For the purposes of this 
discussion, a microcapsule can be considered as a discrete particle of drug or 
drug-loaded material which is enclosed within a coat of well-defined thickness. In 
contrast, microspheres generally do not possess a discrete coat, although the terms 
are sometimes used interchangeably. There are several methods of production of 
microcapsules, which result in systems which possess differing dissolution 
characteristics. It must be emphasised that microencapsulation does not always 
produce systems where dissolution is the rate-controlling mechanism of drug 
release, and thus microcapsules will in addition be referred to subsequently in the 
sections dealing with other mechanisms of release control. Furthermore, a series of 
papers has been published by Hoffman and co-workers (48 -  51) in which the authors 
warn that the drug release mechanism from microcapsules can sometimes be inferred 
erroneously from studies on drug release rates of heterogeneous populations of 
microcapsules. The authors conclude that previous workers may have drawn invalid
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conclusions from such data and postulate the technique of measurement of drug 
release from individual microcapsules as a more reliable method of determining true 
drug release mechanisms.
Coacervatlon is one of the earliest reported and most frequently used 
techniques of microcapsule preparation (52). A coacervation process occurs as the 
result of interaction between two oppositely charged polyelectrolytes in solution 
to form a polymer-rich system termed a coacervate. At elevated temperature, the 
coacervate coats the solid or liquid drug to form the basic structure of the 
microcapsule. The system is cooled, causing the coating solution to gel, which is 
then crosslinked to form the capsule wall. Such a system consisting of gelatin and 
acacia has been described by Harris (53), in which water-soluble drugs can be 
encapsulated providing they have been previously coated with a water-impermeable 
material such as carnauba wax or ethylcellulose. Benita and Donbrow (54) have 
described the production of ethylcellulose coated microcapsules using a 
coacervation method from which drug release was found to be controlled by the 
dissolution of the coat Further examples of microencapsulation include the 
interfacial polymerisation technique which involves dispersing an organic phase 
containing drug particles into an aqueous phase containing monomer (55). 6 The 
monomers react at the liquid/liquid interface, forming a capsule wall, a process 
which may require a cross-linking agent. An electrostatic technique has also been 
described (11) which can be used when the coating material and drug are both 
aerosols and oppositely charged. The drug and coating substance are atomised 
together and cooled, and the resulting microcapsules are collected using an aerosol 
collection system.
1.4.1.2 Matrix Systems
The second group of dissolution controlled drug delivery systems are termed 
matrix systems. It should however be noted that the term matrix is also used to 
describe a class of systems from which drug release is controlled by diffusion
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(section 1.4.5 below). Dissolution controlled matrix systems are usually formed by 
compressing the drug with a slowly dissolving carrier. Two methods of producing 
such systems for oral use were described by Becker and co-workers in a series of 
papers (56 -  61). The first method investigated was an aqueous dispersion
technique, in which particles were prepared by pouring a heated aqueous solution of 
surfactant into melted wax in which drug particles had been dispersed. The mixture 
was then slowly cooled to room temperature whilst being stirred. The resultant 
drug-loaded wax particles were recovered, washed, dried and sieved into various 
size fractions. The second method used was spray-congealing (prilling), which 
involved mixing drug and surfactant in molten wax, and spraying the resultant 
mixture through an atomising nozzle into a collecting chamber. This also caused the 
production of drug-loaded wax particles. The drug release characteristics of the
c
particles produced by both methods were found to be affected by drug loading, type 
of wax, type of surfactant, processing variables and size of particles produced.
The mechanism of drug release was also found to vary depending on the nature of the 
particles produced, with dissolution control predominating for particles with a 
coating of drug and diffusion control predominating for particles in which drug was 
dispersed.
1.4.2 Ion-exchange Controlled Systems
The use of ion-exchange to control drug delivery has been reviewed by Amsel et 
al (62). Ion-exchange resins are water insoluble materials, usually polymers, which 
contain salt-forming groups in repeating positions on the resin chain. The 
functional group can be cationic (usually an amine) or anionic (usually a sulfonic 
or carboxylic moiety). A drug-loaded resin is prepared by exposing resin to 
concentrated drug solution, either by repeatedly loading a chromatography column 
with drug solution or simply by leaving the resin in contact with drug solution for 
extended periods of time. The drug-loaded resin is then washed and dried to form 
particles or beads. Thus appropriately charged ionic drugs bind to the functional
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groups and when the resin is placed in a fresh ionic environment, eluting ions 
diffuse into the resin and an equilibrium is established in which drug ions are 
exchanged for eluting ions in solution. This situation can be described in the 
following manner:-
Resin-F+Z“ + S“ Resin-F+S" + Z~ 
or Resin -  F“Z+ + S+ ^  Resin -  F"S+ + Z+ 4
where F = functional group 
Z = drug ion 
S = eluting ion
The diffusion of drug ions from the resin will depend on the diffusional area 
and pathlength, and the amount of solvent within the resin. This will be influenced 
by the porosity of the resin, which in turn will be influenced by the size of the 
drug-loaded resin particles and the preparative conditions. Drug release from ion- 
exchange resins has also been modified by coating, in some cases by using the 
technique of microencapsulation as described above (section 1.4.1.1) (63, 64).
Ion-exchange resins have been used to prepare oral controlled delivery systems 
(65), but a possible disadvantage of their use is the potential variability in 
ionic content which might be expected to occur in the gastrointestinal tract due to 
differences in diet and fluid content. Also, the system is obviously limited to ' 
ionic drugs. Furthermore, in addition to the complex and time-consuming method of 
preparation of ion-exchange resins, it has been postulated (11) that the rate- 
controlling mechanism in drug release from uncoated resins is predominantly 
diffusion from the resin. It is therefore possible that such systems may offer no 
advantage over the more common matrix-type of diffusion controlled device described 
below (section 1.4.5.2), which also rely on this mechanism to control drug release 
but are generally simpler to prepare.
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1.4.3 Osmotically Controlled Systems
The osmotically controlled drug delivery device is in principle a simple 
system which is capable of releasing drug at a zero-order rate and it was first 
described by Theeuwes (66). The system is fabricated by applying a rigid, 
semipermeable polymer membrane around a tablet core which includes drug and an 
osmotically active salt, or drug alone if it is itself sufficiently osmotically 
active. A single, microscopic orifice is made in the coat, and when the device is 
placed in an aqueous environment, water passes through the semipermeable membrane 
into the core, causing an osmotic pressure gradient to be established. Since the 
coat has been designed to be impermeable to drug solution, the pressure is reduced 
by drug solution being pumped out through the delivery orifice at a rate equal to 
the volume uptake of water. Thus, the drug delivery rate is controlled by the rate 
of water uptake, which is dependent on the osmotic pressure of the formulation. 
Theeuwes (66) used osmotic theory to derive the following equation to describe the 
drug delivery rate d Q /d t:-
dQ /dt = (am/lm)kf dP0Cs  equation 1.7
where kf = constant
am = membrane area
lm = membrane thickness
dP0 = osmotic pressure of the formulation
In order to achieve a constant drug delivery rate, the hydrostatic pressure 
generated within the device must remain negligibly small compared to the osmotic 
pressure, and this can be achieved by using a delivery orifice which is larger than 
a minimum diameter. The orifice must not though be larger than a certain size in 
order to minimise the contribution to the delivery rate made by drug diffusion 
through the orifice. Theeuwes (66) derived equations to determine the minimum and
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maximum sizes of orifice for a formulation.
Theory predicts that zero-order drug release will be maintained until the 
concentration of drug solution in the device falls below the drug’s saturation 
solubility, whereafter a parabolically decreasing drug release rate will occur.
Drug release rates determined experimentally in vitro have shown that the 
theoretical release profile is achieved (67, 68), with zero-order drug release 
occurring for approximately 70% of the total content of the device. Since drug 
delivery rate is controlled by rate of water uptake, the permeability to water of 
the material selected as the semipermeable membrane will be a rate-controlling 
factor in drug release, and many polymers with different water-permeabilities are 
available to design a system with a suitable drug release rate (11). Some examples
c
and their water permeabilities are given below:-
Semipermeable membrane Water permeability
_______________________________ (g cm '2 hr-1 mm-1 )
Polyethylene 0.134 -  0.323
Polyesters 0.538
Polycarbonate 2.15
Polyvinyl chloride, cast 2.69 - 5.38
Cellulose acetate butyrate 13.4
Polyurethane 8.07 --  40.3
Cellulose acetate 10.7 - 20.1
Many semipermeable membranes are applied by organic film coating techniques,
which suffer from the disadvantages associated with the use of solvents on a large
scale. Bindschaedler et al (69) produced osmotically controlled tablets using 
cellulose acetate as the semipermeable membrane, which was applied as an aqueous
dispersion instead of an organic solution.
The osmotic controlled device has several potential advantages when considered 
for oral use. Firstly, it delivers drug at zero-order rates which can be higher
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than those which are achieved with reservoir or matrix-type devices (sections
1.4.5.1 and 1.4.5.2 below respectively), and therefore higher doses can be
accommodated. Secondly, drug release from the device is unlikely to be affected by 
conditions within the gastrointestinal tract such as variability in stationary 
diffusion layer thicknesses caused by differing intestinal motility, or pH 
variation (70). Unfortunately, the first clinically used commercial osmotic device,
"Osmosin", had to be withdrawn from the market because the incidence of severe
gastrointestinal toxicity due to its use was found to be increased compared to
treatment with conventional dosage forms of the same drug, indomethacin (71).
Subsequently the system has been used to deliver salbutamol without such side-
effects being reported so far.
A more complex osmotically-driven pump system termed the generic osmotic pump 
has been developed to deliver liquids, solutions and suspensions of drug (72). This 
system consists of a drug reservoir which is separated by a flexible membrane from 
a compartment containing an osmotically active salt A semipermeable membrane 
surrounds this compartment, which imbibes water along the osmotic pressure 
gradient The influx of water compresses the flexible membrane, causing drug 
solution to be pumped out of the delivery orifice. A flow moderator is placed into 
the delivery orifice after filling: this device restricts diffusional and
convective tosses from the device so that the osmotic process controls the drug 
delivery rate. The system has been widely used as a research tool in pharmacology, 
since the devices are capable of delivering drug for several weeks when implanted 
into laboratory animals (72) and are re-usable. Several studies have reported the 
modification of the system to oral drug delivery requirements of shorter release 
periods (16, 73, 74) although the devices have the disadvantage that they are more 
complex than the elementary osmotic pump and therefore have only been used as 
simulators of the latter during pharmacokinetic studies (74).
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1.4.4 Methods of Prolonging Gastric Residence Time
As discussed above (Section 1.3.1), total gastrointestinal transit time has 
been found to have wide inter- and intrasubject variation, with gastric residence 
time of oral controlled delivery systems varying from a few minutes to ten hours. 
Combined with the observation that small intestinal transit time is relatively 
constant and short at approximately three hours (17), and the fact that many drugs 
appear to be absorbed best in that portion of the tract, this has led to much 
research interest in attempting to prolong the gastric residence time of controlled4 
delivery dosage forms. The objective of such research is to ensure that drug is
only released from the device in the stomach, and is then passed to the small
intestine in solution where it can be absorbed. There have been several approaches 
to allow these aims to be achieved, one utilising materials termed mucoadhesives 
which adhere to the wall of the stomach, and another in which the density of 
formulations is manipulated so that the delivery systems float on the gastric
contents. Other approaches have included using pellets with high density, and 
administering dosage forms with saturated fat (75) to inhibit gastric motility.
1.4.4.1 Methods using Mucoadhesion
The term bioadhesion can be used to describe any form of adhesion to 
biological surfaces, whereas the term mucoadhesion is used specifically to describe 
reversible adhesion to mucous membranes (75). However, in the literature concerning 
the applicability of various adhesive systems to controlled drug delivery the terms 
have been used interchangeably. The principles of the use of mucoadhesion in 
controlled drug delivery have been reviewed recently (75, 76). Since adhesion is 
required to be reversible, the bonding forces are weak in nature, for example
hydrogen bonds or van der Waals forces. Hence mucoadhesive materials for controlled 
drug delivery must be capable of both bonding the delivery system to the mucous 
membranes and of releasing drug at the required rate.
The gastrointestinal mucosa secretes a gel termed mucus which is highly
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viscous and whose physiological function is to protect the mucosal cells from 
damage. The principal component of mucus, apart from water, is a glycoprotein with 
a high molecular weight (approximately 2 x 106 daltons), and which causes a gel
structure to form due to intermolecular associations, the exact nature of which is 
unclear (75). Several polymeric materials have been studied as potential 
mucoadhesives for use in controlled delivery systems (76 -  83), and the conclusions 
which have been drawn regarding the ideal properties of such polymers are as 
follows. Firstly, the polymer should possess strong hydrogen -  bonding groups such as 
hydroxyl or carboxyl functions; secondly, it should be anionic in nature; thirdly, 
the polymer should be sufficiently flexible to penetrate the mucus gel structure; 
fourthly, it should have surface tension characteristics suitable for wetting mucus 
and/or mucosal tissue and lastly it should have a high molecular weight Polymers 
which have been found to best satisfy these requirements include sodium 
carboxymethylcellulose, polyacrylic acid and hydroxypropyl cellulose, although many 
others have been investigated (75).
Several techniques have been used to study the phenomenon of mucoadhesion and 
the adhesive strength of polymers to mucosa. Gurny et al (84) used a system 
involving the separation of two perspex discs which had mucoadhesive material 
placed between them. Stress was jrecorded as a function of elongation of the
material using a tensile tester. Smart et al (85) used a technique based on the
Wilhelmy plate method of measuring surface tension. A thin glass plate coated with 
the polymer was dipped into a preparation of purified mucin and removed slowly at a 
constant rate. The force exerted on the plate was measured with a microforce 
balance and compared to the force exerted on an uncoated glass plate. Park and
Robinson (78) used a technique which examined the change in fluorescence of a probe
molecule attached to the lipid bilayer of the cell wall of a mucous membrane caused 
by the compression of the bilayer when mucoadhesion to the membrane occurred. The 
same authors (81) also developed a tensiometer method to measure the force required 
to remove a mucoadhesive polymer from a section of rabbit stomach mucosa. More
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recently Ponchel et al (86 -  88) have used a similar method to study mucoadhesion 
to bovine sublingual mucosa.
Oral controlled drug delivery systems based on mucoadhesive polymers have been 
investigated for the release of chlorothiazide and metronidazole (80, 88). The 
chlorothiazide delivery system, a multiparticulate dosage form based on polyacrylic 
acid, was found to release drug in vitro over a period of approximately eight 
hours. Gastrointestinal transit was investigated in rats, and It was found that 90% 
of the particles remained in the stomach six hours after Ingestion. In addition, 
bioavailability of the drug was almost doubled compared with a non -  mucoadhesive 
control formulation. The metronidazole mucoadhesive system, also based on 
polyacrylic acid, was found to be capable of delivering drug in vitro over a period 
of eight hours, but no in vivo studies were performed. The technique of gamma 
scintigraphy described above (section 1.3.1) has been used recently to investigate 
the gastrointestinal transit of a mucoadhesive dosage form in humans (89). A 
multiparticulate dosage form again based on polyacrylic acid was used, but the 
gastric emptying of the particles was found to be no different from control 
particles which did not contain mucoadhesive. Clearly, more research needs to be 
performed to demonstrate clearly whether mucoadhesive systems can achieve 
clinically their intended function of prolonged gastric residence.
1.4.4.2 Methods using Altered Density of Formulations
The density of particles has been reported to affect their gastrointestinal 
transit (90), with an increase in relative density from 1.0 to 1.6 resulting In an 
Increase in mean gastrointestinal transit time from 7 to 25 hours. These results 
were obtained in ileostomy patients and further studies (91) were unable to repeat 
the findings in patients with normal gastrointestinal tracts. An alternative 
approach is to prepare dosage forms with a relative density of less than 1 which 
float on the stomach contents. This has been accomplished using hydrophilic 
polymers which form gels and swell on contact with water. Sheth and Toussounian
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(92) described a device which they termed a hydrodynamically balanced system 
consisting of a capsule of a gel-forming hydrocolloid. Drug dissolved on hydration 
of the hydrocolloid and then diffused through it before being released from the 
surface of the swollen gel. Stockwell et al (93) investigated alginate gel 
formulations which included sodium bicarbonate, the intention being that the 
effervescent release of carbon dioxide which occurred on contact of the formulation 
with gastric fluid would become entrapped in the gel network producing a buoyant 
system. This concept was carried further by Ingani et al (94), who produced both 
tableted and encapsulated floating dosage forms and compared the bioavailability in 
vivo of a riboflavin derivative as determined by urinary excretion of a metabolite' 
with that from a non-floating controlled release dosage form. It was found that the 
bioavailability of the floating dosage forms was increased compared to the standard 
controlled release dosage form, and it was concluded from this indirect evidence 
that gastric retention time of the floating dosage forms was Increased compared to 
the standard formulation. Park (95) synthesised swelling polymers which increased 
in mass several hundred times on gelation, and which were digestible by enzymes 
present in the gastrointestinal tract. The intention was that the dosage form would 
swell to such a degree that it could not be passed through the pylorus to the small 
intestine, but that once drug delivery was complete, the gel would be broken down 
by enzymatic activity. This would eliminate any possibility of the gastrointestinal 
tract becoming blocked by the dosage form.
A gamma scintigraphy study of the gastrointestinal transit of floating dosage 
forms (96) yielded results which indicated that there was no difference in gastric 
emptying time between a floating dosage form and a non -  floating, non-disintegrating 
tablet. This may be due to an inherent disadvantage of the system, which is that 
for such a dosage form to float on the stomach contents, the stomach must contain 
fluid over the period during which drug is released. This requirement would not be 
satisfied if the dosage form was administered on an empty stomach, and even if 
taken after food and/or fluid, may require the repeated ingestion of further fluid.
- 3 5 -
This would obviously be inconvenient for the patient, with non-compliance possibly 
rendering the system inefficient
1.4.5 Diffusion Controlled Systems
Diffusion controlled devices constitute the most widely investigated systems 
for the controlled delivery of drugs. There are two principal classes of diffusion 
controlled device, reservoir devices and monolithic devices. Monolithic devices can 
be further subdivided into dissolved systems, dispersed systems, inert porous 
systems and hydrophilic swelling systems. Polymers have been widely used in the
c
manufacture of these types of device, and thus diffusion of drugs in polymers has 
been a subject of wide research interest (97 -  99)
1.4.5.1 Diffusion Controlled Reservoir Systems
Diffusion is the process by which a concentration difference of a molecular 
species across a volume is reduced by the flow of material from a region of high 
concentration to a region of low concentration. This process is described by Fick’s 
first law of diffusion described above (equation 1.1). If steady-state conditions 
are assumed, equation 1.1 can be integrated to give the following equation:-
J = -D if& C /y   equation 1.8
where AC = concentration gradient
lc = distance over which the concentration gradient exists
c
A diffusion controlled reservoir device consists essentially of a core of drug 
surrounded by a water-insoluble coat through which drug must diffuse. The rate of 
drug release is given by a modified form of equation 1 .8 :-
dQ/dt = a ^ K ^ C /lc   equation 1.9
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where K = partition coefficient of the drug between the core and the membrane
In this case, lc is the diffusional pathlength, which in ideal conditions can 
be assumed to be the thickness of the membrane, and AC is the concentration 
difference across the membrane. In order for zero-order drug release to be achieved 
from a reservoir device, examination of equation 1.9 shows that the surface area, 
diffusional pathlength, concentration difference, diffusion coefficient and 
partition coefficient must remain constant In some reservoir devices this may not 
be possible, and zero-order release is not achieved. Also, it is possible that in 
vivo an unstirred boundary layer of release medium may exist immediately adjacent 
to the membrane. This situation has been analysed by Baker and Lonsdale (100), who 
proposed the following equation to describe the situation:-
Q = CsKDmDbt  equation 1.10
(KDJm + Dblb)
where Q = cumulative amount of drug released at time t per unit of surface 
area
Dm = diffusion coefficient of the drug in the membrane
Db = diffusion coefficient of the drug in the boundary layer
lb = thickness of the boundary layer
The evaluation of polymers as potential reservoir device coating materials has 
been the subject of numerous investigations. The diffusion of various model drugs 
in films of ethylcellulose was studied by Donbrow et al (101, 102). Polymer films 
were prepared by the solvent casting method, which involved dissolving the powdered 
polymer and drug in a suitable organic solvent and evaporating the solvent from the 
solution. Drug release from the films was found to be controlled by diffusion. 
Similar results were obtained by Adel El Egakey and Speiser (103), who studied the 
release of model drugs from cast films of a series of poly(alkyl)cyanoacrylates,
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which have the added advantage of being biodegradable. The methyl- and ethyl -  
substituted polymers were found to release drug over periods potentially useful for 
oral controlled delivery devices. Borodkin and Tucker (104) prepared films cast 
from varying proportions of a hydrophobic polymer, polyvinyl acetate and a 
hydrophilic additive, hydroxypropyl cellulose. Drug release rates were found to 
increase with increasing proportion of hydroxypropyl cellulose.
Although studies of polymer permeability to drugs are of vital importance to 
the design of controlled delivery devices, the drug release kinetics of true 
reservoir devices are not modelled by release from drug-loaded cast films, since 
no drug reservoir is present Borodkin and Tucker (105) extended their study of 
polyvinyl acetate-hydroxypropyl cellulose to the reservoir situation by laminating 
a film which did not contain drug to a drug-loaded film. The latter acted as a drug 
reservoir, and the former as the rate-controlling membrane, and zero-order drug 
release was observed. Li and Peck (106 -  108) studied films of silicone elastomer 
modified with polyethylene glycols. They prepared coated tablets using
chlorpheniramine maleate as a model drug (108) and measured drug release rates, 
which were found to be zero-order and which increased with increasing proportion of 
polyethylene glycol in the film. It was hypothesised that this additive, because of 
its water-solubility, was leached from the membrane coat, leaving water-filled 
channels through which drug diffused from the core. Similar conclusions were
reached by Ritschel and Udeshi (109) after studies on tablets coated with a 
methacrylate polymer which included dextrose as a water-soluble additive in the 
coat, although zero-order release was also obtained without including dextrose.
Multiparticulate reservoir systems have also been investigated as oral 
controlled drug delivery systems. The technique of microencapsulation by 
coacervation discussed above (section 1.4.1.1) was used to prepare coated
microcapsules of clofibrate (110). Drug release was found to decrease with
increasing coating membrane thickness, as predicted by equations 1.9 and 1.10., The 
Wurster air-suspension coating technique was used to coat particles of aspirin with
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a mixture of ethylcellulose and methylcellulose (111, 112). Drug release was found 
to be affected by the ratio of methylcellulose to ethylcellulose, with rates 
increasing with increasing methylcellulose content. This was hypothesised to be due 
to the methylcellulose dissolving in the dissolution medium and leaving water -  
filled pores in the ethylcellulose coat for drug to diffuse through. An acrylic 
polymer was investigated as a coating material for a multiparticulate system, and 
was applied in a fluidised bed granulator (113). It was concluded that diffusion 
through water-filled pores was the rate -  controlling mechanism of drug release in 
this case also.
One of the problems associated with the use of reservoir devices is that zero- 
order drug release can only be maintained if the concentration of drug in the core 
reservoir Is maintained constant As drug is depleted from the core, this condition 
may not be met and the release rate may therefore decrease with time. With 
reservoir systems for long term drug administration it may be possible to maintain 
constant concentration in the core for the majority of the drug release period by 
preparing the core as a highly saturated solution of drug. The problem of 
maintaining the same concentration gradient in an oral system was overcome by 
Laghoueg et al (114) who utilised a slowly dissolving coating material consisting 
of a mixture of polyglyceride fatty esters. As the drug reservoir became depleted, 
the coating membrane was synchronously eroded, effectively becoming thinner and 
presenting less diffusion resistance. By selection of a suitable initial coat 
thickness, it was found that zero-order release was possible for up to 
approximately 70% of the total amount of drug released. A further problem which may 
be encountered with reservoir devices is the phenomenon of dose -  dumping, which 
occurs if the rate -  controlling membrane fails to function correctly, leading to the 
immediate or inappropriately rapid release of the entire dose. This could occur 
with an oral device if it was crushed or chewed before it was ingested. Since oral 
controlled delivery devices generally carry a greater drug load than their 
conventional counterparts, this could result in an overdose.
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1.4.5.2 Diffusion Controlled Matrix Systems
Matrix systems have been widely used as controlled drug delivery systems6 and 
earlier systems have been reviewed by Cardinal (115, 116). The theoretical 
treatment of drug release from such devices depends on such factors as the 
soiubility of the drug in the matrix material, its concentration in the device, the 
method of manufacture and the choice of matrix material. Depending on how these 
parameters are manipulated, matrix systems can be classified into one of four 
different types. If the matrix material does not interact with the dissolution 
medium, the drug is soluble in the matrix material and present at a concentration 
in the device below its solubility, then the system is termed a dissolved system, 
and drug is released from the device by diffusion through the matrix material 
itself. If in a similar device, the drug is present at a concentration greater than 
its soiubility in the matrix material, the system is termed a dispersed system, and 
only dissolved drug diffuses through the matrix material. As drug is removed the 
concentration of drug in the device decreases, and dispersed drug is able to 
dissolve and diffuse out. A third type of system occurs where the drug is present
c
at a concentration above its solubility in the matrix material, but where the 
dissolution medium is able to enter through pores in the matrix. Drug dissolves in 
the dissolution medium and diffuses out of the device through the liquid -  filled 
pores. This type of system is termed a porous device. A fourth class of system is 
where the matrix material interacts with the dissolution medium, usually by 
hydration, becoming swollen and forming a gelled system in which drug can dissolve 
and diffuse out These devices are usually termed hydrophilic matrices.
The first classes of matrix to be subjected to investigation from the 
pharmaceutical standpoint were the dissolved, dispersed and porous systems. These 
were first analysed by W. I. Higuchi and T. Higuchi who extended work concerned 
with drug delivery from ointments (117 -  120) to dispersed and porous matrices 
(121). The case of the dissolved system had already been treated by Barrer (122), 
who proposed the following equation describing drug release from a planar surface: -
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Q = hC0[1 -  (8/n)Z“m=0 1/(2m + 1)2e x p {-D M(2m + 1)2n2t/4h2}]  equation 1.11
where h = thickness of the device
Dm = diffusion coefficient of drug in the matrix material 
m = an integer between 0 and °°
When the percentage of the drug load released from a dissolved matrix system 
is less than approximately 30%, the following simplified form of equation 1.11 was 
proposed: -
Q = 2C0(DMt/n )*  equation 1.12
Higuchi (119) proposed a moving boundary model to describe drug release from a 
dispersed matrix system, where the amount of drug present per unit volume of matrix 
is substantially greater than the solubility of the drug in the matrix material. He 
postulated that drug was first removed from the surface layer of the matrix; after 
this layer had been depleted to the saturation level, removal was initiated at the 
next layer, leading to a concentration discontinuity at a boundary. This model is 
based on the so-called pseudo steady-state assumption, that the concentration 
profile in the extracted region is always at steady state with respect to the 
movement of the extraction boundary. This implies that the rate of movement of the 
extraction front must be much slower than the rate of removal of drug from the 
device. The model is therefore restricted to devices where the drug loading A is 
greater than solubility of drug in the matrix Cd by a factor of approximately 3.
The second assumption is that the dissolution of the drug in the matrix material 
does not influence the rate of release i.e. release is diffusion controlled with 
dissolution being relatively rapid. Finally, it is assumed that the medium to which 
drug is delivered acts as a perfect sink.
Figure 1.1 is a representation of a concentration profile existing after a
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time t in such a system. The solid line in the diagram represents the concentration 
gradient in the system normal to the surface of the matrix. The concentration 
gradient shows a sharp discontinuity at a distance h from the surface. The gradient 
to h from the surface is constant, which follows only if A is significantly greater 
than Cd, as in the diagram. This linearity follows from Fick’s first law of 
diffusion described above (equation 1.1). The change in concentration gradient 
after a time 5t is depicted as a dotted line, and corresponds to the extension "of 
the depleted zone by a distance 5h. Based on this diagram, the amount dQ depleted 
by the movement of the front by dh is given by the following equation: -
dQ = Adh -  V£Cddh  equation 1.13
According to Fick’s first law of diffusion: -
dQ/dt = DMCd/h   equation 1.14
Combining equations 1.13 and 1.14 results in :-
Adh/dt -  V£Cddh/dt = DMCd /h  equation 1.15
Equation 1.15 can be rearranged to give:-
{(2A -  Cd)h/2DMCd}dh = dt  equation 1.16
Both sides of equation 1.16 can be integrated to give:-
t = (2A -  Cd)(h2/4D MCd) + Kx  equation 1.17
where Kx = integration constant





Figure 1.1 Concentration profile existing at time t in a dispersed matrix
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The constant KT equals 0 when t Is measured from 0, therefore:-
t = (2A -  Cd)(h2/4D MCd)  equation 1.18
Equation 1.18 can be rearranged to make h the subject:-
c
h = 2{(DMCdt)/(2A -  Cd)}*   equation 1.19
From the diagram it can be seen that the amount of depletion Q at time t is :-
Q = hA -  hCd/2   equation 1.20
Substitution of equation 1.19 in equation 1.20 gives:-
Q = (A -  Cd/2)2{(D MCdt)/(2A -  Cd)}*  equation 1.21
Rearrangement of equation 1.21 gives the following equation: -
Q = {DMCd(2A -  Cd)t}±  equation 1.22
This is one form of the relationship which has become known as the Higuchi 
equation. It is evident that a plot of amount of drug released versus time will not
be linear and hence zero-order, but a linear relationship will exist between amount
released and the square root of time. The relationship can be simplified in the
case where A » Cd to give the following equation:-
Q = (2ADMCdt)*  equation 1.23
The Higuchi pseudo steady-state analysis only applies to unidimensional
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diffusion from a single planar surface. Baker and Lonsdaie (100) extended the 
analysis to three dimensions for devices of cylindrical geometry and also analysed 
the case of spherical geometry. As described immediately above, because of the 
pseudo steady-state assumption, the Higuchi analysis is restricted to cases where 
the drug loading A is greater than the solubility Cd by a factor of approximately 
3. As A tends to the value of Cd, the model becomes more approximate, and an exact 
analysis by Paul and McSpadden (123) which did not make the pseudo steady-state 
assumption has been proposed for all values of A greater than Cd. This analysis was 
simplified by Lee (124) in a model which results only in small errors as A tends to 
Cd-
As discussed above (section 1.4.5.1), a factor which cannot be influenced by 
the characteristics of a controlled delivery device, but which may have a 
considerable influence on the release rate from it, is the possible existence in 
vivo of a hydrodynamic diffusion boundary layer at the releasing surface. The 
boundary layer acts as an extra diffusional resistance and restricts transport of 
drug from the surface of the device. The models described so far have not included
the influence of such a layer, each one assumes that the drug is released into a
well -  agitated sink. Roseman and Higuchi (35) extended the pseudo steady-state model
to include the effects of a boundary layer on a planar device, and also examined 
the case of a device with cylindrical geometry. Paul and McSpadden (123) also 
extended their exact model to include boundary layer effects.
Higuchi (121) extended the pseudo steady-state moving boundary analysis for 
dispersed systems to porous matrix devices, and proposed the following equation:-
Q = Dg / t(2A -  e C s)Cst±  equation 1.24
where g  =  porosity of the matrix after leaching of drug
t  = tortuosity factor
D = diffusion coefficient of drug in dissolution medium
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Equation 1.24 can be reduced to the following form :-
Q = kHt*................................................. ......equation 1.25
where kH = Higuchi constant
It can be seen that equations 1.24 and 1.25 are anaiagous to equation 1.22, 
which is the Higuchi equation for drug release from dispersed matrices. In the 
modified form applicable to porous matrices, the diffusion coefficient of the drug 
is altered from that in the matrix material to that in the dissolution medium. It
is then further modified by multiplying it by the porosity (or volume fraction) of
the leached matrix and dividing by a correction factor, tortuosity, to account for 
the increased diffusional pathlength caused by the heterogeneous nature of the pore 
structure. Tortuosity is hence defined as the ratio of the length of the average 
diffusional path to the thickness of the device, and according to Higuchi could be 
expected to be of the order of 2 -  3 (121). The same model was also used by Higuchi
(121) to describe drug release from porous spherical matrices and Roseman and
Higuchi (35) applied the model to cylindrical porous matrices. Cobby et al (125,
126) derived a cubic equation in t which utilised kH and various adjustable 
parameters to allow it to be applied to different geometrical shapes:-
ft  = G ^ t *  + G2(Krt*)2 + G3(Krt* )3  equation 1.26
where ft  = fraction of the drug load released at time t
G i-3 = constants dependent on the geometry of the device (125)
Kr = 1/AadKH* where ad is the radius of the device (sphere, cylinder)
More recently, Peppas and co-workers (127 -  130) proposed a simple exponential 
relationship to describe drug release from controlled release devices of various
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geometrical shapes and regardless of drug release mechanism: -
ft  = ketn  equation 1.27
where ke = constant
n = exponent which is characteristic of the release mechanism and device 
geometry
The equation is valid for values of ft  up to 0.6. For porous matrices where 
Fickian diffusion is the rate-controlling mechanism, it is evident from comparison 
with equation 1.25 that ke equals the Higuchi constant kH. It also follows that the
exponent n for a planar surface equals 0.5, and for cylinders and spheres Ritger
and Peppas (130) showed n to equal 0.45 and 0.43 respectively.
Fessi et al (131) examined the case of a porous matrix where the drug 
concentration A is less than e C s. Again assuming pseudo steady-state conditions 
they proposed the following equation:-
Q = A(Dt)* .... equation 1.28
Equation 1.28 predicts that in this case drug release is independent of
solubility and porosity, but that it is still dependent on the square-root of time.
An alternative approach has been taken by Miller and Peppas (132), who treated 
cases where values of A were both greater than and less than Cs with an approach 
which did not require the pseudo steady-state assumption.
Although of little relevance to oral delivery systems at present, Langer (133) 
has described the use of porous polymers for the delivery of macromolecules where 
drug release does not conform to square-root of time kinetics. Peppas and c o - 
workers (134, 135) have developed a dissolution -  diffusion model to account for the 
zero-order release kinetics observed with these systems.
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A complete analysis of diffusion in a particular porous system would require 
the exact mathematical description of the pore space, which would require precise 
knowledge of its structure, which in turn is unlikely. Rowe et al (136) proposed a 
model in which instead of modifying the diffusion coefficient with porosity and 
tortuosity factors as in the Higuchi equation (equation 1.24), the pore structure 
of the matrix was taken into account in the following manner. A bimodal model pore 
structure was assumed, with the length and radius of one pore taken to be the mean 
diameter and radius respectively of the drug particles and those of a second pore 
taken as the mean distance between drug particles in the matrix and the mean pore
diameter as determined by mercury porosimetry. Experimentally determined drug
release rates agreed reasonably with rates predicted using this model. More
recently, mathematical simulations based on a probabilistic approach to diffusion, 
the so-called "random walk" interpretation of diffusion (137) have been proposed. 
These have included the application of percolation theory to drug release from
porous matrices (138) and also a stochastic approach based on a mathematical
technique termed "Monte Carlo" simulations of pore structure (137).
The remaining class of monolithic diffusion controlled systems is termed the 
hydrophilic matrix. Roorda et al (139) have reviewed the properties and use of 
hydrophilic polymers as matrix systems. The interaction of certain polymers termed 
hydrogels with water is used as the basis for the system. If a glassy polymer is 
thermodynamically compatible with water, on hydration the polymer’s glass 
transition temperature may be lowered below the ambient temperature. The polymer 
subsequently undergoes a transition to a rubbery, gel state during which the volume 
of the polymer increases. In this swollen gel state, the polymer chains are more
mobile than in the glassy state and allow the drug to diffuse out of the device
through the gel region. Lapidus and Lordi (140, 141) utilised
hydroxypropylmethylcellulose as a hydrophilic polymer and prepared compressed 
tablets containing this material and a model drug. Sustained drug release over
several hours was achieved and drug release was found to be linear with square-root
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of time. The authors therefore concluded that the rate-controlling mechanism was 
diffusion, and that the system was analogous to a non-swelling porous matrix. 
Further investigation of the rate-controlling mechanism in hydrophilic matrices was 
performed by Bamba et al (142), who found that drug release was controlled by the 
* rate of water penetration and the rate of diffusion of the drug through the swollen 
gel. Square -  root of time kinetics were also found with the various natural polymers 
used in this study. As further research was performed on hydrophilic matrices cby 
other workers (e.g. 143), it became clear that square root of time kinetics were 
not always followed, with approximately zero-order kinetics observed for a system 
consisting of a copolymer of 2-hydroxyethylmethacrylate and N -vinyl-2-pyrro lidone. 
A distinction emerged between two different rate-controlling mechanisms, depending 
on the properties of the particular polymer chosen. This was described by Peppas 
(144), who attributed the zero-order kinetics to a non-Fickian transport 
phenomenon. The release process was envisaged as progressing in the following 
manner. As water enters the glassy polymer, an interface separating the swollen gel 
region from the glassy core develops and moves into the matrix as gelatinisation 
proceeds. Release occurs by diffusion from the the gel region; however, the 
diffusivity is governed by the "macromolecular relaxation" phenomenon of the 
polymer chains in this region and is not dependent solely on the concentration 
gradient Depending on the rate of polymer relaxation at the interface, the drug 
release behaviour may either be Fickian or described as C ase-II. If the rate of 
relaxation is very slow compared to the rate of drug diffusion then the rate of 
relaxation controls the release and a time-independent, C ase-II drug release 
process occurs. This type of system is usually termed a swelling -  controlled system, 
as opposed to the swollen, diffusion controlled system described immediately above. 
However, drug release behaviour from some polymers may not accord with either of 
these two extremes (145), with both Fickian and and C ase-II transport occurring 
synchronously, such transport being described as anomalous. The approach of Peppas 
described above to the analysis of drug release from polymers, where equation 1.27
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was used to indicate the release mechanism, has also been applied to hydrophilic 
matrices (145 -  147). If the exponent n in equation 1.27 equals 0.5, then the
release mechanism is considered to be Fickian diffusion. In cases where the 
exponent equals 1 then C ase-II transport is considered to occur and the system is 
swelling controlled. A value of n between 0.5 and 1 indicates anomalous transport.
Fan and Singh (137) recently reviewed the more fundamental models which have been
proposed to describe drug release from hydrogels.
Numerous polymers have been investigated for use as hydrophilic matrices, and 
many studies using them as oral controlled delivery systems have been published. 
Amongst the first were investigations of sodium carboxymethylcellulose, 
hydroxypropylmethylcellulose and carboxypolymethylene (148, 149). Different 
release kinetics ranging from first- to zero-order were observed for the different 
polymers. Hydroxypropylmethylcellulose was further investigated by Ford et al 
(150), who examined the effect of various formulation factors on drug release from 
matrices prepared with this material. Drug solubility was found to have an effect 
on drug release mechanism, with anomalous diffusion predominating for drugs of 
medium to high water solubility. Relatively insoluble drugs were found to undergo 
largely C ase-II transport, with near zero-order release profiles. Both soluble and 
insoluble tableting diluents were found to increase drug release rate only when 
included at high initial concentrations in a formulation. A linear relationship was 
found to exist between release rate and initial tablet surface area. Other 
materials including hydroxypropyl cellulose (151), a-starch (152), some modified 
starches (153) and various natural gums such as carrageenan, locust bean gum, guar
gum, gum tragacanth and sodium alginate (154) , have also been investigated as
hydrophilic matrices for use in oral controlled drug delivery. Zero-order drug 
release was found when an anionic polymer such as sodium carboxymethylcellulose and 
the non-ionic hydroxypropylmethylcellulose were mixed in certain ratios and with 
certain drug loadings (155 -  157). A further phenomenon exhibited by swelling 
polymers was discussed and modelled by Lee and Peppas (158). This *was the
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dissolution of some polymers after the swelling process was complete. This 
phenomenon could be made use of in oral delivery systems, since a device which is 
bioerodible after It has delivered drug cannot lodge in the gastrointestinal tract 
Shah et al (159) found that some grades of hydroxypropylmethylcellulose appeared to 
dissolve after swelling, causing a sigmoidal drug release pattern with the latter 
portion of release being faster than the earlier portion. An interesting but rather 
complex approach to obtaining zero-order release from hydrogel matrices was 
proposed by Kuu and Yalkowsky (160). A w ater- and drug -  impermeable membrane was 
laminated to a diffusion controlled, hydrophilic, swollen-type matrix, and several 
hemispherical cavities were made in the surface of the device. The number, size and 
arrangement of the cavities was discussed and an optimum arrangement for zero-order 
drug release was predicted. Pywell and Collett (161, 162) extended the analysis to 
the practically simpler case of planar holes in the membrane and predicted that 
zero-order release would not be achieved. In vitro drug release studies from such 
devices showed that zero-order drug release was achieved, and a modified model was 
proposed.
1.4.5.2.1 Porous Matrix Systems
Both porous and hydrophilic matrix systems have been widely used as oral 
controlled delivery devices. Since the work to be described in subsequent chapters 
is concerned with porous matrices, the properties and use of these types of device 
will be reviewed here.
Subsequent to the original work concerned with the proposal of the Higuchi 
equation (121), Higuchi and co-workers in a series of papers (163 -  167) attempted 
to validate the equation by measuring each of the variables in the equation and 
assessing their effect on in vitro drug release rates. They studied the release of 
various drugs from single faces of matrices containing polyethylene and polyvinyl 
chloride. Drug release was found to be proportional to the square root of time from 
polyethylene matrices, but a sigmoidal shaped curve was obtained with polyvinyl
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chloride matrices. This latter result was attributed to the incomplete removal of 
air from the matrices during the release process. The effect of increasing initial 
drug concentration, and of increasing drug solubility, was in both cases found to 
cause an increase in drug release rate. The increases in drug release rate were not 
however found to be directly proportional to the increases in drug concentration 
and solubility, and it was concluded that tortuosity was also affected. The 
tortuosity factors determined from slopes of release data and from an independent 
technique were generally less than 10, except for sulphanilamide release into water 
from polyethylene matrices, where slightly sigmoidal release profiles were obtained 
and tortuosity factors several orders of magnitude greater were found. This was 
also hypothesised to be due to the incomplete removal of air from the matrix due to
the low wettability of polyethylene. Drug release studies from the same matrices in
surfactant solutions yielded tortuosity values of less than 10, which was 
considered to support this hypothesis. Further evidence was provided by an 
experiment in which the air in a sulphanilamide -  loaded polyethylene matrix was 
evacuated and water allowed to enter the matrix under the pressure difference 
caused by the vacuum in the pores. Drug release into water from such a matrix was 
found to be linear with square-root of time and tortuosity values of less than 3 
were obtained. It was concluded from these results that in practice, matrix tablets 
may not always conform to the Higuchi model, since it effectively assumes a totally 
interconnected pore structure within the matrix which is immediately wetted by
dissolution medium. Further studies (168 -  171) on the release of mixtures of non-
interacting and mutually interacting drugs, and of acidic and amphoteric drugs into 
various media, were also performed to extend the Higuchi equation to a wider range 
of practical situations.
In addition to the plastic materials used in the studies described, Higuchi 
and co-workers also investigated the use of waxes as matrix materials (172). A 
matrix composed of equal parts of propylene glycol monostearate and hydrogenated 
castor oil was prepared by suspending or dissolving drug in the molten wax mixture,
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which was then cooled whilst being stirred. The solidified mixture was granulated 
and compressed into tablets. Drug release was found to be linear with square-root 
of time, but the data was also found to fit a first-order model. A data analysis 
technique to determine which model was appropriate was developed which involved 
evaluating the change in drug release rate with amount released, and the square-
root of time, diffusion controlled model was found to be the model which was
applicable to the data obtained. A further study (173) using the same wax matrix 
but using sulphanilamide as the drug was conducted to investigate the system 
mentioned above where tortuosity factors of the order of 1000 had been found. It 
was hypothesised that at low drug concentrations, drug diffusion out of the pores 
which had been created by dissolving drug was a limiting factor in drug release, 
due to the low incidence of interconnecting pores. An equation for - the 
determination of permeability in two-phase systems, the Bruggeman equation, was 
used to analyse the results, with the pores due to dissolved drug being regarded as 
one phase and the interconnecting pores as the other phase. Reasonable agreement 
between theory and experimental results was found.
Goodhart et al (174) investigated release of phenylpropanolamine hydrochloride 
from wax matrix tablets prepared from a granulation, but no details of the wax, 
diluent or the method of granulation were given. Drug release was found to be 
linear with square-root of time. Penetration of dissolution fluid into the matrices 
was also investigated by removing tablets from dissolution fluid at intervals and
measuring the thickness of the wetted portion of the tablet. Dissolution fluid
uptake was found to take approximately seven hours, and was also found to be 
proportional to the square root of time. Dakkuri and co-workers (175 -177) examined 
various drug-wax combinations by differential scanning calorimetry and found that 
there was no significant interaction between the drugs and wax which could be 
detected using this technique, and concluded that drug release was influenced Gnly 
by the physico-chemical interaction of the matrix with dissolution fluid. They also 
investigated the effect on drug release rate of the incorporation of various
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surfactants and polyvinyl pyrrolidone into the matrix during preparation. 
Approximately zero-order release was found to occur in some cases, and this was 
explained by the existence of a channeling effect caused by the surfactants which 
increased the porosity during the drug release process. This explanation does not 
account for the fact that the porosity term in the Higuchi equation is the porosity 
of the leached matrix, and one possible alternative explanation is that the 
surfactants solubilised part of the matrix, causing drug release to be due to a 
combination of diffusion and erosion.
Groves and Galindez (178) prepared wax matrix tablets by a heat granulation 
process. Brompheniramine was used as the drug and the matrices were composed of a 
mixture of carnauba wax, cetostearyl alcohol and glyceryl monostearate. Drug 
release was found to be linear with square-root of time and it was concluded that 
the diffusion controlled model was applicable to this system. Drug release into 
buffers of acid and alkaline pH was also studied, and it was found that there was 
no effect on drug release, other than what would be expected from the change in 
solubility of the drug with changing pH. Najib and Suleiman (179) prepared matrices 
of beeswax by two different methods. Firstly the drug was suspended in molten wax 
and the resultant mixture cooled whilst being stirred. The solidified mixture was 
then granulated, though the granulation methods and conditions were not specified. 
Secondly, a simple physical mixture of the drug and beeswax was prepared in a 
mortar and tablets were compressed directly with this mixture. Drug release from 
both types of matrix was found to conform to the Higuchi diffusion model, with the 
release rate exhibited by the directly-compressed matrix being greater than from 
the matrix prepared from granules. This was attributed to differences in porosity 
and tortuosity between the two formulations, but these parameters were not 
measured.
Kopcha and Lordi (180) prepared spray-dried powders of o il-in -w a te r emulsions 
of castor wax and a commercial wax "Durkee 07". The spray-dried emulsion powders 
were then mixed with drug and an aqueous dispersion granulation technique was used
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to prepare granules for tableting. Drug release in artificial gastric and * 
intestinal fluids was found to conform to the Higuchi diffusion model, although 
short lag times were noticed before drug release began, followed in intestinal 
fluid by a burst effect The burst effect was attributed to the dissolution of drug 
present on the tablet surface. Trigger et al (181) prepared matrices containing 
concentrations of glyceryl stearate in the range 0.48 -  14.69%, using a granulation 
process which was not specified. The exponential equation of Peppas (equation 1.27) 
was applied to the drug release data to elucidate the mechanism of drug release, 
and it was found that at low glyceryl stearate concentrations drug was released 
predominantly by an erosion mechanism, but at higher concentrations, drug release 
was predominantly diffusion controlled.
Polymers have also been widely investigated as materials for preparation of 
porous matrices. In a series of papers, Farhadieh and co-workers (182 -  184) 
investigated drug release from matrices of methyl acrylate-methyl methacrylate 
copolymer. The Higuchi model was found to apply, and tortuosities were determined
c
from drug release data. Tortuosity values up to 18.8 were found for matrices 
prepared with sodium pentobarbital, methapyrilene hydrochloride and 
dextromethorphan hydrobromide as model drugs, but values exceeding 30 were found 
with ephedrine hydrochloride. This was attributed to the particle size range of 
this drug, which had a median particle size larger than the others investigated. It 
was also found (183) that exposing the matrices to acetone vapour caused a decrease 
in drug release rate proportional to the amount of acetone absorbed. This decrease 
was attributed to an increase in tortuosity, with values up to approximately 200 
being obtained. No hypothesis for the mechanism by which acetone vapour increased 
tortuosity was proposed. The effect on drug release rate of the inclusion of the 
tableting excipients sodium chloride and dextrose was also investigated (184), and 
drug release was found to be explained by the equation postulated by Singh et al 
(168) for the release of non-interacting mixtures of solutes from porous matrices.
The effect on drug release of including tableting excipients in porous matrices was
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further investigated by Kristofferson and Hannuia (185), who examined the effect of 
microcrystalline cellulose on release from matrices of copolymers of 
acrylic/methacrylic esters. Matrix tablets were prepared in three ways. Firstly a 
direct compression mix of polymer, drug and microcrystalline cellulose in the ratio 
1:4:1 was prepared; secondly the same mix was granulated using a 1:1 mixture of 
isopropyl alcohol and acetone; and thirdly granules of the drug and polymer in the 
ratio 4:1 were prepared in the same manner and microcrystalline cellulose was mixed 
with the dried granules to produce the same overall ratio of the constituents as in 
the previous formulations. Drug release from the direct compression mix was found 
to be 90% complete within 3 hours, with the tablets also disintegrating in this 
period. Drug release from tablets of the formulation containing intragranular 
microcrystalline cellulose was found to be slower than from tablets of the 
formulation containing intergranular microcrystalline cellulose. It was 
hypothesised that these results could be explained by the disintegrant action of 
microcrystalline cellulose, which although insoluble in water, exerted a disruptive 
effect as a result of uptake of water destroying hydrogen bonds formed during 
tablet compaction between adjacent cellulose micro-crystals. In tablets containing 
Intragranular microcrystalline cellulose, less hydrogen bonds were able to form on 
compaction and therefore there was less disintegrant action during the drug release 
process.
The kinetics of liquid penetration into matrices was investigated by Carli and
Simioni (186), who prepared matrices from several different polymers. They measured
contact angle of water on the matrices, and the volumetric uptake of water with
time into the matrices. Matrices of polyvinyl chloride and a vinyl chloride-vinyl
acetate copolymer were found to be saturated within tens of seconds, whereas a
period of approximately 2.5 hours was required for matrices of an acrylic polymer,
and of a mixture of the vinyl chloride -  vinyl acetate copolymer and
polytetrafluoroethylene, to become saturated. Water was not found to enter matrices
<*
of polyethylene. Contact angles of greater than 90° (i.e. non-wetting) were found
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for the matrices of polyethylene and the mixture of copolymer and
polytetrafluoroethylene, and of less than 90° (i.e. wetting) for the other
matrices. The fact that water penetrated the matrix prepared from the polymer 
mixture, but exhibited a non-wetting contact angle on the surface of that material, 
was explained on the basis that since the drug and one of the components of the 
mixture had wetting contact angles, the non-wetting polymer surface contact angle 
was not representative of the actual wetting conditions at some pore walls within 
the matrix. Pore size distributions were determined by mercury porosimetry and drug 
release studies were performed, but no attempt was made to relate the wetting 
phenomena to a quantitative application of the Higuchi equation to the release 
data.
A co-precipitation method was used to prepare matrices of polymers of the 
"Eudragit" type (187). Drug and polymer were dissolved together in an appropriate 
solvent, either ethanol or acetone, and the solvent evaporated off. A particle size 
fraction of 200 -  500 pm of the resulting powder was collected and tablets were 
compacted directly from the granules. Drug release was found to be linear with 
square-root of time. Jambhekar and Cobby (188) showed that pH -  independent release 
from porous matrices of a drug whose solubility changed with pH was possible using 
a matrix composed of a mixture of polyvinyl chloride and polyethylene. This was 
attributed to the buffer capacity of the buffer solutions used as dissolution media 
being exceeded within the matrix. The drug solution in the microenvironment within 
the matrix would hence not be properly buffered and solubility would not be 
affected. This is an advantage which is particularly useful for oral controlled
c
delivery systems, where the varying pH conditions along the gastrointestinal tract 
would not affect drug release. It Is also possible that although drug would be 
released from the device in solution, it may precipitate in the bulk solution of 
the gastrointestinal contents, whose buffer capacity might not be exceeded. The effect 
of compaction pressure on drug release from matrices prepared using two different 
methods was studied by Fassihi (189). Matrices were prepared by dispersing drug in
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molten polymer mixtures, and casting the molten mixture onto cold glass plates. The 
solid mixture was then milled and compressed into tablets. Direct compression of 
powder mixes in the same ratios was also used to prepare tableted matrices. 
Compaction pressure was found to exert a significant effect on drug release rates 
from the matrices prepared by fusion, with matrices produced using higher 
compaction pressures exhibiting decreased release rates. This was considered to be 
due to the decreased porosity of the matrices produced using higher compaction 
pressures. The same effect was not observed with the matrices produced using direct 
compression, with only a slight decrease in release rate being observed. No 
explanation was proposed for this observation. Diffusion controlled drug 
release was found in porous matrices composed of polyhydroxybutyrate-valerate 
copolymers (190). These were prepared by direct compression of powder mixes which 
included either microcrystalline cellulose or lactose, two tableting excipients 
which are used in direct compression tableting. Drug release rate was found to 
increase with increasing concentration of both microcrystalline cellulose and 
lactose, which was attributed to the wicking into the matrix of water caused by the 
insoluble microcrystalline cellulose and the increase in porosity caused by the 
dissolution of lactose, respectively. An added advantage of these copolymers was 
that they are biodegradable, and devices would therefore not potentially become 
lodged in the gastrointestinal tract
1.4.6 Other Systems for Oral Controlled Drug Delivery
Several systems for oral controlled delivery have been described in the 
literature which do not fall readily into the categories discussed above. Also, 
certain geometrical modifications to diffusion controlled matrices in order to 
obtain zero-order release will be discussed in chapter 5 (section 5.1 below).
Farah and co-workers (191, 192) have prepared a system which was termed a dry 
adsorbed emulsion. This was prepared by dissolving drug in water and producing an 
o il-in -w a te r emulsion. A hydrophilic silica was then added to the emulsion and the
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mixture stirred at the very high rate of 12000 rev m irr1. A hydrophobic silica was 
then added, with stirring at 5000 rev min-1  > which produced a dry, particulate 
mass. Drug release rate from these particles was found to decrease with time, and 
the rate controlling mechanism was found to be diffusion, de Haan and Lerk (193 -
195) proposed a system which was described as megaloporous. It was prepared from 
tableted mixtures of two granulations, one termed the housing phase, and the other 
the restraining phase. The housing phase controlled the rate of liquid penetration 
into the device, producing large pores within the device, and the restraining phase 
controlled the release of drug into the pores and thus out of the device. Drug 
release was found to be zero-order from such a system, and independent of 
compaction pressure above a certain value. A capsule dosage form was described by 
Jain et al (196) which simply comprised a water-insoluble capsule filled with drug 
and a soluble excipient, and which was sealed to prevent fluid ingress. A number of 
holes were drilled in the capsule with a laser and drug release studies showed a 
zero-order release profile. Lee (197) proposed a matrix system where the drug 
loading was non-uniform, and predicted suitable concentration profiles for zero- 
order and other drug release kinetics for various geometrical shapes of polymers 
where drug release was either diffusion or dissolution controlled.
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Chapter 2
Investigation of the use of Hydrogenated Vegetable Oil as a Directly-Compressible
Controlled Release Tableting Excipient
2.1 Materials
Potassium chloride: Analar grade, Lot 9917130F, supplied by BDH Chemicals, 
Poole, Dorset, U.K.
Potassium phosphate, monobasic: Analar grade, Lot 9822033f, BDH Chemicals 
Magnesium stearate: GLR grade, Lot 9595340E, BDH Chemicals 
Amaranth: Technical grade, Lot 8549670P, BDH Chemicals 
Sodium salicylate: GLR grade, Lot 51S109OJ, BDH Chemicals 
Theophylline, anhydrous: Lot 70, supplied by Boehringer Ingelheim, Ingelheim,
FRG.
Lactose, hydrous NF: "Fast-Flo", Lot 3RG504 supplied by Foremost Whey 
Products, Wisconsin, U.S.A.
Hydrogenated vegetable oil: "Emvelop", Lot V4317E, supplied by Edward Mendell 
Co., Inc., Carmel, NY 10512, U.S.A.
Dicalcium phosphate dihydrate: "Emcompress", Lot 9101, Edward Mendell Co. 
Microcrystalline cellulose: "Emcocel", Lot 5115, Edward Mendell Co. 4
Sodium hydroxide: Lot MU4093, supplied by May and Baker, Dagenham, U.K. 
Hydrochloric acid: Lot MU4060, May and Baker
"Slow-K" Tablets 600 mg: Lot PA16577, supplied by Ciba Laboratories, Horsham,
U.K.
Potassium chloride and sodium salicylate were each milled in an end-runner 
mill and the sieve diameter fraction < 355 pm was collected and used. The same size 
fractions of hydrogenated vegetable oil (unless otherwise stated) and theophylline 
were collected and used. All other materials were used as received.
2.2 Methods
2.2.1 Apparatus and Techniques for Drug Release Studies
In this part of the study the feasibility of producing controlled release oral
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devices by direct compression tableting of hydrogenated vegetable oil (HVO) was
examined. HVO is refined cottonseed oil which is hydrogenated, then prilled to
produce the final powder form, it is widely used in the food industry and is also 
available as a pharmaceutical excipient. It has official status in the National 
Formulary (198) and is hence generally regarded as safe for human use. it has been 
used pharmaceutically as a tableting lubricant at levels of approximately 0 .5 -2%  
w/w (199). Use of HVO as a lubricant led to the suggestion that it might be capable 
of delaying drug release from conventional tablets, a property which is possessed 
by other lubricants such as magnesium stearate (MS) (200). Unlike magnesium 
stearate, HVO has been found not to reduce tablet crushing strength (201). The
ability of HVO to be capable of tablet lubrication and its potential for delaying 
drug release as a result of its water insoluble, waxy and therefore hydrophobic 
nature, together with its ability to flow uniformly, suggested that the material 
may be useful as a directly-compressible controlled release tableting excipient A 
direct compression excipient vehicle with such wide properties is not currently 
available and the overall aim of these initial studies was to assess the 
feasibility of using HVO, possibly in combination with other excipients, as a
c
vehicle for producing oral solid dosage forms which would release drug over
therapeutically significant periods.
Potassium chloride (KOI) was chosen as a model drug for these initial studies 
for several reasons. Firstly, it is freely soluble in water (approximately 1 part 
KCI in 3 parts water at 20 °C (202)) and hence provides a rigorous test of the 
ability of a given system to control drug release. Secondly, it is conveniently 
assayable in solution by measurement of specific conductance. Lastly, it is used 
clinically for the treatment of hypokalaemia and commercial controlled release 
formulations are available for comparison with any HVO -  based systems produced.
2.2.1.1 Preparation of Tablets
Powder mixes for direct compression were prepared by weighing 100.0 g of each
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formulation into a cylindrical polythene bottle of approximately 300 cm3 internal 
volume. Each formulation was blended for 15 minutes by attaching the container with 
rubber bands to the powder container of a cube blender (Model AR400, Erweka GMBH, 
Frankfurt, F.R.G.). When magnesium stearate was included in a formulation, it was 
added to the mix after this blending stage and the final mix was blended for a 
further 3 minutes. Tablet compaction was performed volumetrically using a single 
punch tableting machine (Model F3, Manesty Machines, Speke, U.K.), which was fitted 
with 12.7 or 10 mm diameter flat-faced punches according to the formulation. The 
target mass was adjusted according to that required for a specific formulation, as 
given below. Compaction pressure was set to produce tablets with a diametral 
crushing strength in the range 59 -  78 N (6 -  8 kPond), which was measured on a 
tablet strength tester (Model 2E, K. Schleuniger and Co., Switzerland). This was 
achieved by producing a small number of tablets at one compaction pressure, 
measuring the diametral crushing strength of 5 tablets and adjusting the compaction 
pressure accordingly, repeating the process if necessary until tablets were 
produced of a crushing strength within the desired range.
2.2.1.2 Assay of Potassium Chloride using Specific Conductance Measurements
A series of aqueous solutions of increasing concentrations of KCI in the range 
0.1 -  0.5 mg cm-3 was prepared by dissolving the appropriate amount of KCI in 
distilled water followed by equilibration of the solutions at 20 °C  in a water bath 
(Grant Instruments, Cambridge, U.K.). Specific conductance of solutions was 
measured with a conductivity meter and cell (Models PW9505 and PW9514/60 
respectively, Philips, Eindhoven, Holland) which had been factory calibrated to 
measure at that temperature. The specific conductance measured was corrected for 
conductance due to distilled water in which the solutions were prepared by
measuring the specific conductance of the water and subtracting the value obtained 
from each test measurement.
In order to establish whether any interference in the assay would be caused by
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excipient which might dissolve from tablets during dissolution testing, solutions 
containing excipients used in a formulation were prepared. 500 mg of each excipient 
was added to 1000 cm3 of water to provide excess ions available in comparison with 
those available from a tablet, and stirred overnight on a magnetic stirrer. Any 
insoluble matter remaining was filtered out by passing the solution through 
qualitative filter paper in a filter funnel and the specific conductance of the
resulting solution was measured.
2.2.1.3 Measurement of Release Characteristics of Potassium Chloride by 
Dissolution Testing using a Manual Sampling Technique
The release of KCI from tablets jwas measured with time using the rotating I
paddle method of tablet dissolution testing described (as Apparatus 2) in the 
United States Pharmacopoeia, (198). This method was chosen in preference to the 
rotating basket method since the tablets produced were denser than water and
formulations generally remained discrete throughout the period of release. The test 
was performed using a tablet dissolution test apparatus equipped with 6 individual 
dissolution vessels (Model 6ST, G. B. Caleva, Basingstoke, U. K.) on 6 tablets of 
each formulation, and with the temperature of the dissolution fluid maintained at 
37 ± 0.5 °C. Dissolution fluid was degassed prior to use by bubbling helium through 
2 dm3 batches for at least 10 minutes. Except where otherwise stated, the volume 
and type of dissolution fluid used was 1000 cm3 of freshly distilled water in eaqh 
vessel and paddle stirring rate was 50 revolutions per minute (rev min-1 ). 10 cm3 
samples of dissolution fluid were removed using 10 cm3 volume plastic syringes 
from each of the 6 vessels at pre-determined times via the standard sampling tubes 
fitted in compliance with the USP test method (198). Samples were then transferred 
to measuring cylinders of 50 cm3 volume and covered with plastic film (Nescofilm, 
Nesco, Japan) to prevent evaporation, before being placed in a water bath 
maintained at 20 °C. Equilibrated samples were diluted to 25 cm3 with water at 20 °C  
and their specific conductance was measured as described in section 2.2.1.2 above.
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After each sample had been removed, 10 cm3 volumes of water were replaced In each 
dissolution vessel in order to maintain the same volume of dissolution fluid 
throughout the test.
2.2.2 Effect of Drug Loading on Drug Release Characteristics
N.B. The work described in this section had already been performed (203); and
is repeated here for completeness. In order to obtain an initial indication of the
ability of HVO to sustain drug release, tablet formulations containing the
following proportions of drug and HVO were prepared as described in section 2.2.1.1 
using 12.7 mm flat-faced punches to produce tablets having a target mass of
600 m g:-
Formulation Composition
2A KCI 80% /  HVO 20%
2B KCI 70% /  HVO 30%
2C KCI 60% /  HVO 40%
Note 1: Information relating to the composition of all formulations used in this 
chapter is given in table 2.1 at the end of the chapter.
Note 2: All percentages stated are on a weight in weight basis.
r
KCI release rate was determined by subjecting tablets to dissolution testing 
as described in section 2.2.1.3 above, except that in this initial ranging study, 2 
tablets from each formulation instead of 6 were tested.
2.2.3 Effect of Microcrystalline Cellulose Content on Drug Release Characteristics
The effect of microcrystalline cellulose (MCC) content on drug release 
characteristics was studied by preparing tablets of the following formulations 
using 10 mm diameter flat-faced punches (which were used for all further
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formulations unless otherwise stated) to a target mass of 500 mg and subjecting 





2D KCI 40% /  HVO 20% J MCC 39% /  MS 1%
KCI 40% /  HVO 30% /  MCC 29% /  MS 1%
KCI 40% /  HVO 40% /  MCC 19% /  MS 1%
KCI 40% /  HVO 50% /  MCC 9% /  MS 1%
2.2.4 Effect of Different Types of Inert Directly-Compressible Diluents on Drug 
Release Characteristics
The effect on drug release characteristics of replacing MCC with direct 
compression forms of either spray-dried hydrous lactose (HL) or dicalcium phosphate 
dihydrate (DPD) was investigated by preparing tablets of the following formulations 
and subjecting them to dissolution testing: -
2.2.5 Measurement of Drug Release Characteristics of a Commercially-Available 
Controlled Release Formulation of Potassium Chloride
6 "Slow-K" Tablets, each nominally containing 600 mg of KCI, were obtained and 
subjected to dissolution testing using the method described above for tablets 
containing HVO.
2.2.6 Effect of Drug Solubility on Drug Release Characteristics
The effect of drug solubility on drug release characteristics was investigated 





KCI 40% /  HVO 40% /  HL 19% /  MS 1%
r
KCI 40% /  HVO 40% /  DPD 19% /  MS 1%
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solubility. Sodium salicylate was chosen because it was more soluble than KCI 
(approximately 1 part in 1 part water at 20 °C  (202)) and theophylline because it 
was relatively insoluble (approximately 1 part in 120 parts water at 20 °C  (202)).
2.2.6.1 Assay of Sodium Salicylate using Ultra-Violet Spectrophotometry
A series of aqueous solutions of increasing sodium salicylate concentration in
the range 5 -  100 mg dm-3 was prepared. A scan of 30 nm on either side of the
wavelength of maximum absorption at 294 nm (202) was performed using a double beam 
ultra-violet/visible spectrophotometer (Model CE954, Cecil Instruments, Cambridge,
U.K.) and 1 cm pathlength quartz cuvettes. This procedure was carried out in order 
to determine the exact wavelength of maximum absorption for sodium salicylate on 
that particular instrument. The absorbance of the sodium salicylate solutions was 
determined at 296 nm wavelength against a blank of distilled water.
Excipient solutions were prepared as described above in section 2.2.1.2 and 
any absorbance was also determined.
2.2.6.2 Assay of Theophylline using Ultra-Violet Spectrophotometry
A series of aqueous solutions of increasing theophylline concentration was 
prepared and a UV scan performed as described above (section 2.2.6.1) around the 
wavelength of maximum absorption for theophylline at 270 nm (202). The maximum
concentration at which absorbance at the wavelength of maximum absorption was
accurately measurable was found to be approximately 35 mg dm-3 . This concentration 
corresponded to a maximum possible theophylline content in any formulation of 
35 mg. Given that the drug concentration in a formulation was likely to be 40% of 
the total tablet mass, this would result in tablets weighing only 87.5 mgj, if the 
automated dissolution testing system described immediately below was to be used. 
Tablets of this mass having a diameter of 10 mm were unacceptably thin for 
practical purposes. For this reason, in order to maintain tablet diameter constant 
for comparability between formulations, a larger theophylline mass was required. To 
allow more theophylline to be incorporated and assayed accurately, the absorbance
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at a wavelength of 290 nm, i.e. on the shoulder of the absorption peak was 
therefore determined for a series of concentrations of theophylline. This procedure 
allowed theophylline to be assayed over a wider measurable concentration 
range.
The absorbance of theophylline solutions in buffers of pH 2.0 and 6.0 was also 
determined. (For details of buffer formulae see section 2.2.8 below). Excipient 
solutions were prepared as described immediately above both in water and in each of 
the buffers and any absorbance was determined against the appropriate blank 
solution.
2.2.6.3 Measurement of Release Characteristics of UV -  Assayable Drugs using an 
Automated Dissolution Testing Technique.
In order to automate the dissolution testing procedure, a cell controller 
attachment with motorized cell changer (Model CE830, Cecil Instruments) and 6 flow­
through quartz cuvettes of 1cm pathlength (Cecil Instruments) were obtained for the 
UV spectrophotometer. Solutions were pumped out of the 6 dissolution vessels and 
through the appropriate cuvettes in the cell changer via 3.2 mm internal diameter 
plastic tubing using a peristaltic pump (Model 502S, Watson Marlow, Falmouth, 
U.K.). Vinyl peristaltic tubing (Type 980 -  0279 -  000, Watson Marlow) was used at the 
pump head. Both inlet and outlet tubing was inserted into the vessels to the same 
depth of 10 cm as used for the manual sampling tubes, so that fluid was always 
removed from and returned to the same points in each vessel. The pumping rate used 
was 39% of the maximum rate attainable by the pump. At this rate, dissolution fluid 
took 110 s to circulate through the UV cells and back to the dissolution vessels.
This was considered appropriate considering the need to minimise both turbulence in 
the dissolution vessels caused by returning fluid and pump wear, and to maximise 
peristaltic tubing life. The cell changer was programmed to move each cell into the 
beam at the required time intervals and the resulting absorbance reading was 
relayed to a microcomputer (BBC Model B, Acorn Computers, Cambridge, U. K.) which
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was interfaced with the spectrophotometer. A "Basic" programme (listed in Appendix 
1) was written to record the absorbance readings, which were then converted to 
concentration values according to data obtained from calibration curves. 
Dissolution profiles were determined by calculating the cumulative percentage drug 
released with time and these data were then saved on disc for subsequent analysis.
It was possible to record for each tablet a minimum of 1 and a maximum of 20 sample 
analyses per hour, up to a maximum of 25 sample analyses per test
The effect of drug solubility on dissolution characteristics was investigated 
by preparing tablets of formulations containing the following concentrations of 
drug and excipients, and subjecting them to automated dissolution testing as 
described immediately above: -
Formulation Composition
2J Sodium Salicylate 40% /  HVO 40% /  MCC 19% /  MS 1%
2K Theophylline 40% /  HVO 40% /  MCC 19% /  MS 1%
The target mass for formulation 2J was 220 mg and for 2K, 180 mg. This allowed 
the full range of UV absorbance to be used in the assay for each drug.
2.2.7 Determination of Release-Controlling Mechanism for Tablets Containing 
Hydrogenated Vegetable Oil
2.2.7.1 Effect on Drug Release Characteristics of Paddle Stirring Speed
The effect of paddle stirring speed was studied by preparing tablets of the 
following formulation to a target mass of 180 mg and subjecting them to dissolution 
testing at paddle stirring speeds of 50, 100 and 150 rev min-1 .
Formulation Composition
2L Theophylline 40% /  HVO 30% /  MCC 29% /  MS 1%
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2-2.7.2 Measurement of Tablet Thickness
In order to assess whether HVO -  containing tablets underwent significant 
dimensional changes as the result of swelling or erosion during the dissolution 
test period, the diameter and thickness of tablets of formulation 2L were measured 
with a digitally-reading micrometer (Model 601-906, RS Components, Corby, U. K.) 
both before and after the dissolution test which was performed at a paddle stirring 
speed of 50 rev min-1 . The latter measurement was performed after rinsing the 
tablets with a small volume of distilled water and removing excess moisture from 
the tablet surfaces by blotting with tissue paper.
2.2.7.3 Data Analysis
Drug release data from formulation 2L was transferred to a statistics software 
package written for BBC computers (Instat, University of Reading, U.K.) and 
analysed according to zero-order, first-order and square-root of time kinetic 
models to further elucidate the release controlling mechanism.
2.2.7.4 Qualitative Assessment Of Water Penetrability of Tablets containing 
Hydrogenated Vegetable Oil
The water penetrability of HVO-based tablets was studied qualitatively by 
observing whether a dye dissolved in dissolution fluid entered the tablets during 
the drug release process. An aqueous solution of amaranth which appeared deep red 
in colour was prepared (at a concentration of approximately 0.5 g dm-3 ). Two 
tablets of formulations 2F, 2H and 21 were each placed in 1 dm3 of dye solution in 
the dissolution apparatus. A dissolution test was carried out as described in 
section 2.2.1.3 except that no samples were removed or analysed. After 12 hours, 
the tablets were removed from the vessels, rinsed with a small volume of water and 
excess water was removed from their surfaces by blotting with tissues. The tablets 
were then cut in half with a scalpel blade and examined visually for ingress of the 
dye.
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2.2.7.5 Scanning Electron Photomicrography of Tablet Surfaces
The outer flat tablet faces and diametral fracture surfaces of tablets
produced from formulation 21 which had been recovered after dissolution testing had 
been performed on them, were examined using a scanning electron microscope (Model 
JSM T330, Japanese Electron Optics Ltd., Tokyo, Japan). The samples were mounted on 
10 mm diameter cylindrical aluminium stubs of approximate thickness 5mm using
colloidal graphite adhesive. A layer of gold was deposited onto the sample surface 
using a sputter coater (Model S150B, Edwards High Vacuum, Crawley, U.K.). Sputter 
coating was carried out for 5 minutes using a voltage of 1.4 kV and a current of 20 
mA applied across specimen stubs held in a vacuum of approximately 100 pm rig. The 
coated samples were then examined at various magnifications using a working
distance of 39 mm and an electron beam potential of 5 keV. Higher potentials were 
used but were found to cause overheating which led to sample degradation.
2.2.7.6 Fitting of Drug Release Data to the Higuchi Square-Root of Time Kinetic 
Model
The drug release data obtained were fitted to the Higuchi square-root of time 
model using least squares regression analysis of the linear portions of the
dissolution curves.
2.2.8 Effect of pH of Dissolution Medium on Drug Release Characteristics
A study was carried out to examine the effect on drug release rate of 
dissolution testing in solutions having a pH approximating to that which would be 
experienced by tablets in the stomach and the small intestine. Values of pH 2.0 and
ft
6.0 were selected for use in the present study and buffers were prepared to the 
following U.S.P. formulae (198): —
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pH = 2.0: 0.2 M Potassium chloride solution 250 cm3
0.2 M Hydrochloric acid solution 65 cm3
Distilled water to 1000 cm3
pH = 6.0: 0.2 M Potassium phosphate,monobasic 250 cm3
0.2 M Sodium hydroxide solution 28 cm3
Distilled water to 1000 cm3
Dissolution testing was performed on tablets produced using formulation 2L in 
both of the buffers described above. This formulation was chosen because the 
solubility of theophylline has been shown not to vary significantly in the pH range 
2 -  7 (204).
2.2.9 Effect of Hydrogenated Vegetable Oil Particle Size on Drug Release 
Characteristics
HVO was sieved into 2 size fractions; (a) <  125 pm and (b) 125 -  355 pm. 
Tablets produced using formulation 2L were prepared from these two size fractions 
and subjected to dissolution testing as described above.
2.3 Results and Discussion
2.3.1 Apparatus and Techniques for Drug Release Studies
2.3.1.1 Preparation of Tablets
Some general observations regarding the preparation of tablets produced using 
formulations containing HVO will be discussed here. The principal problem 
encountered was that of adhesion of formulations to the punches of the tablet 
machine, in particular the upper punch. At low HVO concentrations the problem was 
slight, however at the HVO concentrations required to produce sustained drug
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release the problem was more evident. For this reason, formulations prepared after 
the initial binary mixes containing KCI and HVO (section 2.2.2) included magnesium 
stearate at a proportion of 1% w /w  as an anti -  adherent. The punch diameter was also 
reduced from 12.7 to 10.0 mm at this stage in order to reduce the overall surface 
area of the punches in contact with the formulation during compression. In 
addition, the target tablet mass was reduced to 500 mg. The problem of adhesion was 
considered to be caused by melting of HVO as a result of increased friction at 
point contacts at the punch face during tablet compression; HVO has a relatively 
low melting point of 61 -  66 °C  (199). The formulations were found to be well 
lubricated in terms of achieving acceptable ejection forces, even when not
containing magnesium stearate. This result was not unexpected since all
formulations contained at least 10 times the proportion of HVO considered to be 
suitable for use as a tablet lubricant All the formulations were found to produce
tablets of the required diametral crushing strength and it was concluded that HVO
was capable of producing tableis by direct compression with mechanical strength 
suitable for general handling.
2.3.1.2 Assay of Potassium Chloride using Specific Conductance Measurements
The measured specific conductance of the solutions prepared was plotted
against their concentration (figure 2.1) and a linear relationship between the 
variables was considered to exist. Least squares regression analysis of this data 
produced the following statistics: -
Slope = 1.842 x 10" 3 S cm-1 /  g dm-3
Intercept = -1 .429  x 10~6 S cm-1 
r2 = 0.9996
These results were considered to show that the assay was appropriate for 
analyses in the concentration range measured.
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Figure 2.1 Calibration curve of specific conductance versus concentration of
potassium chloride in water
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2.3.1.3 Measurement of Release Characteristics of Potassium Chloride by
Dissolution Testing using a Manual Sampling Technique
The amount of KCI released from each tablet at the first time point was 
calculated in the following manner. Given that the measured conductivity at time t 
= St> then the conductivity of the dissolution medium Sd =  2.5 x St . This was 
converted to a concentration value Ct  in g dm-3  using the calibration curve 
constructed in section 2.3.1.2:-
C t = (Sd -  intercept) /  slope .... equation 2.1
Letting the mass of drug In the tablet at time 0 = Mz gram, then the percentage 
released B% was calculated a s :-
R* = (Ct /  Mz) x 100  equation 2.2
At each subsequent time point t i( the value Ct  had to be corrected for the 
amount of KCI withdrawn at each previous time point t ( i _ 1)f and was calculated in 
the following manner:-
R* = {[C t +  /  100)] / M2} x 100  equation 2.3
where n = (total number of samples taken -  1)
This calculation procedure was incorporated into a "Basic" programme (listed 
in Appendix 1) which was run on a BBC microcomputer. This allowed each conductivity 
reading to be entered into the computer and the corresponding percentage released 
values to be calculated and displayed. The data was then stored on disc for 
subsequent analysis.
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2.3.2 Effect of Drug Loading on Drug Release Characteristics
Figure 2.2 (reproduced with data from reference 203) shows the mean cumulative 
percentage KCI released versus time for the three formulations 2A -  2C (table 2.1).
It can be seen that HVO causes a sustaining in the time over which KCi is released 
from tablets and that increasing drug loading results in an increased release rate.
Tablet formulations containing 20 and 30% HVO both released all their drug within 
approximately 2 and 4 hours respectively, whereas the formulation containing 40% 
HVO shows that drug was released over approximately 8 hours. In terms of clinical 
usage, this latter result is a potentially useful sustained release profile.
2.3.3 Effect of Microcrystalline Cellulose Content on Drug Release Characteristics
It was decided that in view of the problems with adhesion which occurred when 
formulations containing high concentrations of HVO were compressed into tablets 
(section 2.3.1.1) and in order to improve the ultimate compressibility of the 
system, it would be of interest to examine the effect on release rate of including 
another directly-compressible inert diluent in some HVO-based formulations. The 
excipient microcrystalline cellulose was chosen initially because it is one of the most 
compressible insoluble inert diluents available. Figure 2.3 shows the release data 
obtained for formulations 2D -  2G (table 2.1). It can be seen that drug release rate 
increased with increasing MCC content and concomitantly decreased with increasing 
HVO content. Visual observation of the tablets containing 29 and 39% MCC showed 
that the tablets did not remain discrete throughout the dissolution process. A 
split in the tablets containing 29% MCC occurred around the tablet edge, giving the 
appearance that the tablet had capped. Those tablets containing 39% MCC were found 
to have partially disintegrated into several fragments by the end of the 
dissolution test The reason for these effects was considered to be due to the 
interaction of MCC with water. Although it is insoluble, MCC is hydrophilic and 
draws water into a tablet by wicking or capillary suction potential. As a result of 
compaction during tableting, adjacent MCC particles are considered to undergo
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Figure 2.2 Effect of drug concentration on release from formulations 2A - • 2C
(table 2.1)
Key: •  = KCI 80% /  HVO 20%
■ = KCL 70% /  HVO 30%
▲ = KCI 60% /  HVO 40%
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Figure 2.3 Effect of microcrystalline cellulose concentration on drug release from 
formulations 2D -  2G (table 2.1). (N. B. Error bars on this and all subsequent plots
are 95% confidence intervals)
Key: • = 9% MCC /  50% HVO
■ = 19% MCC /  40% HVO
A = 29% MCC /  30% HVO
♦ = 39% MCC /  20% HVO
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hydrogen bonding between the hydroxyl groups on the polymeric cellulose chains.
Since water is thought to disrupt these bonds, causing the crystals to separate 
(205), this may account for the loss of tablet integrity at higher concentrations 
of MCC. If there is sufficient MCC in a tablet it will hence effectively act as a 
disintegrant and this was concluded to be the case when it was included in H VO - 
based formulations, with the effect increasing with increasing proportion of MCC.
Formulations containing 40 and 50% HVO both exhibited potentially useful
release kinetics and it was decided to prepare further formulations containing 40% 
of HVO, as this appeared to represent a suitable compromise between useful
sustaining of release and minimal adhesion to the punch faces.
2.3.4 Effect of Different Types of Inert Directly-Compressible Diluents on Drug 
Release Characteristics
The effect on drug release characteristics of tablets prepared from 
formulation 2F (KCI 40% /  HVO 40% /  MCC 19% /  MS 1%) of replacing MCC with DPD or
HL was examined. The reason for studying this was that these excipients may be
required in a formulation in order for example to improve its flow characteristics, 
or because of chemical incompatibility of particular drugs with a specific
excipient DPD was chosen because it is an example of a directly-compressible 
diluent which like MCC is insoluble but unlike MCC does not possess any intrinsic 
disintegrant action, and HL because it is soluble. The release data obtained are 
shown in figure 2.4. It can be seen that the formulation containing MCC has the 
highest release rate, the one containing HL an intermediate rate and the 
formulation containing DPD the slowest rate. These results will be discussed in the
light of further analysis in section 2.3.7 below.
2.3.5 Measurement of Drug Release Characteristics of a Commercially-Available 
Controlled Release Formulation of Potassium Chloride c
The drug release data obtained for "Slow -K1 tablets are shown in figure 2.5
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Figure 2.4 Effect of different types of directly-compressible diluents on drug 
release from formulations 2F, 2H and 21 (table 2.1)
Key: •  = 2F (microcrystalline cellulose)
■ = 2H (spray-dried hydrous lactose) 
▲ = 21 (dicalcium phosphate dihydrate)
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Figure 2.5 Drug release profile of "Slow-K" tablets in comparison with drug 
release profile of formulation 2H (table 2.1)
Key: •  = formulation 2H
■ = "Slow-K" tablets
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with the corresponding drug release data for tablets from formulation 2H (table 
2.1) for comparison. It can be seen that tablets prepared from the HVO formulation 
had drug release profiles which were similar to those for the commercial 
formulation. Visual observation of the "Slow-K* tablets during the release process 
showed that an initial dissolution of the coat occurred followed by a slow 
swelling of the core and in the final stages of release, some evidence of core 
disintegration. It was concluded that "Slow-K* was a hydrophilic matrix type of 
device. The release rate of "Slow-K* is slower than that of the HVO formulation at 
first, probably reflecting the fact that initial coat dissolution must occur 
before release begins. Towards the end of the release period there is evidence of a 
burst effect which was probably caused by the breaking up of the swollen core. The 
similarity of the HVO formulation’s release kinetics showed that HVO-based systems 
possess some potential as oral controlled delivery systems, especially in view of 
the fact that the HVO system was prepared using direct compression technology. It 
is unlikely that the system could be used for KCI, however, because the drug 
loading of the formulation exhibiting a similar release profile to "Slow-K* was 
only 40%, whereas the "Slow-K* tablets had a loading of 80%. A therapeutic dose of 
600 mg of KCI would hence result in a tablet mass of 1.5 g for the HVO formulation, 
which is probably unacceptably high. The system may hence be limited to more 
potent drugs where high drug loading would not be necessary.
2.3.6 Effect of Drug Solubility on Drug Release Characteristics
2.3.6.1 Assay of Sodium Salicylate using Ultra-Violet Spectrophotometry
The wavelength of maximum absorbance of sodium salicylate in aqueous solution 
was found to be 296 nm. The measured absorbance of the solutions prepared was 
plotted against their concentration (figure 2.6) and it was considered that a 
linear relationship existed between the variables. Least squares regression 
analysis was performed on the data and it produced the following statistics:-
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Figure 2.6 Calibration curve of UV absorbance at 296 nm versus concentration of
sodium salicylate in water
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Slope = 21.68 (g dm-3 )-1
Intercept = 0.01095
r2 = 0.9999
These results were considered to show that the use of this assay was 
appropriate for analyses In the concentration range measured.
No significant difference in absorbance was noted between any of the excipient 
solutions prepared and a blank of distilled water and It was concluded that any 
dissolved excipient did not interfere with the assay.
2.3.6.2 Assay of Theophylline using Ultra-Violet Spectrophotometry
The measured absorbance of the solutions prepared in water and buffers of pH
2.0 and 6.0 was plotted against concentration (figure 2.7) and it was considered 
that linear relationships existed between the variables in each case. Least squares 
regression analysis was performed on the data and it produced the following 
statistics: -
Water: Slope = 10.32 (g dm-3 )-1  
Intercept = 0.02426 
r2 = 0.9996
Buffer pH 2.0: Slope = 9.873 (g dm-3 )" 1 
Intercept = 0.01405 
r2 = 0.9996
Buffer pH 6.0 Slope = 10.54 (g dm-3 )-1  
Intercept = 0.01347 
r2 = 0.9997
These results were considered to show that the use of these assays was 
appropriate for analyses In the concentration range measured.
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Figure 2.7 Calibration curve of UV absorbance at 290 nm versus concentration of
theophylline in water and buffers of pH 2.0 and pH 6.0
Key: a  = water
■ = buffer pH 2.0
•  = buffer pH 6.0
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No difference in absorbance was noted between any of the excipient solutions 
prepared in water and buffers and their respective blanks and it was concluded that 
any dissolved excipient did not interfere with the assay.
2.3.6.3 Measurement of Release Characteristics of UV Assayable Drugs using an 
Automated Dissolution Testing Technique
The release profiles of the sodium salicylate and theophylline formulations 
measured by the automated system and the corresponding KCI formulation are shown in 
figure 2.8. It can be seen that the effect of increasing drug solubility whilst 
maintaining the other proportions of the formulation constant was to produce an 
increase in drug release rate. These results will be discussed in the light of 
further analyses in section 2.3.7 immediately below.
2.3.7 Determination of Release-Controlling Mechanism for Tablets Containing 
Hydrogenated Vegetable Oil
In order to be able to quantify the release kinetics from HVO-based systems, 
the data was analysed according to various models. As can be seen from the release 
profiles shown above in section 2.3.4 -  6, the zero-order model does not apply to
drug release from HVO tablets, since release is not linear with respect to time. It
/
was concluded from the general shape of the profiles obtained in sections 2.3.4 -  6 
that either a first-order or a square-root of time model could possibly describe 
the release process and the data was therefore fitted to these models. Other tests
i
described below were also performed to further elucidate the model of best fit for 
the data produced using HVO-based systems.
2.3.7.1 Effect on Drug Release Characteristics of Paddle Stirring Speed
If the release process was dissolution controlled, then the agitation 
conditions during the release process would be expected to have a significant 
effect on drug release rate. For this reason, the effect of increasing paddle 
stirring speed on the release profile of formulation 2L (table 2.1) was studied,
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Figure 2.8 Effect of drug solubility on drug release profile of formulations 2F,
2J and 2K (table 2.1)
Key: ■ = sodium salicylate
•  = potassium chloride
▲ = theophylline
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and the data obtained are shown In figure 2.9. It was found that the effect on drug 
release rate of Increasing the paddle stirring rate from 50 to 100 and 150 
revolutions per minute was negligible. Furthermore, no simple relationship between 
drug release rate and paddle stirring speed was evident, since drug release for the 
test carried out with a paddle speed of 150 rev min-1  was slightly slower than that 
at 100 rev min-1 , although both are faster than at 50 rev min-1 . These results 
provide evidence that the release process is not erosion controlled.
Visual examination of this formulation during the release process showed that 
tablets remained whole throughout, indicating that the extent of the disintegrant 
action of MCC found in formulations containing KCI, was not based on an absolute 
MCC concentration, but rather, it also varied with other formulation factors. For 
example, formulation 2L contained MCC at a concentration of 29% w/w, which at the 
same concentration in formulation 2E (table 2.1) had caused "capping" to occur 
during the release process (section 2.3.3).
2.3.7.2 Measurement of Tablet Thickness
When examined visually, HVO -  based tablets did not appear to swell or erode 
during the release process. Quantitative evaluation was carried out by measuring 
both tablet diameter and thickness for formulation 2L before and after dissolution 
testing at 50 rev min-1 . No consistent increase or decrease was found, with a 
difference of no greater than 0.008 mm in thickness and 0.003 mm in diameter being 
recorded. This represents percentage changes of 0.38% and 0.03% respectively and 
was taken as further evidence that the release process was neither swelling nor 
erosion controlled.
2-3.7.3 Data Analysis
Since all the drug release profiles obtained conformed to the pattern of 
apparently exponentially decreasing cumulative drug release with increasing time it 
was decided to analyse the data according to first-order and square-roof time
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Figure 2.9 Effect of paddle stirring speed on drug release profile of formulation
2L (table 2.1)
Key: O = 50 rev min-1
A = 1 0 0  rev min-1 
□ = 1 5 0  rev min-1
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models, since both models could be expected to give such release profiles. The 
release data from formulation 2L (table 2.1) was analysed according to a first-
order model using the following relationship: -
log 10 M = K ,t + log10 M0  equation 2.4
2.303
where K: = first-order rate constant
M = mass of drug remaining at time t
M0 = initial mass of drug
For drug release from a tablet according to this first-order model a plot of 
log10 M versus time would produce a straight line having a slope| -(K i/2 .303 ). Data
for formulation 2L was plotted according to this relationship except that
percentage remaining was used in place of mass remaining (figure 2.10).
The data was also analysed according to the square-root of time model using
the simplified form of the Higuchi equation (section 1.4.5.2 above):-
Q = kHt*  equation 1.25
A plot of Q versus t* should therefore give a linear plot having slope kH, and 
the data is plotted according to this relationship in figure 2.11 except that 
cumulative percentage released is used instead of mass. Examination of these two 
plots indicate that both are approximately linear, with slight curvature observed 
after a lag period in figure 2.11 and hence both models appeared to be potentially 
applicable to the data. The method of further analysing the data to distinguish 
between the two models which was described above (section 1.4.5.2.1) was therefore 
employed. It involves differentiating the above equations with respect to time in 
order to examine the time dependency of release rate.
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Figure 2.10 Log10 percentage original drug concentration remaining versus time for
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Figure 2.11 Cumulative percentage drug released versus square-root time for
formulation 2L (table 2.1)
- 92 -
Differentiation of equation 2.4 gives:-
dQ = kM0 -  kQ 
dt
equation 2.6
since M = M0 -  Q equation 2.7
and -d M  = kM = dQ equation 2.8
dt dt
Differentiation of equation 2.2 gives:
dQ = k f 
dt 2Q
equation 2.9
Hence the first-order model predicts that rate is proportional to Q and the 
square-root model predicts that rate is proportional to 1/Q. The data was analysed 
according to these latter two equations in the following manner: the rate of 
release at each time point t i on the cumulative percent drug released versus time 
curve (i.e. the derivative) was approximated by use of the equation given below:-
where Q ^ ) = cumulative amount released at time ti
Figure 2.12 shows the slopes (i.e. rates) obtained using equation 2.10 plotted against 
drug released and figure 2.13 shows the same data plotted against 1/Q . It is clear that 
only the second plot is approximately linear, proving that the square-root time model is 
the most appropriate description of the release profiles obtained.
Since drug release from HVO tablets was found to conform to the Higuchi model, 
drug release was concluded to be controlled by diffusion. As discussed above in 
section 1.4.5.2, devices from which release conforms to Higuchi model kinetics are
equation 2.10
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Figure 2.12 Drug release rate versus cumulative percentage drug released for
formulation 2L (table 2.1)
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Figure 2.13 Drug release rate versus reciprocal cumulative percentage drug
released for formulation 2L (table 2.1)
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termed matrices, of which there are several types. There are two types where * the 
drug is dispersed in the matrix phase at a concentration in the delivery system 
above its solubility in the matrix phase -  dispersed systems and porous systems. In 
dispersed systems drug release occurs via a diffusion process through the matrix 
material itself, and the matrix remains unpenetrated by the dissolution medium.
This process is described by equation 1.22. In porous systems the matrix is 
penetrated by the dissolution medium and drug diffusion occurs along the fluid -  
filled channels within the matrix, a process which is described by equation 1.24.
It was postulated that the second process was likely to be the predominant 
mechanism controlling drug release from HVO matrices for the following reasons. 
Firstly, drug release from dispersed systems generally takes place over periods of 
days rather than hours (35). This substantial prolongation of drug release occurs 
because the diffusion coefficient of a drug solute molecule in a solid is several 
orders of magnitude smaller than that of a drug solute molecule in water. Secondly, 
the process of matrix production by compression of powdered drug and matrix 
material is unlikely to produce a system which is compressed to such a low porosity 
that the drug is effectively completely dispersed in a continuous matrix phase. 
Thirdly, since matrices containing a high proportion of MCC have been observed to 
disintegrate to some degree during the release process, and this has been explained 
by the disintegrant effect of MCC caused by its interaction with water, this 
indicates that water penetrates HVO-based matrices containing MCC. The fourth 
reason was the results of the qualitative examination of leached matrices described 
immediately below.
2.3.7.4 Qualitative Assessment of Water Penetrability of Hydrogenated Vegetable 
Oil-based Tablets
After removal from the amaranth solution, tabiets produced from formulations 
containing HL and MCC were found on sectioning to be coloured red throughout. A 
small, uncoloured portion was found in the centre of the tablets containing DPD but
the majority of the sectioned surface of the tablets was coloured red. This 
confirmed that water penetrated HVO tablets during the release process and that the 
porous model was applicable.
2.3.7.5 Scanning Electron Photomicrography of Tablet Surfaces
Photomicrographs of the flat and diametral fracture surfaces of tablets are 
shown in figure 2.14. Clefts or pores can be seen on the surfaces of the tablets 
and a pore structure is also evident within the tablet itself. This is further 
evidence that a pore structure is formed which can be penetrated by dissolution 
medium.
2.3.7.6 Fitting of Drug Release Data to the Higuchi Square-Root of Time Kinetic 
Model
Data and information obtained in sections 2.3.7.2 et seq above showed that the 
form of the Higuchi equation applicable to HVO matrices was equation 1.24, which is 
repeated here:-
Q = D g / i (2A -  e C s)Cst*  equation 1.24
where Q = mass of drug released per unit surface exposed to dissolution medium 
D = diffusion coefficient of drug in the dissolution medium 
g  = void fraction or porosity of the fully leached matrix
Cs = solubility of the drug in the dissolution medium 
A = initial mass of drug in the matrix per unit volume 
t =  tortuosity factor of the matrix 
t = time
From a comparison of equation 1.24 with equation 1.25 it can be seen that the 
constant kH in equation 1.25 is hence equal to the term (D e /i)(2 A  -  e C s)Cs, each
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Figure 2.14 (Overleaf). Scanning electron photomicrographs of outer flat surface 
(upper photomicrograph) and diametral fracture (lower photomicrograph) surface of
tablets of formulation 21 (table 2.1)
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M
M
factor of which is constant. This indicates that a change in any of these constants 
would alter Q, thereby providing several factors which could potentially be used to 
regulate drug release characteristics.
Application of the porous Higuchi model for drug release may be useful in 
explaining different release rates observed with the HVO formulations studied 
above. All the release data obtained above were re-analysed according to the 
Higuchi model and plotted against square-root time. Those formulations for which 
almost complete release was measured showed some tailing off in the latter stages 
of release (e.g. figure 2.11). This can be explained by the fact that the Higuchi 
model is not applicable during the latter stages of release, above approximately 
60% released. This is because the pseudo-steady state assumption cannot be made 
when drug is no longer present in the tablet as a solid. The slight curvature of 
the data was also attributed to the fact that drug release studies were performed 
on whole tablets rather than from single planar faces, which as discussed above 
(section 1.4.5.2) would cause a slight deviation from linearity. Least squares 
regression analysis was performed on only the linear portion of each release 
profile (i.e. up to less than approximately 60% released) to obtain slope and 
intercept values for each formulation. These data are tabulated in table 2.2.
For many of the formulations, a positive intercept was obtained. This can be 
explained by the presence of drug on the surface of the tablet which dissolved when 
the tablet was first immersed in dissolution fluid. For the theophylline 
formulation however, a negative intercept was obtained, reflecting the existence of 
a lag time of approximately 1 hour before a constant, higher slope was achieved.
In section 2.3.2, the effect of drug loading was investigated and examination 
of the slopes of formulations 2A -  2C indicated that drug release rate increased with 
drug loading. This follows from the Higuchi equation since an increase in the A 
factor, which will also result in an increased porosity, will cause an increase in 
release rate.
In section 2.3.3 the effect of MCC content was investigated. Examination of
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the slopes indicates that drug release rate increased with increasing MCC 
concentration (and concomitantly decreasing HVO) concentration. In this case the A 
factor remains approximately the same. The differences between the formulations 
must therefore be explained on the basis of differences in either porosity and/or 
tortuosity. Although linear portions of the profiles for tablet formulations which 
did not remain discrete throughout the release process were obtained, the Higuchi 
equation could not be applied quantitatively to the data since the surface area for 






2D 70.3 8.19 0.9982
2E 64.6 9.42 0.9974
2F 42.0 4.49 0.9925
2G 15.9 10.9 0.9963
2H 26.4 12.0 0.9990
21 15.2 14.4 0.9951
2J 74.1 -3 .4 9 0.9972
2K 18.3 -7.61 0.9926
2L 25.2 -3 .40 0.9987
(50 rev min"1)
2L 28.3 -7 .7 4 0.9936
(100 rev min"1)
2L 26.5 -2 .93 0.9974
(150 rev min"1)
Table 2.2 Least squares regression analysis of drug release data for formulations 2 C -2 L
(table 2.1)
In section 2.3.4 the effect of different inert directly-compressible diluents 
on drug release was examined, whilst the drug:HVO ratio was maintained constant at
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1:1. Examination of the slopes indicates that the formulation containing MCC 
exhibited the fastest release rate, that containing HL exhibited the next fastest 
and the formulation containing DPD exhibited the slowest release rate. As before, 
the A factor for these tablets is approximately similar, but since HL is soluble, 
the porosity of this formulation was higher than for the other two formulations and 
the drug release rate consequently higher. This explains the difference in drug 
release rates when comparing the HL formulation with the formulation containing DPD 
but does not explain why the formulation containing MCC exhibits the fastest 
release rate of the three formulations. This apparently anomalous result can 
probably be explained in terms of the disintegrant action of MCC discussed above 
(section 2.3.3). However it is also possible that the MCC causes water to be drawn 
into the tablet when first immersed in water much more rapidly than would be the 
case with either HL or DPD. As discussed above (section 1.4.5.2.1), slow wetting 
has been shown to be a factor in decreasing release rate from matrix systems and 
since HVO is known to be considerably hydrophobic and hence slow to wet, release 
from HVO matrices may be decreased as a result of this mechanism. Further evidence 
to support this hypothesis is the fact that when the water penetrability experiment 
was performed (section 2.3.7.4), an uncoloured and therefore unwetted section was 
found in the centre of the tablet containing DPD after 12 hours in amaranth 
solution, indicating that the wetting process was not complete.
The effect of drug solubility was investigated in section 2.3.6 above and 
it was found that increasing drug solubility increased release rate, which was 
reflected in the slopes of the appropriate curves and can be explained by the 
increase in the Cs term in the Higuchi equation. The lag time which was found to 
occur with the theophylline formulation was taken as further evidence that wetting 
of the matrix takes place slowly.
It is interesting to note that the Higuchi equation assumes that the entire 
matrix is wetted at time = 0 and hence contains no factors to account for any 
wetting phase which may occur during a portion of the release process. If slow
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wetting does have an influence on release rate as the data above suggests, then the 
Higuchi equation can only reflect this by using a falsely high value for the matrix 
tortuosity factor, which would not be an accurate representation of the true matrix 
pore structure.
2.3.8 Effect of pH of Dissolution Medium on Drug Release Characteristics
Since an HVO matrix would encounter different pH environments during release 
in vivo, the effect on release rate from the system was studied by performing 
dissolution testing in buffers of pH 2.0 and 6.0. The drug release data obtained 
are shown in figure 2.15. Least squares regression analysis of the linear portions 
of the release data yielded the following statistics:
Buffer pH = 2.0





= 24.9% hr- *
Intercept = -1.11%
= 0.9982
= 22.4% hr- *
Intercept = 1.84%
= 0.9947
= 25.2% hr- *
Intercept = -3.40%
= 0.9987
It can be seen that the difference between the drug release rate in water and 
that in buffer solution of pH = 2.0 is small but that there is a slightly larger 
difference in drug release between that in water and buffer of pH = 6.0. A test was 
hence required to determine whether there was a statistically significant 
difference between the slopes. A suitable test is to calculate the slope of each 
one of the 6 tablets in a release rate determination and calculate mean <and
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Figure 2.15 Effect of pH of dissolution medium on drug release profile of 
formulation 2L (table 2.1) in comparison to drug release profile in water
Key: □ = water
O = buffer pH 2.0 
A = buffer pH 6.0
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standard deviation values. A Student - t  test can then be used to test for 
significant difference between the mean slopes calculated in this way. The mean and 
standard deviations of the slopes of the release data in water and the two buffers 
were hence calculated and the following statistics obtained: -
Buffer pH = 2.0 Mean slope (s.d.) = 24.9% hr- * (2.96)
Buffer pH = 6.0 Mean slope (s.d.) =  22.4% hr- * (0.672)
Water Mean slope (s.d.) = 25.2% hr- * (0.837)
Student-1 values for the comparison between the mean slope for water and those 
for the two buffers were calculated. The value of t for the difference between 
water and buffer at pH = 2.0 was 0.274 and the result is hence not significant (p = 
0.7856). The value of t for the difference between water and buffer at pH = 6.0 was 
6.43 and this result suggests that a small but significant difference between 
release rates in water and buffer at pH = 6.0 exists (p < 0.0001). Since HVO is 
composed of saturated hydrocarbons, it was considered unlikely that dissolution 
medium pH would affect it chemically. One possible explanation is that the 
diffusion coefficient of theophylline was decreased in phosphate buffer compared 
with in water, and it was also hypothesised that the difference might be due to 
changes in the wicking and disintegrant behaviour of MCC in phosphate buffer 
compared with in water.
2.3.9 Effect of Hydrogenated Vegetable Oil Particle Size on Drug Release 
Characteristics
The drug release data obtained from the two batches of formulation 2K (table 
2.1) prepared from two different sieve size fractions of HVO are shown in figure 
2.16. The data were analysed by least squares regression of each individual slope 
and the following statistics were obtained: -
Size fraction < 355 pm Slope (s.d.) = 25.2% hr- * (0.837)
Intercept = -  3.40%
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Figure 2.16 Effect of particle size of hydrogenated vegetable oil on drug release
profile of formulation 2L (table 2.1)
Key: •  = < 355 pm
■ = 125 -  355 pm 
A = < 125 pm
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= 0.9987
Size fraction 355 -  125 pm Slope (s.d.) = 27.1% h r *  (1.51) 
Intercept =  -1.76%  
r2 = 0.9961
Size fraction < 125 pm Slope (s.d.) = 19.7% h r *  (0.228) 
Intercept = -2.14%  
r2 = 0.9986
Comparisons of the mean slopes of the release data of the <  355 pm and the 355 
-  125 pm size fractions using a t-te s t yielded a t value of 2.80, which is
indicative of a significant difference (p=0.019). The same test on the < 355 pm and 
the < 125 pm size fraction release data yielded a t value of 17.9 which is also
indicative of a significant difference in drug release (p < 0.0001).
These results indicate that drug release rate decreased significantly with 
decreasing HVO particle size fraction, with the decrease caused by removal of 
particle sizes above 125 pm being particularly marked. Since the formulations were 
identical apart from HVO size fraction the only factors in the Higuchi equation 
which could be changed to account for the differences in release rate are porosity 
and tortuosity. Porosity would not be expected to vary widely between these 
formulations and it was thus concluded that a smaller particle size fraction of HVO 
resulted in the formation of matrices with higher apparent tortuosity than with 
larger size fractions. This increase in tortuosity may either be due to physical 
differences in the way the matrices were formed during compaction and/or may be due 
to differences in rates of matrix wetting, as described in section 2.3.7.6 above.
These differences could be usefully exploited during formulation of an H VO - 
based delivery system, since release rate could be adjusted to some extent by 
varying the size fraction of the HVO used to produce tablets of a given 
formulation.








2B KCI 70% / HVO 30%
2C KCI 60% / HVO 40%
2D KCI 40% / HVO 20% / MCC 39% /  MS 1%
2E KCI 40% / HVO 30% / MCC 29% /  MS 1%
2F KCI 40% / HVO 40% / MCC 19% /  MS 1%
2G KCI 40% / HVO 50% / MCC 9% /  MS 1%
2H KCI 40% / HVO 40% / HL 19% /  MS 1%
21 KCI 40% /  HVO 40% /  DPD 19% /  MS 1%
2J NaS 40% / HVO 40% / MCC 19% /  MS 1%
2K THE 40% / HVO 40% / MCC 19% /  MS 1%
2L THE 40% / HVO 30% / MCC 29% /  MS 1%
Table 2.1 Composition of tablet formulations prepared in chapter 2
Key: KCI = potassium chloride
HVO = hydrogenated vegetable oil
MCC = microcrystalline cellulose
MS = magnesium stearate
HL = hydrous lactose
DPD = dicalcium phosphate dihydrate
NaS = sodium salicylate
THE = theophylline
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Chapter 3
Determination of Tortuosity Factors I: Measurement of Air Flow Rate and Pressure
Drop through Matrices
3.1 Materials
Silica gel: self-indicating, lot 5735980P, supplied by BDH Chemicals Ltd., 
Poole, U.K.
Sodium dodecyl sulphate: specially pure, lot 5201860J, BDH Chemicals 
Polyvinyl chloride: high molecular weight (approximately 200,000), GLR grade, 
lot 4573670G, BDH Chemicals
White Beeswax BP: lot OFQ2968, supplied by Evans Medical Ltd., Speke, U.K.
LR White Resin: medium grade, lot R1281/3, supplied by Agar Aids Ltd., 
Stansted, U.K.
Molecular Sieve: supplied by Silica Gel Ltd., London, U.K.
Acetone: lot 5313410J, supplied by Fisons Scientific Apparatus Ltd.,
Loughborough, U.K.
Mercury: triple-disilled, supplied by Belgrave (Mercury) Ltd., London, s
U.K.
Helium: supplied by British Oxygen Company, Brentford, U.K.
Ain British Oxygen Company
Vacuum Grease: "Apiezon -  N", supplied by Apiezon Products, London, U. K. 
Polyacrylic Adhesive: "Uhu", supplied by Beecham UHU, Brentford, U.K.
Epoxy Resin Adhesives: "Araldite" and "Araldite Rapid", supplied by Ciba-Geigy 
Plastics, Duxford, U.K.
3.2 Methods
3.2.1 Determination of Tortuosity Factors from Drug Release Data
It was hypothesised in Chapter 2 that some of the differences in drug release 
profiles which were observed between a number of different formulations of HVO - 
based matrices were due to differences in tortuosity of the tablet cores. It was 
proposed to test this hypothesis by quantitative application of the Higuchi 
equation to release data from HVO matrices to allow tortuosity values to be
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determined. This would also allow further exploration of a second hypothesis, that 
release from some HVO-based matrices may be decreased by a wetting phase. As 
discussed in section 2.3.7.6 above, if wetting of matrices was a significant factor 
controlling drug release, then the Higuchi equation (equation 1.24) can only 
account for this phase by indicating a falsely high value for the tortuosity 
factor. Hence if the tortuosity values calculated from release data were too high 
to be physically realistic (i.e. greater than approximately 10) as discussed above 
(section 1.4.5.2.1), this would provide evidence that a wetting phase may be the 
true practical reason for decreased release rates. Further evidence to support this 
hypothesis would be provided by the determination of tortuosity factors by a method 
which was completely independent of drug release data, for comparison with those 
calculated from release data.
In order to apply the Higuchi equation quantitatively, release kinetics must 
be measured from one single planar surface of a matrix. The release data described 
in chapter 2 were obtained from all faces of the tablet matrices and hence equation 
1.24 could not be used to determine tortuosity values.
As described above (section 1.4.5.2), modifications of the Higuchi equation 
have been proposed (equations 1.26 and 1.27) which describe drug release from 
cylindrical matrices. The use of equation 1.26 or 1.27 would allow analysis of the 
release data in chapter 2 to be performed, and would also enable calculation of 
tortuosity factors. However, the aqueous solubilities and diffusion coefficients of 
the drugs used would have to be accurately known, and in the case of equation 1.26, 
a method of non-linear regression employed to determine the constant Kr. It was 
decided that a simpler and more accurate approach would be to prepare some model 
HVO-based formulations and perform drug release studies from one planar surface, 
thus allowing the direct application of the Higuchi equation to the release data.
The drug chosen was sodium salicylate, since values for aqueous solubility and 
diffusion coefficient have been already determined by Desai et al (164) in some of 
the original experimental work performed on porous matrices.
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Equation 3.16 is thus substituted back into equation 3.12, which is then
modified in the same way as equation 3.14 by the inclusion of (L/Le) to give:-
u = (L/Lp)2 e 36P ......equation 3.17
2S2vL
Since Le/L  is equivalent to tortuosity i, the Carman -  Kozeny equation can be 
re-written as:-
u = e 36P  equation 3.18
2t 2S2v L
The factor B0 in equation 3.8 can therefore be defined a s :-
B0 = e 3/(2 r2S2) ......equation 3.19
The Carman -  Kozeny equation thus constitutes a relationship which includes a 
tortuosity factor. It has been used to predict flow rates with applied pressures 
and vice versa by measurement of B0. One of its other main uses has been in the 
determination of specific surface area of porous media, whether "unconsolidated" 
such as packed samples of powder or "consolidated" such as rocks or concrete.
Matrices can hence be regarded as porous media for the purposes of this equation. 
When the Carman -  Kozeny equation is used to measure specific surface area a value
for tortuosity must be either assumed or determined.
The product 2t2 is often referred to as the Kozeny constant Kk, and is further 
defined as :-
Kk =  kx(Le/L )2 ......equation 3.20
where kx = factor dependant on the cross-sectional shape of a pore (which
equals 2.0 for a pore of circular cross-section)
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Hence, pore cross-sections with shapes other than circular can be accounted 
for. Other values range from 1.67 to 2.65 for pores having equilateral triangular 
cross-sectional shape and rectangular (with the longest side greater than the 
shortest by a factor of 10) cross-sectional shape respectively. Experimental 
determinations showed that for unconsolidated media, i.e. powder beds, Kk generally 
equals 5.0. Carman (207) observed the path of a coloured streamline through a
loosely packed bed of glass spheres. The streamline appeared to adopt an average 
direction at an angle of 45° to the direction of flow and therefore he took Le/L  as 
1/cos 45° or 1.414. This agreed well with experimental data on Kk, giving a shape 
factor of approximately 2.5.
Tortuosity has been determined more directly by the measurement of
conductivity of fluid-filled porous media (208). If the pore space is filled with 
an electrically-conducting solution such as an aqueous solution of sodium chloride, 
then the specific conductance of a unit cube of the medium will be less than that 
of the solution itself (assuming that the porous medium itself is a non-conductor).
The fluid-filled cross-section of the medium available to pass current will be 
equal to the total cross-section multiplied by the porosity e . The current must 
follow a tortuous path which is longer than the length of the sample, further 
reducing the conductance. Hence the ratio Jc of apparent specific conductance to 
true specific conductance (i.e. in solution) will b e :-
Jc = e /q   equation 3.21
where q =  a tortuosity factor greater than 1.
A similar relationship should exist between the apparent diffusion coefficient 
of a gas in air-filled porous medium, and the true diffusion coefficient of the gas
in air. Specific conductance and diffusion measurements hence provide methods for
determining the tortuosity factor q directly. The relationship of q to Le/L  is
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given by (209): —
q = (Le/L)2 .... equation 3.22
This relationship will be discussed further in chapter 4. Values of q
determined by conductance and diffusion measurements on unconsolidated media have
been found to be in the range 1.1 to 2, with many values around 1.5 (208). These 
agree reasonably well with the observed value of 5 for the Kozeny constant, since 
some variability of the shape factor kx would also be expected. Values of q have 
also been determined for consolidated media, and have been found to be higher than 
those for unconsolidated media, with values up to 22 being recorded (210).
Where matrices are concerned, the method of measuring tortuosity by specific 
conductance could not be used, since the porous medium must be completely saturated 
with conducting solution. Since it was hypothesised that drug release is decreased 
by slow or incomplete wetting, this method cannot be used in the present study.
This leaves the diffusion method which will be investigated in chapter 4. It was
considered that it may be possible to use the Carman-Kozeny equation itself to
determine tortuosity, providing that matrix specific surface area was known or 
could be determined using an independent method.
3.2.2.2 Development of a Constant Pressure Air Permeameter
As discussed in the above section, the Carman -  Kozeny equation has been used as 
a basis for determining the specific surface area of powder samples, by assuming 
that the Kozeny constant always equals 5. One of the most common types of apparatus 
used to perform these kinds of measurement is the constant pressure air 
permeameter, which is often known as the Lea and Nurse permeameter, after its 
originators (211). A schematic diagram of the Lea and Nurse apparatus is shown in 
figure 3.1. Air at constant pressure above atmospheric is applied to the upper 
surface of the sample; the pressure drop across the sample is measured using the
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Figure 3.1 Schematic diagram of Lea and Nurse constant pressure air permeameter
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first manometer, and the volume rate of flow is calculated using the second 
manometer.
A modified version of the Lea and Nurse apparatus, including a sample cell, 
was designed and constructed using mild steel for the cell. A schematic diagram of 
the cell is shown in figure 3.2. Air was supplied from a bottled compressed 
source, fitted with coarse and fine head valves to allow small adjustments of 
pressure to be made. The air was dried by passing it through a packed column of 
length 50 cm and diameter 0.95 mm containing "Molecular Sieve" gas drying agent, 
which was dried periodically by leaving the column overnight in a fan oven at 
approximately 80 °C. The column was connected at one end to the compressed air 
cylinder with copper tubing having an internal diameter of 6.4 mm using 
"Simplifix" screw connectors and at the other end to the sample cell using plastic
c
tubing having an internal diameter of 1 cm. A branch was taken off the line between 
the drying column and the sample cell by means of a T -  piece connector and connected 
to a glass manometer of length 1 m (Gallenkamp Ltd., Loughborough, U.K.). The 
manometer was attached to a mounting board using clips and secured in a vertical 
position. An air flow-m eter ("Sho-Rate" Model 1350/1/A, Brooks Instrument Division, 
Stockport, U.K.) with a measuring range of 0.2 -  4 dm3 hr-1 was obtained. The flow 
meter was connected to the bottom of the sample cell using 6.4 mm internal diameter 
nylon tubing, and clamped vertically to a retort stand. Hose clips were used to 
secure all plastic tubing joints.
All the joints in the system were checked for leaks by smearing a film of 
detergent solution on them, and observing for the appearance of soap bubbles when 
the system was under pressure. Any leaks were rectified by tightening the 
appropriate joints or clips. A sample tablet was attached to the top of the tube in 
the sample holder with adhesive PVC tape and the inlet and outlet parts of the 
holder were secured to the main section of the cell using hexagonal headed screws.
A dilute aqueous solution of amaranth was used as the manometer fluid to facilitate 
the location of the meniscus position against the white mounting board.
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Figure 3.2 Schematic diagram of original permeametry cell: scale 1 cm = 1 cm
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Permeametry was performed by application of pressure in small increments to 
the upper surface of the tablet in the holder and noting the flow rate as measured 
by the flow meter at each pressure. Equation 3.23 was used to calculate the 
pressure drop 5P between the upper and lower faces of the tablet from the
measurements of height increase caused in the manometer:-
5P = hmog  equation 3.23
where hm = height increase
a = density of manometer fluid 
g = acceleration due to gravity
The density of the amaranth solution used as the manometer fluid was
determined by equilibrating it at 20 °C  in a water bath, pipetting 100.0 cm3 into a 
tared beaker and noting the mass. The density was calculated by dividing the mass 
of the amaranth by its volume.
Unfortunately, initial trials of the system using formulation 3A (table 3.1)
Indicated that repeatable results using the same tablet might not be obtainable. 
Apparently linear relationships between pressure drop and flow rate were obtained, 
but when a repeat series of measurements was performed, the flow rate at each 
pressure increased. It was considered that this might be due to allowing 
insufficient time for the flow rate to equilibrate at each pressure and for this 
reason the system was left under pressure for 24 hours, and the pressure and flow 
rate noted at intervals of time. This exercise was repeated using increased 
pressures. It was found that at lower pressures, flow rate equilibrium was reached
within one minute, but that at higher pressures, the flow rate tended to increase
with time. This suggested that an air leak was occurring at the higher pressures, 
and it was concluded from these trials that the seal formed around the tablet by 
the adhesive PVC tape was not robust and that higher pressures were liable to cause
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the tape to separate from the tablet surface, breaking the seal around the tablet 
It was evident that some modification of the sample cell was required, in 
order to ensure that an air-tight seal was obtained around the sides of the tablet 
even at high pressures. A piece of apparatus which had been previously used to 
measure the gas permeability of tablet coating films was modified according to the 
design shown in figure 3.3. The plastic tubing used with the first cell between the 
drying column and the cell was replaced with copper tubing and re-tested for air­
tightness. The space in the cell for the tablet sample was circular with a diameter 
of 21 mm and depth 5 mm. It was decided that a good seal around the tablets might 
be achieved either by setting them in a resin mould shaped to fit this space or by 
gluing them Into suitable holders. Sealing around the sides of such moulds or 
holders would be achieved by the pressure on the O -rings above and below them 
caused by the bolting down of the lid of the cell directly onto the upper O -ring.
This arrangement was tested for air-tightness by obtaining a cylindrical piece of
mild steel having similar dimensions to the sample holding space -  21 mm in
diameter with a thickness of 5 mm. The metal cylinder was sealed in the sample 
holding space as described above; the O -rings were lightly greased with vacuum 
grease prior to insertion. The manometer used to measure the pressure drop was 
disconnected from the system, and the pressure gradually increased up to a reading 
of approximately 100 psi (690 kPa) as measured using the compresed air cylinder 
head gauge. This pressure was approximately 70 times the maximum used with the
previous cell and no flow was registered at this pressure. It was concluded that
the modified sample holding arrangement provided a good seal around the holder. The 
whole system was also re-checked for leaks at the same time, using the method 
described above.
A chemically-cured resin used for holding samples for microscopy was obtained 
and a circular mould of diameter 6 cm and thickness 6 mm with a circular hole of 
diameter 21 mm was constructed from mild steel. Initial experimentation indicated 
that the optimum ratio of curing agent to resin for a suitably rapid curing time
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Figure 3.3 Schematic diagram of modified permeametry cell: scale 1 cm = 1 cm
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was 3 drops to 5 cm3 respectively. This hardened quickly enough to hold the tablet 
in the centre of the hole in the mould. The mould was lined with double-sided 
adhesive tape without the backing paper removed from the side in contact with the 
resin. This facilitated removal of the cured resin from the mould. The mould was 
placed on a steel plate supported on ice in a suitable container, in order to 
prevent heat from the exothermic curing reaction causing melting of any HVO in the 
matrices. The resin was prepared and pipetted into the mould around the tablet and 
allowed to cure for 15 minutes, after which time it was solid enough to be removed 
from the mould and was then allowed to cure completely overnight. Following trials 
using several tablets it was found that some could be pushed out from the resin 
after curing and it was considered that the air pressure in the permeameter would 
have the same effect.
For this reason it was decided to glue tablets into modified sample holders 
and holders were manufactured to the following design using stainless steel. In 
order to fit into the sample space in the cell described above, the modified sample 
holders were made cylindrical with a diameter of 21 mm, a thickness of 5 mm and 
with a central hole of diameter 10.4 mm to accommodate the tablet. This hole was 
slightly larger than the tablet diameter of 10.0 mm so as to allow space for a glue 
bond between the tablet and the wall of the sample holder. It was decided to test 
the air-tightness of the bonds formed by various types of glue between the tablet 
and the sample holder by gluing a piece of steel of the same dimensions as a tablet 
into a sample holder. The three glues tested were the epoxy resins "Araldite" and 
"Araldite Rapid" and the polyacrylic adhesive "UHU" and were allowed to set 
overnight. It was found that no flow was registered at pressures up to 690 kPa at 
the cylinder head gauge with any of the three glues. It was decided to utilise the 
polyacrylic adhesive as this was the simplest to use, since the mixing of two 
components did not have to be performed as it did with the two epoxy resins.
Initial trials of the system using tablets of formulation 3A (table 3.1) glued 
into holders with polyacrylic adhesive showed that no flow was observed at
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3.2.1.1 Determination of True Density of Drugs and Excipients using Helium-Air
Comparison Pycnometry
In order to measure the porosity of matrices, it was necessary to determine 
the true density of the matrix components. A helium -air comparison pycnometer 
(Model 1302, Micromeritics Instrument Corporation, Norcross, U.S.A.) was used for 
these measurements, connected to a helium source and a vacuum pump (Model E2M2,
Edwards High Vacuum, Crawley, U.K.). Samples of drug and excipient were dried by 
placing them in a vacuum oven (Model OVL570, Gallenkamp, Loughborough U.K.) over
dry silica gel; applying a vacuum of approximately 100 pm Hg for at least four 
hours with the vacuum pump attached to the oven and then leaving overnight under 
vacuum at room temperature. Following this treatment, samples were removed from the 
oven and immediately transferred to a desiccator containing dry silica gel. Samples 
were only removed from this container immediately before analysis and the 
desiccator was immediately re-sealed. The instrument was checked each morning with 
one of the standard masses supplied (a steel sphere of volume 8.58 cm3). It was 
found that the instrument could take 30 -  60 minutes to give an accurate reading 
for this standard and so the machine was left switched on overnight before 
measurements were commenced each morning. It was also found that temperature 
fluctuations affected the precision of the measurements, and for this reason the 
instrument was situated In a position as isolated as possible from air currents 
originating from windows and doors. The sample container and standards were 
transferred to and from the instrument using forceps and a magnet respectively and 
the machine was not handled any more than was absolutely necessary.
Once an accurate reading for the standard had been established, measurements 
on the various samples were carried out until three results with a coefficient of 
variation of less than 3% had been obtained.
3.2.1.2 Production Of Model Matrices and Drug Release Studies
Tablets of the following formulations were prepared:-
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3A: Sodium salicylate 20% / HVO 40% / DPD 39% / MS 1%
3B: Sodium salicylate 10%/ HVO 40% / DPD 49% / MS 1%
3C: Sodium salicylate 5% / HVO 40% / DPD 54% / MS 1%
Key: HVO -  hydrogenated vegetable oil 
DPD -  dicalcium phosphate dihydrate 
MS -  magnesium stearate
Note 1: Information relating to the composition of all formulations used in this 
chapter is given in table 3.1 at the end of the chapter.
The reasons for choosing DPD as the filler were as follows: firstly, since DPD
was insoluble it would remain in the matrix during the drug release process and 
therefore would not affect the final porosity of the matrices. Secondly, DPD would 
not prevent the application of the Higuchi application unlike the soluble filler 
HL, since HL would dissolve and therefore act as a second diffusing species in 
addition to drug, which cannot be taken into account by the Higuchi equation in its 
basic form. Thirdly, it had not been found to exert any disintegrant action, unlike 
MCC, and therefore would not potentially disrupt the matrix during the drug release 
process.
The tablets were produced as described above in section 2.2.1.1, apart from 
the following differences. In order to make the matrices of a particular 
formulation as similar to each other as possible, tablets were produced manually 
from pre-weighed powder samples instead of under power using the normal volumetric 
filling system. Individual powder samples of 500 ± 1 mg were weighed into glass 
sample tubes and subsequently transferred to the tablet die. The powder was then 
compacted by actuating the tablet punches manually using the flywheel. This 
procedure was performed at approximately the same speed each time, in order to 
ensure that the compaction event was as reproducible as possible.
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In these experiments, formulations were all prepared to approximately the same 
initial porosity rather than to the same diametral crushing strength, in order to 
minimise variability between formulations. The tablets of the first HVO formulation 
were prepared to a diametral crushing strength in the range 59 -  78 N and their 
diameter and thickness measured with a micrometer. The mean porosity of 10 tablets 
was calculated and the other formulations were prepared to approximately this 
porosity by adjusting die depth and compaction pressure accordingly. Porosity was 
calculated using the following equation:-
E = 1 -  (Vm/V t )  equation 3.2
where Vm = volume occupied by each component of the matrix 
Vt  = volume occupied by the matrix itself
Vm was calculated from the mass of the tablet and from a knowledge of the true 
density of each component (section 3.2.1.1). Vt  was calculated from the geometrical 
formula for the volume of a cylinder using tablet radius and tablet thickness 
measurements.
In order to further test the hypothesis that slow wetting may decrease release 
rate from HVO-based matrices, it was also decided to prepare a matrix system which 
had been shown to wet rapidly when placed in dissolution fluid. This would allow 
comparison of release data and hence tortuosity factors. Matrices produced using 
polyvinyl chloride (PVC) have been shown by Carli and Simioni (186) to wet 
completely In 40 s. Tablets were therefore prepared using the following formulation 
in order to examine the influence of wetting on drug release from matrices: -
3D: Sodium salicylate 10%/ Polyvinyl chloride 90%
Magnesium stearate has been shown to inhibit penetration of liquid into
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conventional tablets (200), although the time for uptake of 0.1 cm3 of water only 
increased from 55.5 s to 80 s when magnesium stearate was included in a previously 
unlubricated formulation at a proportion of 1%. Nevertheless, it was decided not to 
include magnesium stearate in formulation 3D, since any inhibition of wetting was 
considered undesirable. Die wall lubrication was achieved by brushing with a 
suspension of magnesium stearate in acetone at a concentration of 5% w/v. The 
acetone was allowed to evaporate prior to tableting and the operation was repeated 
before each tablet was compacted. The tablets prepared in this manner were removed 
from the tablet machine and stored with the face which had been in contact with the 
upper punch of the tablet machine uppermost This procedure was adopted because the 
lower punch was also covered with magnesium stearate when the die wall was 
lubricated which inevitably contaminated the lower surface of the tablet with 
lubricant The uncontaminated upper tablet face was hence used as the surface from 
which drug release was studied.
Drug release studies from single planar faces of matrices have generally been 
achieved by forming some type of water-impermeable barrier around the other 
surfaces (163). This was accomplished in these experiments by melting approximately 
30 g of white beeswax in a porcelain evaporating dish using an electric heating 
mantle and allowing it to cool to just above its melting point A tablet from which 
release was to be studied was then carefully lifted by its upper surface using 
suction applied through a glass pasteur pipette attached by a flexible hose to a 
vacuum pump, and placed in the cooling wax so that the lower planar and cylindrical 
surfaces were immersed. It was then immediately removed, which resulted in a solid 
coat of wax being deposited on the immersed surfaces. This process was repeated 
rapidly three further times, which resulted in the build up of a wax coat 
approximately 2 mm thick. The wax was allowed to cool to room temperature before 
drug release studies were commenced. '
An advantage of coating with this material was that since the white beeswax 
was slightly malleable at room temperature, it was found that it could easily be
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removed from a tablet by making a small incision in the coat with a scalpel blade 
and peeling the coat off. This property was desirable in order to allow studies of 
leached matrix cores to be carried out.
In order to confirm that the wax coat was impermeable to water and drug, 6 
tablets of formulation 3A (table 3.1) were coated in the manner described except
that all their faces were covered in the wax. The small hole left by the suction 
pipette was sealed using a small drop of molten wax applied from a pasteur pipette.
A dissolution test was then carried out for 24 hours as described in section
2.2.6.3 above. No release of sodium salicylate was detected and it was concluded 
that this method produced a suitable w ater- and drug -  impermeable barrier coat.
The partially-coated tablets were attached to metal discs of diameter 20 mm 
and thickness 2 mm with a small amount of molten white beeswax which was allowed to 
cool. This procedure ensured that the uncoated surface of the tablet could be 
placed in a reproducible orientation in the bottom of the dissolution vessel, i.e. 
parallel to the plane of rotation of the paddle. Dissolution testing was carried 
out as described above in section 2.2.6.3.
Desai et al (167) have shown that drug release rate from some porous matrices 
can be increased in the presence of surfactant dissolved In the dissolution medium.
This was attributed to one or | both of the following two effects.
Firstly, the incomplete removal of air from the matrix when dissolution is
performed in water and hence the incomplete wetting of the available pore space.
This could result in a falsely high porosity being used in the Higuchi equation and 
consequently inaccurate tortuosity values would be obtained. Secondly, in the
presence of surfactant the rate of permeation of the matrix could be increased,
indicating that slow wetting was decreasing release rate.
l b  uoa.fr c o v a t l ^  d e c .; cLcdl t 0
perform release studies in surfactant solutions. The surfactant selected for use in
the present study was sodium dodecyl sulphate (SDS). Desai et al (167) found no
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change in sodium salicylate solubility, diffusion coefficient or the absorbance 
versus concentration curve in the presence of SDS at a concentration of 0.2% w/v. 
For this reason SDS solution was used at this concentration and dissolution testing 
was performed on formulations 3A -  3C (table 3.1) using this solution as the 
dissolution medium. The drug release profiles obtained were compared with those 
obtained using water as the dissolution medium.
3.2.1.3 Calculation of Tortuosity Factors
Least squares regression analysis was performed on the linear portions of the 
drug release data. The slope thus estimated was equal to the constant term in the 
Higuchi equation: -
slope = {(D e C s/x)(2A -  e C s)}*   equation 3.3
Rearrangement of equation 3.3 to make tortuosity the subject results in :-
x = {D e C s(2A -  e C s)}/slope2  equation 3.4
The term A (initial concentration of drug in the tablet), was calculated from 
a knowledge of the proportion of sodium salicylate in the tablet and the volume of 
the tablet calculated from its radius and thickness. The porosity term e  was 
calculated, assuming that 100% of the drug had been leached out of the tablet, by 
adding the porosity caused by drug removal to the initial porosity. The values used 
for aqueous solubility Cs and diffusion coefficient D of sodium salicylate were 
those determined by Desai et al (164), as mentioned in section 3.2.1. Tortuosity
factors for the various formulations could hence be calculated and compared.
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3.2.2 Rationale for Determination of Tortuosity Factors Independently of Drug 
Release Data
A serious limitation of use of the Higuchi equation is that the tortuosity 
factor can only be calculated indirectly, by means of drug release studies. It is 
therefore impossible to determine every parameter of the Higuchi equation prior to 
drug release studies, and thus produce matrices which will release drug at a 
particular desired rate. For the same reason, it has not been possible to 
quantitatively validate the Higuchi equation by the fully independent determination 
of each of its factors. Desai et al (165) developed a method to measure tortuosity 
which involved the complete leaching of drug from matrices, followed by re - 
saturation with drug in solution, and finally immersion in fresh dissolution medium 
and re-measurement of drug release. It was postulated that drug release from this 
solution -  saturated matrix could be described by the following relationship:-
Q = 2 e C r(Dt/Tn)*  equation 3.5
where C r = concentration of drug solution used to re-saturate the matrix
It is possible to determine tortuosity from the slope of the solution release 
data, by rearrangement of this equation.
This method suffered from the disadvantage that it required the completely 
leached matrices to be resaturated with drug solution, a process which took 2 - 3  
weeks to accomplish. It also relied on further drug release studies. Measurement of 
tortuosity by a method independent of release studies was hence desirable. If such 
a method could be developed, then the effect of various formulation parameters on 
tortuosity could be studied and matrix formulations produced which would exhibit 
desired drug release profiles. It would also enable a test of the validity of the 
Higuchi equation, since it would be possible to measure every parameter 
independently of release data, predict a release rate for a given matrix and hence
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test the equation against the experimentally determined rate.
3.2.2.1 Theory of Gas Flow Under Pressure through Porous Media
Darcy’s law describes the basic relationship governing fluid flow in pipes or 
cylindrical tubes and permeability. It states that the rate of flow is directly 
proportional to the pressure gradient causing flow. If a volume V flows in time t 
across a cross sectional area Ax the apparent linear flow velocity u is given by: -
u =  V /A xt  equation 3.6
Darcy’s law further defines u in terms of the pressure drop SP across a sample 
of thickness L and a permeability coefficient B ii-
u = (BiSPJ/L  equation 3.7
If it is assumed that the flow is entirely viscous streamline in nature i.e. 
the fluid is incompressible and does not interact in any way with the medium it Jis 
flowing through, then flow rate will be inversely proportional to the viscosity v 
of the fluid. The permeability coefficient can be modified: -
u = (B0SP)/(vL)  equation 3.8
where B0 = specific permeability coefficient for viscous flow
In order to be able to calculate pressures required to achieve certain flow
rates, it has been attempted to quantify B0 in terms of measurable parameters of
porous media. The Carman -  Kozeny equation is an attempt to achieve this and is
derived from Poiseuille’s law which describes flow through a tube of circular 
cross-section. It is assumed that the pore space can be modelled as a set of 
cylindrical tubes arranged in parallel. Poiseuille’s law states: -
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ut  = dt 25P .equation 3.9
32vLt
where dt = diameter of the tube
ut  = flow velocity in the tube
Lt  =  length of the tube
The problem of defining a pore diameter is surmounted by using the concept of 
hydraulic radius. For a tube of complex cross-section hydraulic radius is defined 
as the cross-sectional area normal to flow divided by the wetted perimeter. If the 
tube is of uniform cross-section throughout its length, hydraulic radius will be 
equal to the volume filled with fluid divided by the wetted surface area. For a 
tube of circular cross-section, the hydraulic radius is the diameter divided by 4.
A porous medium can be considered to have a fractional free cross-section equal to 
its porosity e  and if this pore space is assumed to be a single tube of complex 
cross-section, then using the concept of hydraulic radius:-
where rh = hydraulic radius
S = surface area of the pore space
Substituting hydraulic radius for diameter in Poiseuiile’s equation (3.9) 
gives: -
rh = e /S equation 3.10
u =  (4rh)25P .equation 3.11
32vL
Substituting equation 3.10 into equation 3.11 gives:-
u =  e 25P 
2S2vL
equation 3.12
It was realised by Dupuit (206) that the actual velocity in the pore space was
larger than the apparent linear velocity of flow. He deduced that the relationship
between the two factors w as:-
ue = u /e   equation 3.13
where ue = effective velocity in the pore space
If this relationship is substituted into equation 3.12, since the velocity
term in that relationship is describing the velocity in the pore space, we get:-
u =  e 3 5P  equation 3.14
2S2vL
Kozeny further assumed that the path through the porous medium would be 
tortuous, with an average effective pore length Le greater than than the thickness 
of the medium L. Equation 3.14 can hence be re-written in terms of L and Le: -
u = L e 3 5P  equation 3.15
Le2S2vL
The ratio Le/L  is termed the tortuosity factor. It was noted by Carman (207) 
that If a tortuosity factor is to be introduced, then the Dupuit relationship 
(equation 3.13) must be modified. This is because If the path of fluid flow is 
tortuous, the velocity in the pore must be larger than than the equivalent linear
velocity of flow. He deduced that the time taken to pass through a tortuous path of 
length Le at a velocity ue corresponded to the time taken to pass through a 
distance L at a velocity u /e . The velocity ue was hence defined a s :-
uft = uLfi  equation 3.16
eL
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pressures measurable with amaranth solution as the manometer fluid Le. up to 
approximately 10 kPa. Higher pressures up to approximately 130 kPa were applied and 
measured using mercury as the manometer fluid. (The density of mercury at 20 °C  
(13546 kg m~3) was obtained from tables (212)). No flow was recorded. These trials 
confirmed that the results obtained with flow at low pressures with the first 
sample cell were erroneous, but it was clear that higher pressures than were 
measurable with a manometer would be required before there would be a possibility 
of achieving measurable flow through the tablets.
Trials were conducted using tablets of formulation 3D (table 3.1), since these 
had been produced to a slightly higher porosity than tablets of formulations 3A -
3C (table 3.1) and hence might have been expected to be more permeable. It was
found that flow was achieved at pressures measurable with mercury as the manometer 
fluid and that linear relationships between pressure drop and flow rate could be
obtained. Again though, these were not found to be consistently repeatable on the 
same tablet, and wide variability was found between different tablets. Also it was 
sometimes not possible to achieve a linear relationship; in these cases a gradually 
increasing slope of gas flow with pressure was obtained. As well as measuring the 
change in flow rate as pressure was increased, changes in flow were also measured 
as pressure was decreased and in some cases a hysteresis effect was found with the 
flow at a given pressure always being higher in the decreasing pressure cycle.
A digital -  reading pressure meter (Model KM5007 I.S., Kane-May, Welwyn Garden 
City, U.K.) was obtained and incorporated into the permeameter in place of the 
manometer so that the two could be interchanged as necessary. The meter was capable 
of measuring pressures up to a maximum of 700 kPa. Tablets of formulation 3A were 
subjected to pressure up to 700 kPa, however, inconsistent results were again 
obtained. Out of a total of 10 tablets tested, no flow was registered with 5; low 
flow rates of less than 0.4 dm3 hr-1 were registered at approximately 600 kPa and 
above with 3 tablets and with 2 tablets flow was registered at low pressures of 
approximately 5 and 10 kPa.
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These results further suggested that the seal formed between the tablet and 
the holder was leaking in some cases and this was confirmed by examining the 
tablets which had been subjected to high pressures. Several had been partially
forced downwards out of the sample holders, indicating that the polyacrylic 
adhesive bond was insufficiently strong to withstand high pressure. The tests were 
repeated with tablets glued into the holders with "Araldite Rapid" epoxy resin
adhesive and no flow was registered at pressures up to 700 kPa with any tablets of 
formulation 3A (table 3.1). All future tests were hence carried out on tablets 
glued into holders with this adhesive.
It was concluded that the problem of no flow being registered with HVO 
matrices of formulation 3A (table 3.1) was due to the low initial porosity of the
matrices (section 3.3.1.2 below), which suggested the absence of sufficient
continuous paths through the matrix for enough flow to be measurable at the 
pressures used. For this reason it was decided to carry out permeametry on matrices
which had been completely leached of drug. Using leached tablets also effectively
allowed measurement of the tortuosity of the path taken by a dissolved drug 
molecule, since the space which dissolved drug particles left would contribute to 
the final porosity of the matrix.
Air permeametry was therefore performed as described on matrices produced from 
formulations 3A -3D  (table 3.1), which had been leached of drug using the method 
described in section 3.2.2.3 immediately below. A further modification to the
permeameter which was carried out at this stage was the replacement of the original
flow meter with a more accurately calibrated capillary flow meter (Model "Meterate"
RS1/GF/P AIR, Glass Precision Engineering, Hemel Hempstead, U.K.), which measured
flow over the range 2 - 5 0  cm3 min-1 (0.12 -  3.0 I hr-1 ).
3.2.2.3 Preparation of Leached Matrices
Matrices were leached of drug in the following manner. A dissolution test was 
carried out on 6 tablets each of formulations 3A -  3D (table 3.1). Instead of
- 1 3 2 -
removing the matrices from the dissolution apparatus after the test had finished
c
they were left in the dissolution vessels with the paddles stirring and the pump 
circulating fluid to the spectrophotometer. The matrices were left in these 
conditions until the absorbance readings from each sample were constant These 
readings were noted and the matrices removed from the vessels. The time taken from 
the start of the test until constant readings were reached was also noted. Leached 
matrices were gently rinsed with distilled water and excess water was removed from 
their surfaces by blotting with tissues. The matrices were then dried by placing 
them in a vacuum oven over silica gel; a vacuum of approximately 100 pm Hg was
maintained for at least four hours and then the leached matrices were left under 
vacuum overnight at room temperature. The wax coat was then removed from the
tablets as described in section 3.2.1.2. Data from these experiments were then used 
to establish a leaching method which did not require prolonged use of the 
dissolution apparatus.
Two shaking water baths were obtained and each fitted with 12 conical flasks 
of 100 cm3 capacity sealed with ground glass stoppers. 100.0 cm3 of water was 
pipetted into each flask and allowed to equilibrate to 37 #C. Matrices were set in 
white beeswax as described in section 3.2.1.2 and one matrix was placed in each 
flask. Although the volume of water in each flask was only 1/10th that in the 
dissolution vessels, this still represented sink conditions for the drug used. Sink 
conditions are defined as being at least 5 to 10 times the volume required to 
dissolve the total amount of drug in the matrix (213). The solubility of sodium 
salicylate is 0.65 g cm-3  (164) and the maximum amount of drug present in a matrix 
is 100 mg. Sink conditions would hence be achieved by ((100 -r 650) x 10) =
1.54 cm3. The volume of 100 cm3 was hence well in excess of that required.
The shaking water baths were set to 40 strokes per minute and each formulation 
was left for the same amount of time as it had taken for the absorbance readings to 
become constant as described above. 10.0 cm3 aliquots were then removed from the 
relevant flasks, diluted to 100.0 cm3 and their absorbance measured. In cases where
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the concentration of drug leached from a matrix was the same as that found when the 
formulation was leached in the dissolution apparatus, the tablets were removed from 
the flasks and dried as described above. When leaching was found to be incomplete, 
10.0 cm3 of water was replaced in the flasks and the tablets were left for a 
further 24 hours. The process was repeated until complete leaching had been 
achieved. 1
3.2-2.4 Determination of Specific Surface Area of Leached Matrices using Mercury
Intrusion Porosimetry
As discussed in section 3.2.2.1, the Carman -  Kozeny equation could only be used 
to determine tortuosity values if an independent method of determining specific 
surface area was employed. It was decided that the method of mercury intrusion 
porosimetry would be the most appropriate, since it would give a value for specific 
surface area which had effectively been wetted by mercury. This would in a sense be 
analogous to the surface area term in the Carman -  Kozeny equation, since that 
relationship was derived from the concept of hydraulic radius which is defined in 
terms of wetted surface area. The other method of specific surface area 
determination considered was gas adsorption, but this was rejected on the grounds 
that it might give a value which included surface which effectively took no part in 
the process of viscous flow.
The technique of mercury porosimetry is based on the law governing liquid 
penetration into capillaries. Mercury is a non-wetting liquid for virtually all 
solid surfaces i.e. its contact angle is greater than 90° and external pressure 
must be applied to enable it to enter a capillary in a solid. The relationship 
governing penetration is: —
d = -(1/P)4ycos0  equation 3.24
where d = capillary diameter, assuming cylindrical geometry
- 1 3 4 -
P = pressure required to achieve penetration
y = surface tension of mercury
0 = contact angle of mercury on the pore surface
This relationship and the related expression describing the penetration of a 
wetting liquid into pores, the phenomenon known as capillarity, were first described by 
Washburn (214) and are often referred to by his name.
The instrument used for the porosimetry analyses (Model "Poresizer 9310", 
Micromeritics Instrument Corporation, Norcross, U.S.A.) provided manual low 
pressure (i.e. hypobaric) and automated high pressure (i.e. hyperbaric) control, up 
to a maximum pressure of 30,000 psia (approximately 2x105 kPa). Data on intruded
volume at each pressure was recorded and subsequent data manipulation performed by
an IBM compatible microcomputer (running proprietary software written by 
Micromeritics), which was linked to the instrument via a serial interface 
connector. In order to carry out a pore size analysis, a porous sample was first 
evacuated and then brought into contact with mercury. Hypobaric analysis was 
carried out by allowing mercury to flow into any macropores as pressure was allowed 
to rise in increments to atmospheric. For hyperbaric analysis, external pressure 
was applied to the mercury and the volume of mercury forced into any m eso- and
micro-pores was recorded. The pore diameter equivalent to a particular applied 
pressure was then calculated using equation 3.24. The pressure was then further 
increased and the volume intruded at each new pressure recorded; in this way a
complete analysis of pore diameters present in a sample was obtained. The pore 
surface area was calculated from the pore diameter and the intruded volume at each 
pressure, assuming cylindrical pore geometry. From a knowledge of the sample mass, 
a measure of the intruded specific surface area was obtained.
The intruded pore specific surface areas of matrices from formulations 3A -  3D 
(table 3.1) which had been leached of drug as described in section 3.2.2.3 were 
determined in the manner described.
The leached matrices were stored under vacuum in a desiccator over silica gel
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prior to pore surface area analysis to prevent any adsorbed water from entering 
the porosimeter. This was because the presence of adsorbed water can adversely
affect the ultimate vacuum achievable and hence the accuracy of the
measurements. The analyses were carried out on 3 samples from each formulation and 
a mean value for specific surface area was calculated. The data produced by the 
instrument also provided an analysis of pore size distribution and these data were 
also recorded.
3.2.2.5 Calculation of Tortuosity Factors from the Carman-Kozeny Equation and
Comparison with Tortuosity Factors Calculated from Drug Release Data c
The Carman-Kozeny equation predicts a linear relationship between pressure
drop and flow rate for viscous flow through a porous medium. As noted in section
3.2.2.1, the equation takes the form :-
u = e 35P  equation 3.18
2t2S2vL
Equation 3.18 can be presented in the form y = sx, where s is the slope of the 
line. By rearrangement: -
s = E 3  equation 3.25
2tS2vL
Rearrangement of equation 3.25 gives:-
t = ( e 3/(2S 2vLs))*  equation 3.26
Tortuosity was calculated using this relationship from the data obtained and 
the values were compared with those calculated from the drug release data.
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3.3 Results and Discussion
3.3.1 Determination of Tortuosity Factors from Drug Release Data
3.3.1.1 Determination of True Density of Drugs and Excipients using Helium-Air 
Comparison Pycnometry
The true densities of the drug and excipients used in the preparation of 




True Density kg m 3 x 103 
Rep 2 Rep 3 Mean % C.V.
Sodium 1.59 1.58 1.59
Salicylate
Hydrogenated 0.99 1.03 1.00
Vegetable Oil
Dicalcium Phosphate 2.24 2.34 2.35
Dihydrate
Magnesium 1.11 1.07 1.05
Stearate







Table 3.2 True density of sodium salicylate and excipients as measured by helium -  
air comparison pycnometry
3.3.1.2 Production of Model Matrices and Drug Release Studies
The mean initial porosities of the matrices prepared were found to b e :-
Formulation 3A: Mean porosity ± 95% C.l. = 0.11 ± 0.0055 (n =  10)
Formulation 3 B : .......................................... = 0.12 ± 0.0060
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Formulation 3C: " " " " " = 0.13 ± 0.0064
Formulation 3D: " "............ .............. = 0.15 ± 0.0072
The drug release profiles of formulations 3A -  3D in water are shown in figure 
3.4, and the drug release profiles of formulations 3A -  3C in 0.2% w/v sodium 
dodecyl sulphate solution in figure 3.5. It can be seen that increased drug loading 
results in increased release rate, as might be expected. It can also be seen that a 
lag phase occurs before a constant slope is achieved, which may be due to the 
existence of an initial wetting period. A comparison of the release profiles of 
drug from formulations 3A -  3C occurring in water and surfactant shows that no 
marked increase in release rate was evident when surfactant solution was used to 
replace water as the dissolution fluid. These results appear to provide evidence 
against the hypothesis that slow wetting was a mechanism which may be responsible 
for decreasing the release rate of drugs from HVO-based matrices.
The drug release rate from a PVC matrix was faster than that from an HVO 
matrix containing the equivalent proportion of drug. This appears to provide 
evidence for the hypothesis, since If PVC was wetted instantaneously and HVO more 
slowly, then the release rate from the PVC matrix might be expected to be faster 
than that from the HVO-based matrix.
3.3.2.3 Calculation of Tortuosity Factors
The mean slopes of the linear portions of the release curves were calculated 
and are shown in table 3.3. Also shown in this table are the values for the A and e  
terms calculated for use in the Higuchi equation for each formulation. Student-t 
tests were performed to test for significant difference between the release rates 
in water and surfactant.
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Figure 3.4 Drug release profiles in water of formulations 3A -  3D (table 3.1)
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Figure 3.5 Drug release profiles in sodium dodecyl sulphate solution of
formulations 3A -  3C (table 3.1)
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Release Formulation
Parameter 3A 3B 3C 3D
A g cm-3 0.259 0.134 0.067 0.127
Porosity e 0.273 0.203 0.168 0.229
Mean slope (in water) 
g s~* cm-2
2.10X10"4 8.67x10" 5 3.73x10" 5 1.83x10" 4
95% C.l. 1.34x10" 5 3.58x10" 6 2.63x10" 6 1.04x10" 5
Mean Tortuosity t 32.1 55.4 45.6 12.2
95% C.l. 3.86 4.47 6.86 2.4
Mean slope (in SDS) 
g s"* cm-2
2.31x10" 4 9.45x10" 5 4.03x10" 5 -
95% C.I. 2.10x10" 5 1.32x10" 5 9.95x10" 6 -
Mean Tortuosity i 26.7 48.4 43.7 -
95% C.l. 4.60 12.0 28.5 —
Table 3.3 Release parameters for formulations 3A -  3D in water and formulations 
3A -  3C in surfactant (0.2% w/v SDS) solution
The t values obtained by performing this test on the mean release rates 
obtained in water and surfactant for formulations 3A -  3C are shown below with the 
relevant probabilities (p): —
i[
Formulation 3A: t value = 2.21 (p = 0.0516)
Formulation 3B: t value = 1.69 (p =  0.123)
Formulation 3C: t value = 0.990 (p = 0.346)
None of these results are significant at the 5% level. This shows that there 
is no statistically significant difference between drug release rates in water and 
surfactant for any of the three HVO -  based formulations.
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The mean tortuosity values for the four formulations were calculated from the 
release data in water, using the values of Desai et al (164) for aqueous solubility 
(0.65 g cm-3 ) and diffusion coefficient (2.31 x 10”5 cm2 s-1 ) of sodium salicylate.
They are shown in table 3.2 and repeated below:-
Formulation 3A: Mean tortuosity ± 95%C.I. =  32.1 ± 3.9
Formulation 3B: " " " = 55.4 ± 4.5
Formulation 3C: " " " =  45.6 ± 6.9
Formulation 3D: " " " = 12.2 ± 2.4
It can be seen that the tortuosity values for the three HVO-based formulations 
are higher than those obtained by Higuchi and co-workers (163 -  167), as discussed 
above (section 1.4.5.1.2). The tortuosity factors obtained by these workers were 
generally less than 10, and were taken to be physically realistic indicators of the 
pore structure. Tortuosity values several orders of magnitude higher were found by 
these workers for some matrices and incomplete removal of air was hypothsised to be 
the reason. Since the tortuosity factors obtained in this study for HVO matrices 
were greater than 10 but jless than one order of magnitude greater than 
this figure, it was not clear whether these figures could be regarded as physically 
realistic, or whether an artefact caused them to be increased. The PVC based 
formulation has a tortuosity value which is only slightly higher than 10, with a 
95% confidence interval which includes this value. It was therefore thought 
possible that slow or incomplete wetting was decreasing release rate from HVO-based 
matrices and effectively increasing tortuosity values. However, this conclusion 
appeared to contradict the results from studies of drug release rates in water and 
surfactant, which were not significantly different.
There are several possible explanations for this apparent incongruity.
Firstly, it may be possible that the high tortuosities determined are physically
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realistic, and that the rate of wetting of HVO matrices may not decrease release 
rate. Secondly, the porosity in the HVO-based matrices may not be completely 
available even to dissolution media containing surfactant i.e. the compaction 
process results in some voids or pores being completely enclosed by matrix material 
and hence being inaccessible to dissolution fluid. A related explanation is that 
the capillary network of the matrix may not be completely interconnected or 
continuous and hence air may become trapped in "blind" capillaries. Desai et al 
(167) postulated that surfactant effectively prevents this effect by removing air
c
more efficiently, but it is possible that it may not do so completely. This would 
also result in a decreased effective porosity. A reduction in effective porosity 
could hence account for high tortuosities, since according to the Higuchi equation 
a decrease in effective porosity would have to be accompanied by a decrease in 
tortuosity to describe the same release rate.
3.3.2 Rationale for Determination of Tortuosity Factors Independently of Drug 
Release Data
The results obtained from the drug release studies indicated that it was not 
possible to determine whether the high tortuosity factors calculated were 
physically realistic or were an artefact of other processes which could not be 
accounted for in the Higuchi equation. The independent determination of tortuosity 
would hence be useful in the further exploration of these phenomena.
3.3.2.1 Theory of Gas Flow Under Pressure through Porous Media
3.3.2.2 Development of a Constant Pressure Air Permeameter
The final development of the permeameter technique of determining pressure 
drop and flow rate through leached matrices was found to give reproducible results 
using the same tablet. There was also found to be no flow rate hysteresis effect at 
the same pressure when pressure was being increased or decreased. The measurements 
were made using 6 leached samples from each of formulations 3A -  3D and the results
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are shown in figures 3.6 -  3.9. The data are plotted as pressure drop versus volume 
flow rate and it can be seen that two linear phases are evident for the curves 
obtained with the HVO-based formulations, with the second phase having a steeper 
slope than the first. This effect is not seen with the PVC-based formulation. It 
was postulated that the reason for the two phases results from the nature of the 
flow changing from viscous streamline to turbulent at a certain flow rate dependent 
on the nature of the capillary structure of the pore space in each matrix. If the 
capillaries are assumed to be circular in cross-section, then a dimensionless 
number termed the Reynolds number Re can be defined as:-
Re = daf u/v  equation 3.26
where o f = density of the fluid
At a certain value of Re, termed the critical Reynolds number Rc the flow 
becomes turbulent in nature and for a circular capillary Rc is equal to 2.1. For a 
particular fluid passing through a given capillary Re will hence be dependent on 
flow rate. This explains why the inflexions on the curves occur at approximately 
similar flow rates for samples of one formulation but vary between formulations. It 
is not possible to confirm quantitatively whether the effective Reynolds number for 
a matrix is above the critical value at a particular flow rate because the 
effective pore radius is unknown. It is not therefore possible to confirm this 
hypothesis.
Figure 3.10 shows a comparison of a curve representative of each formulation.
It can be seen that the PVC-based formulation is more permeable than any of the 
HVO-based formulations. The permeabilities of the latter increase with increasing 
amount of leached drug and hence final porosity, which is as expected because the 
initial porosities were all similar.
The slopes of the initial linear portions of the two-phase curves and the 
whole of the single-phase curves were estimated by least squares regression 
analysis. This was in order to be able to apply equations 3.18 and 3.19 to
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Figure 3.6 Air flow rate versus pressure drop for 6 tablets of formulation 3A 
(table 3.1)
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Figure 3.7 Air flow rate versus pressure drop for 6 tablets of formulation 3B
(table 3.1)
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Figure 3.8 Air flow rate versus pressure drop for 5 tablets of formulation 3C
(table 3.1)
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Figure 3.9 Air flow rate versus pressure drop for 6 tablets of formulation 3lI
(table 3.1)
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Figure 3.10 Air flow rate versus pressure drop for 1 tablet each of formulations
3A -  3D (table 3.1)
Key: •  = formulation 3A
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A  = formulation 3C
♦  = formulation 3D
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calculate tortuosity when the values for specific surface area had been determined. 
jThe values of the slopes thus calculated are shown below:-
Formulation 3A: Mean slope ± 95% C.I. =  1.79 x 10"7 ± 0.45 x 10"7 m s-1 Pa-1
Formulation 3B: " " " " = 1.29 x 10"8 ± 0.55 x 10~8 m s " 1 Pa"1
Formulation 3C: " " " " = 7.50 x 10"9 ± 1.24 x 10"9 m s"1 Pa"1
Formulation 3D: " " " " = 6.15 x 10"7 ± 2.51 x 10~7 m s"1 Pa"1
3.3.2.3 Preparation of Leached Matrices .
The times taken to reach a constant absorbance for each of the formulations 
and the corresponding cumulative percentage of drug released from matrices for the 
two methods used to obtain leached matrices are shown in table 3.4. It can be seen 
that more than approximately 92% was released from all four formulations studied.
It was concluded that these figures indicated that all the drug had been leached 
from the matrices, with the variability from 100% release being within what would 
be expected to result from inhomogeneity in the powder mixes and experimental 
error.
Formulation________________________Method of Leaching
Dissolution Apparatus Shaking Water Bath








3A 96 >94.8 168 >94.8
3B 116 96.3 168 91.8
3C 168 93.4 264 93.4
3D 96 94.3 168 100.3
Table 3.4 Time for complete release of drug and mean percentage released from 
formulations 3A -  3D in dissolution apparatus and shaking water bath
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It can be seen that leaching In the shaking water baths took longer than in
the dissolution apparatus and this was attributed to the differences in the 
hydrodynamics of the two systems. For example, the paddle method might be expected 
to remove any leached drug from the region at the surface of the matrix more 
effectively than the shaking method, thus reducing the diffusion boundary layer 
thickness. In the shaking method, drug would have to diffuse through a thicker 
boundary layer at the surface, consequently increasing the time for complete 
release.
3.3.2.4 Determination of Specific Surface Area of Leached Matrices using Mercury
Intrusion Porosimetry
Examples of the cumulative volume of mercury intruded and extruded versus pore 
diameter curves are shown for each of the formulations 3A -  3D (table 3.1) in 
figures 3.11 -  3.14. It can be seen that the extruded volume is always greater at a 
given diameter than the intruded volume. This indicates that at any given pressure 
less mercury is extruded than was intruded at the same pressure. This hysteresis 
effect is seen with many different porous media, and it has been postulated to be 
due to several different effects. It is found that the hysteresis loop does not 
close even when the pressure is reduced to zero, which indicates that some mercury 
is entrapped in the pores. If subsequent pressurisation -  depressurisation cycles are 
performed, no additional entrapment usually occurs. It has been shown that during a 
cycle when no entrapment is occurring, the hysteresis disappears if the contact 
angle is adjusted to take account of the fact that the intrusion contact angle is
different to the extrusion contact angle, the former always being the greater
(215). The hysteresis due solely to entrapment has been postulated as being due to 
some pores being "ink-bottle" shaped, i.e. with a narrow neck and a wide internal 
cavity. Thus the mercury becomes trapped in the pore until a lower pressure is 
reached allowing extrusion. A second theory involves the concept of a "pore 
potential" (216) and requires that molecules can "fall" into a potential field at
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Figure 3.11 Cumulative mercury intrusion volume per gram versus log10 pore
diameter for formulation 3A (table 3.1)
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Figure 3.12 Cumulative mercury intrusion volume per gram versus log10 pore
diameter for formulation 3B (table 3.1)
Key: o  = intruded volume
A = extruded volume
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Figure 3.13 Cumulative mercury intrusion volume per gram versus log10 pore
diameter for formulation 3C (table 3.1)
Key: o  = intruded volume
A = extruded volume
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Figure 3.14 Cumulative mercury intrusion volume per gram versus log10 .pore
diameter for formulation 3D (table 3.1)
Key: o = intruded volume
A = extruded volume
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the surface of a solid. This effect would be enhanced in a narrow pore and it was
proposed that this causes a pore potential which prevents extrusion of mercury from
a pore until a pressure smaller than the intrusion pressure is reached. This 
effectively causes entrapment of mercury in the pores, resulting in less mercury 
being extruded at any given pressure than was intruded. The postulators of the pore 
potential theory discount the ink-bottle model as a universal explanation for 
entrapment for the following reasons (217). Firstly, they suggest that all porous 
samples show hysteresis, implying that they all without exception possess ink- 
bottle pores. Secondly, hysteresis curves would always be the same shape If ink- 
bottle pores were present, which is not the case. Thirdly, hysteresis occurs over 
the entire range of pore sizes, indicating that all pores are ink-bottle shaped. 
Fourthly, hysteresis occurs in samples of regularly packed spheres, where the pore 
entrances are wider than the cavities. Lastly, the ink-bottle model does not 
account for the energy needed to break the column of mercury in order for the pore 
entrance to empty while the cavity remains filled.
The results obtained in the present study were also plotted in the form of
incremental intrusion volume per gram of sample versus pore diameter. This gives a 
representation of the cumulative pore size distribution within the samples. Typical 
examples for each of the formulations are shown in figures 3.15 -  3.18. It can be 
seen that a wide pore size distribution exists within all the samples of all the 
four formulations. Formulation 3A shows a bimodal distribution centred on 12.3 pm 
and 1.72 pm, while formulation 3B shows a more unimodal distribution centred on
1.05 pm. Formulation 3C shows a distinctly unimodal distribution centred on 0.82 pm 
whereas the PVC-based formulation 3D appears to have a polymodal distribution. The 
significance of these results will be discussed in section 3.3.2.5 in the light of 
the permeametry data.
The results obtained for specific surface area of the four formulations are 
shown in table 3.5. It can be seen that results showing wide variability were 
obtained with 3 of the 4 formulations. It was unfortunately not possible to perform
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Figure 3.15 Incremental mercury intrusion volume per gram versus log10 pore
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Figure 3.16 Incremental mercury intrusion volume per gram versus log10 pore
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Figure 3.17 Incremental mercury intrusion volume per gram versus log10 pore
diameter for formulation 3C (table 3.1)



























“ 3 - 2 10_1 10°
Pore Diameter (/xm)
Figure 3.18 Incremental mercury intrusion volume per gram versus log10 pore
diameter for formulation 3D (table 3.1)
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further determinations to enable a more accurate estimate of the mean specific 
surface area for each formulation to be determined, and hence the mean values 
calculated must be viewed with some caution. In addition, the instrument used was 
only capable of applying pressures up to a maximum of 30,000 psia whereas the upper 
limit actually measurable with some instruments is reached at a pressure of 
60,000 psia. (N.B. 1 psia = 6896 Pa therefore 60,000 psia = 414 MPa). If pores were 
present which were smaller than would be penetrated at a pressure of 30,000 psia 
(i.e. 6 nm diameter) then their surface area would not be accounted for.
The variability in the values for specific surface area between samples of the 
same formulation is due to small variations in volume intruded at the highest 
pressures, which result in large variations in surface area, since the pores with 
the smallest diameters account for a large proportion of the surface area.
Formulation Specific Surface Area m2 g-1
1 2 3 Mean 95% C.l.
3A 17.78 6.58 14.64 13.00 14.34
3B 12.98 12.37 7.77 11.04 7.07
3C 11.78 12.14 11.23 11.72 1.14
3D 17.47 11.85 17.43 15.58 8.03
Tabie 3.5 Specific surface area of three replicate leached samples of 
formulations 3A -  3D measured by mercury intrusion porosimetry
3.3.2.5 Calculation of Tortuosity Factors from the Carman -  Kozeny Equation and 
comparison with Tortuosity Factors Calculated from Drug Release Data
Tortuosity factors were calculated from equation 3.26 using the mean slopes 
obtained from the permeametry experiments and the mean specific surface areas 
determined by mercury porosimetry. The value for the viscosity of air at 20 °C  was
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It is clear that the tortuosity factors determined in this fashion are 
meaningless, since they are consistently less than 1, and tortuosity factors must 
by definition be greater than or equal to 1.
The reason for the failure of this technique to determine tortuosity factors 
was considered to arise from the wide pore size distributions exhibited by the 
matrix formulations, which were observed from the mercury porosimetry data. A 
limitation of the Carman -  Kozeny equation is that uniformity of pore size is implied 
(218). The equation assumes that the pore space can be represented by a bundle of 
capillaries of one hydraulic radius, hence if the pore space consists of 
capillaries of widely varying radius, a mean hydraulic radius is irrelevant.
Viscous flow through porous media with a wide pore size distribution will 
predominantly occur through the larger capillaries, since these offer the path of 
least resistance. Hence the flow through the larger capillaries will effectively 
swamp the flow through the smaller ones. The surface area over which the flow 
joccurs will therefore only be a very small portion of the actual surface area
within the matrix. This is because the smaller capillaries will contribute
disproportionately largely to the overall surface area, while contributing little 
to the "flow" surface area. The value for specific surface area determined by
mercury porosimetry is hence irrelevant to the surface area term in the Carman-  
Kozeny equation, explaining the failure to calculate valid tortuosity factors.
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Formulation Composition
3A NaS 20% /  HVO 40% /  DPD 39% /  MS 1%
3B NaS 10% /  HVO 40% /  DPD 49% /  MS 1%
3C NaS 5% /  HVO 40% /  DPD 54% /  MS 1%
3D NaS 10% /  PVC 90%
Table 3.1 Composition of all formulations used in chapter 3
Key: NaS = sodium salicylate
HVO = hydrogenated vegetable oil 
DPD = dicalcium phosphate dihydrate 
MS = magnesium stearate 
PVC = polyvinyl chloride
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Chapter 4
Determination of Tortuosity Factors II: Measurement of Effective Diffusion
Coefficients of Gases in Matrices
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4.1 Theory of Gaseous Interdiffusion
The failure of the permeametry method to enable meaningful tortuosity factors 
of matrices to be determined, necessitated the use of an alternative method for 
measurement of tortuosities. For this reason, the diffusion technique mentioned 
briefly in section 3.2.2.1 above was studied further. As previously described, the 
diffusion coefficient of a single gaseous species through a porous medium filled
with air is related to the diffusion coefficient of the gas in free air by the
following relationship: -
De f f  = Dae / q   equation 4.1
where De f f  = effective diffusion coefficient of the gas in the porous medium 
Da = diffusion coefficient of the gas in free air
e  = porosity of the medium
q = tortuosity factor
A method of estimating De f f  has been described by Evans et al (219). It is 
based on the application of Graham’s law of diffusion, which states that when two 
gases interdiffuse at uniform pressure, their fluxes are in the inverse ratio of 
the square-roots of their relative molecular masses. Graham’s original experiments 
(220) utilised an apparatus which was described as a "diffusion tube". As the gas 
diffuses out of the tube through the porous material, the liquid level in the tube 
rises or falls depending on whether the gas is lighter or heavier than air, 
respectively. Constant zero pressure difference across the porous material is 
maintained, and the ratio of the diffused gas and air volumes is given as a 
function of the ratio of their overall fluxes. Graham performed the experiment with 
several gases and found that the law held on a general basis described by the 
relationship: -
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g^as /  a^i r (^r(air) /  r^(gas))^ .equation 4.2
where Ji = flux of species i where i is a diffusing gas
Mr ( i )  = relative molecular mass of species i
Evans et al (219) used this principle in the determination of effective 
diffusion coefficients of gases through air-filled porous media. A differential 
equation was derived which related the rate of change of volume in the diffusion
tube to the effective diffusion coefficient and by using the published values for
the true diffusion coefficients in air of the gases investigated, they calculated 
the ratio e /q  using equation 4.1. In the present study, the porosities of the 
matrices had already been determined, therefore allowing the determination of
tortuosity factors from effective diffusion coefficient measurements.
4.2 Materials
Light liquid paraffin: (Lot 32043), supplied by J.M. Loveridge, Southampton,
U.K.
4.3 Methods
4.3.1 Construction and Validation of A Graham’s Law Diffusion Tube Apparatus
A diagram of the apparatus is shown in figure 4.1. A graduated burette was 
modified by being shortened to a length of approximately 35 cm and by having a 
portion of the tubular section above the zero mark removed so that the latter was 
as close to the top of the tube as possible. A sample holder was made from glass 
and a diagram of it is also shown in figure 4.1. An indentation was made in the 
outer surface of the tubular portion of the holder as a seating for an O -  ring. When 
the holder was pushed into the top of the burette, the O -  ring was lightly greased 
with vacuum grease to seal the holder into the tube to prevent gas from leaking out









Water or light liquid 
paraffin
Figure 4.1 Schematic diagram of diffusion tube apparatus
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through the joint. The sample holder had a circular hole of diameter 10.4 mm 
drilled in the upper cylindrical section, and the remaining upper surface was 
prepared to a ground finish. A cylindrical piece of glass of the same diameter as 
the sample holder was made with a ground finish on one planar surface and with a 
piece of solid glass tubing of diameter 10mm protruding at right angles from the 
opposite surface. This was used to seal the tube immediately above the sample
whilst the tube was being filled with gas, the two ground glass surfaces being made
r
gas-tight by light greasing prior to closure.
In order to ensure firstly that the sample holder sealed into the top of the
burette and secondly that the sealing piece was itself sealed onto the sample 
holder, the following tests were conducted. A piece of steel of the same dimensions 
as those of a tablet matrix was glued into a sample holder using epoxy resin
adhesive, which was allowed to set overnight A vacuum was applied to the top of
the sample holder using a vacuum line attached to a vacuum pump. No change in the 
water level In the tube was observed, indicating that the sample to holder bond was 
air-tight at these pressures. Secondly, the water level in the tube was made to 
rise by applying the vacuum line to the top of the tube without the sample holder
in place. When the level had reached the top of the tube the vacuum line was
removed and the sample holder with the steel test sample was quickly sealed into 
the top of the tube. The water level in the tube was recorded and the apparatus 
left overnight The level was found to have remained unchanged, indicating that the 
sample holder to burette joint was air-tight.
The steel test piece was then replaced with a leached matrix and the following 
tests performed. The vacuum line was applied to the top of the sample holder, 
drawing the water up the burette to the zero mark. The sealing piece was then 
sealed onto the sample holder and the apparatus again left overnight No change in 
the water level was observed, indicating that the sample holder to sealing piece 
joint was air-tight. This was further confirmed by filling the measuring cylinder 
almost full with water, placing the sample holder with the sealing piece sealed
onto it in the burette, and bubbling helium into the burette. The water level was 
allowed to fall almost to the bottom of the burette then the helium was turned off.
The water level was noted and the apparatus left overnight, thus leaving the helium 
in the tube under pressure. No change in the water level was noted, further 
indicating that the system was adequately gas-tight.
c.
Experiments were conducted in the following manner. A leached matrix was glued 
as described into the sample holder which was then inserted into the top of the 
diffusion tube. This was placed inside the measuring cylinder and clamped in a 
perpendicular position. The water level in the measuring cylinder was adjusted 
using the constant head aspirator so that the lower end of the diffusion tube was 
below it. A vacuum was applied to the top of the sample holder using a vacuum line 
in order to draw the water level in the diffusion tube up to slightly above the 
zero mark. The vacuum line was removed and the water level allowed to fall to the 
zero mark when it was prevented from falling further by sealing off the tube above 
the sample with the ground glass-faced sealing piece. Helium was then bubbled into 
the tube, displacing water until the tube was nearly full of the gas; the water 
level in the measuring cylinder was adjusted to the same level as in the burette 
tube and the burette reading noted. At time zero, the sealing joint was removed
from the top of the diffusion tube and the change of the level of water in the
burette recorded with time. Development of a pressure difference across the sample 
was prevented by synchronously increasing the water level in the measuring cylinder 
with the rise in water level in the diffusion tube as the helium diffused out,
using the constant head aspirator. Readings were taken until no further change was
observed. Since the helium became partially saturated with water vapour whilst 
passing through the water in the measuring cylinder, the air diffusing into the 
tube was also humidified by placing a cone of wet filter paper on the sample holder 
at the start of the experiment, taking care to ensure that no droplets of water 
fell onto the sample.
The reproducibility of the technique was assessed by performing this procedure
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five times on the same matrix sample. The applicability of Graham’s Law to the 
system was determined by calculating the ratio of the volume of helium diffused out 
of the tube to the volume of air diffused in. i.e. the initial burette reading 
divided by the final reading. Graham’s Law states that this ratio should be equal 
to the square-root of the inverse ratio of the relative molecular masses. This 
ratio for the helium /  air system is 2.69 (219). It was found that the law was 
obeyed to within 10% on only three of the five occasions, the percentages of the 
volume change in each case which would have given the theoretical ratio of 2.69 
being found to be 95.7, 100.0, 101.7, 86.3 and 82.4%. The test was repeated on a 
further sample and the percentages obtained were 94.5, 91.2, 86.3, 81.0 and 87.4%.
It was clear that the technique appeared to be giving results which were 
generally below what would be expected, even accounting for experimental error. 
Tests of the validity of Graham’s Law (221) have indicated that it is obeyed to 
within a few percent. If this is taken to be ± 5% and experimental error is taken 
to be the same figure, then a maximum variability of 10% from the theoretical 
volume change would be acceptable. The results described immediately above 
indicated that only half of the tests which had been performed satisfied this 
requirement It was considered that the reason for this was the variability in 
water vapour content between the helium and air. The theoretical ratio of 2.69 
assumes that both the helium and the air were dry. If the helium (relative 
molecular mass ~ 4) contained water vapour (relative molecular mass ~ 18) this 
effectively increased its relative molecular mass. Similarly if the air (effective 
relative molecular mass ~ 28) contained water vapour, this effectively decreased 
its relative molecular mass. Since the ratio is calculated as (Mr ( a i r )  /  Mr ( He))*, 
water vapour present in either or both the gases effectively decreased the ratio, 
explaining the generally consistently low results obtained.
The same argument also appeared to explain the variability in the results 
obtained. The degree of saturation of the helium would be a function of the rate at 
which it was passed through the water in the measuring cylinder, the amount it was
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passed through and their respective temperatures. The degree of saturation of the 
air would depend on the temperature and the relative humidity of the air in the 
laboratory at the time of each experiment. (The dampened cone of filter paper 
placed immediately above the sample was not able to saturate the air totally). The 
variability of these factors appeared consistent with the observation that when 
tests were performed on the same day, the results of the percentages of the ratio 
which were obtained were reasonably consistent. In order to eliminate variability 
as much as was practicable, It was decided to ensure that the helium was 
consistently dry and to use non-humidified air. Data from experiments resulting-in 
a variability in ratios of greater than 10% from the theoretical ratio of 2.69 was 
not used.
In the modified experimental procedure, helium was dried by passing it through a 
column of "Molecular Sieve" drying agent (as described in section 3.2.2.1) and prevented 
from passing through water by replacing the water in the measuring cylinder and the 
constant head aspirator with light liquid paraffin. Data obtained using the 
modified method was found to be more consistent
4.3.2 Determination of Effective Diffusion Coefficient
A differential equation for determining diffusion coefficient from the data 
obtained was derived by Evans et al (219): —
dV(t) = - D e f f AJn {______________V(t) + V0_____________ }  equation 4.3
dt L V(co) +  V 0 + [(1 -  5 x)(V(t) -  V(co)]
where V(t) = burette volume at time t 
V(co) = burette final volume
V0 = dead-space volume between the zero mark and lower face of the 
sample
The factor is derived from the following equation:-
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— DK /  (Dk + De f f ) equation 4.4
where DK = Knudsen diffusion coefficient of the diffusing gas
Equation 4.3 predicts an exponentially decreasing rate of change of volume 
with time and the results of the validation tests performed were found to conform 
to this pattern. Leached samples of formulations 3A -  3D were prepared as already 
described above (section 3.2.2.3) and the experiment was performed in duplicate on 
three samples of each formulation. The effective diffusion coefficient was 
calculated by estimating the slope of the curves obtained by plotting {V(0) -  V(t)} 
versus time at each time point t, using the following formula:-
dV(M = V(ti + 1) -  Vftj-T) .equation 4.5
dt t i + 1 -  t-j _!
The value V0 in equation 4.3, i.e. the dead-space volume between the zero mark 
on the diffusion tube and the lower surface of the sample was determined by fixing 
a piece of steel of approximately the same dimensions as a matrix into the sample 
holder using epoxy resin adhesive. The assembly was then inserted into the 
diffusion tube which was inverted and clamped, and a burette of 10 cm3 volume was 
placed above it The upper burette was filled with water and a piece of plastic
tubing narrow enough to fit into the diffusion tube was attached to its tip. The
diffusion tube was then filled with water from the second burette so that the space
between the lower surface of the sample and the zero mark was filled. The dead- 
space volume V0 was equal to the volume of water added from the second burette and 
this value was recorded.
4.3.3 Estimation of and Permeability Coefficient Kn
The factor 5 X is a measure of the relative contributions of continuum and
c
free-molecule (Knudsen) diffusion to the uniform pressure diffusive flux through
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matrices at atmospheric pressure. The more it deviates towards zero from a value of 
1.00, the greater the contribution to the flux from the free -  molecule component, 
and hence the larger the correction factor to account for it in equation 4.3. The 
true Knudsen diffusion coefficient DK can be determined accurately by flux 
measurements at a series of pressures below atmospheric pressure, which 
necessitates the use of a complex apparatus. However, Evans et al (219) estimated 
Dk and hence using an iterative technique which utilised effectively the same
principle as the tablet permeability experiments described above in chapter 3. Air 
was forced under pressure through the porous sample at a pressure difference which 
was small compared to atmospheric pressure. Instead of performing steady-state 
pressure measurements as described in chapter 3 though, a pressure decay technique 
was used. This involved placing the diffusion tube with the porous sample at one 
end into the measuring cylinder which was full of water, to a depth which allowed 
the end of the tube which contained the porous sample to protrude just above the 
surface of the water. The pressure difference caused the air to be forced out of 
the tube through the porous sample until the water level in the tube reached that 
in the measuring cylinder. The rate of change of volume decayed exponentially with 
time and the permeability coefficient Kp (equation 4.8 below) was calculated from 
this data.
The factor was estimated in the following way. The rate of change of volume
at time t in the pressure decay experiment is related to the volume reading V(t) by 
the following equation: -
dV(t) = -CpV(t)  equation 4.6
dt
where Cp = constant
Integration of this equation gives:-
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V(t) = V(0)e"cpt equation 4.7
A plot of In V(t) versus t should hence give a straight line of slope Cp. The 
permeability constant Kp is calculated from the following equation: -
Cp = owgAxKn  equation 4.8
PaxL
where ow = density of water
ax = cross-sectional area of diffusion tube
P = atmospheric pressure
The factor was calculated using the relationship in equation 4.4 by taking
the value obtained for Kp as an estimate of DK. A trial value of Def f  was 
calculated from equation 4.3 assuming that 6 X = 1. This gave the upper bound for
5 lf since Kp is always greater than DK, and hence indicated whether a significant
portion of the flux was in the Knudsen flow regime. If 5 X was found to be 
significantly less than 1.00 then the calculation of De f f  was performed a second 
time using the new value of
In order to estimate 5 1 for matrices, the pressure decay experiment was 
performed on leached samples of formulations 3A -  3D, using the technique described 
immediately above. The diffusion tube with sample holder was sealed above the 
sample with the sealing piece and placed in a perpendicular position in the 
measuring cylinder. At time zero the sealing piece was removed from the holder and 
the volume readings recorded with time.
4.3.4 Calculation of Tortuosity Factors from Diffusion Data and Comparison with
Tortuosity Factors Calculated from Drug Release Data
The value of the e /q  ratio was calculated using equation 4.1, using the values 
of De f f  which were obtained and the published value for the diffusion coefficient
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of helium in air (222) quoted by Evans et al (219). An empirical correction factor 
to the e /q  ratio was applied to account for the resistance to diffusion which 
occurs in the diffusion tube rather than in the porous sample (219). This was 
achieved by calculating an effective "diffusion resistance" by assuming that the 
"conductance" of a section of tube or porous sample is proportional to the area 
over which diffusion can occur divided by the diffusional length:-
1 = 1 +  1  equation 4.9
(DAx/L) t o t a l (DAx/L) t u b e (De f f Ax/L) s a m p l e
The e / q  ratio was then multiplied by the ratio of total diffusion resistance 
to sample diffusion resistance. The true tortuosity Le/L  was calculated from the 
corrected e /q  ratio using equation 3.22. The tortuosity factors thus calculated 
were compared with the values obtained from the leaching data (section 3.3.1.3).
4.4 Results and Discussion
4.4.1 Construction and Validation of a Graham’s Law Diffusion Tube Apparatus 
The results obtained for the change of burette reading V(t) with time for
samples of formulations 3A -  3D are shown in figures 4.2 -  4.5. Of the experiments 
performed using dried helium, it was found that approximately 80% yielded a volume 
change within 10% of the theoretical figure of 2.69. The mean (± 95% C. I.) 
percentage of the theoretical volume change of these experiments was found to be 
94.3% ± 1.48 (n = 24).
4.4.2 Determination of Effective Diffusion Coefficient
The value V0 was found to be 3.20 cm3. Plots of V (0 )-V (t) versus time for 
samples of formulation 3A are shown in figure 4.2. It can be seen that the rate of 
change of volume decreases exponentially with time and the results from all samples 
of formulations 3A -  3D were found to take this form. Values for effective
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Figure 4.2 V(0) -  V(t) versus time from diffusion tube experiment performed on
leached matrices of formulation 3A (table 3.1)
Key: o  = tablet 1, rep. 1 O = tablet 1, rep. 2
▲ = tablet 2, rep. 1 ♦  = tablet 2, rep. 2
A = tablet 3, rep. 1 □ = tablet 3, rep. 2
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Figure 4.3 V(0) -  V{t) versus time from diffusion tube experiment performed on
leached matrices of formulation 3B (table 3.1)
Key: O = tablet 1, rep. 1 O = tablet 1, rep. 2
□ = tablet 2, rep. 1 A = tablet 2, rep. 1
a  = tablet 3, rep. 1 ♦  = tablet 3, rep. 1
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Figure 4.4 V(0) -  V(t) versus time from diffusion tube experiment performed on
leached matrices of formulation 3C (table 3.1)
Key: a  = tablet 1, rep. 1 □ = tablet 1, rep. 2
▲ = tablet 2, rep. 1 ♦  = tablet 2, rep. 1
o  = tablet 3, rep. 1 O = tablet 3, rep. 1
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Figure 4.5 V(0) -  V(t) versus time from diffusion tube experiment performed on
leached matrices of formulation 3D (table 3.1)
Key: O  = tablet 1, rep. 1 o = tablet 1, rep. 2
■ = tablet 2, rep. 1 A  = tablet 2, rep. 1
□ = tablet 3, rep. 1 ▲ = tablet 3, rep. 1
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diffusion coefficient were calculated by estimating the slope of the plots at each 
time point using equation 4.5 and substituting the value obtained into equation 
4.3. This method of calculating De f f  was found to give consistent values from 
approximately the first two-thirds of the complete curve. Values calculated from 
slopes estimated from the latter third of the curve were less consistent due to the 
error introduced by using equation 4.5 to estimate shallow slopes where the time 
interval { t i+1 -  t ^ }  was large. For this reason only the values of De f f
calculated from slopes estimated from approximately the first two-thirds of each 
curve were used to obtain a mean value. The value for used in equation 4.3 was 
determined as described in the section immediately below. A mean value for De f f  
was determined for each sample and the results obtained are shown in table 4.1.
Sample Number Mean Effective Diffusion Coefficient of Helium in air in Matrices
cm2 s-1  x 10“ 3 ( ± 95% C. I.)
(Rep. Number) Formulation
________________  3A 3B 3C 3D
1 (1) 8.11 (0.816) 1.60 (0.066) 2.02 (0.092) 10.9 (1.50)
1 (2) 6.90 (0.576) 1.71 (0.135) 1.99 (0.080) 9.77 (1.02)
2 (1) 7.06 (0.596) 2.66 (0.225) 1.47 (0.076) 11.2 (1.12)
2 (2) 6.36 (0.522) 2.48 (0.069) 1.38 (0.102) 10.0 (1.23)
3 (1) 6.32 (0.402) 1.26 (0.031) 1.28 (0.057) 9.97 (1.05)
3 (2) 6.43 (0.374) 1.15 (0.057) 1.35 (0.063) 11.3 (1.08)
Overall Mean 
(± 95% C.l.)
6.86 (0.716) 1.81 (0.658) 1.58 (0.350) 10.5 (0.719)
Table 4.1 Effective diffusion coefficient of helium in air in leached matrices of
formulations 3A -  3D (table 3.1)
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Figure 4.6 In {V(t) -  V(co)} versus time from pressure decay experiment of leached 
matrices of formulations 3A -  3D (table 3.1)
Key: o  = formulation 3A
□ = formulation 3B 
A = formulation 3C 
<> = formulation 3D
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4.4.3 Determination of 5i and Permeability Coefficient Kp
Typical plots of In V(t) versus t are shown for one sample each of 
formulations 3A -  3D In figure 4.6. Examination of the plots indicated that linear 
relationships could be considered to exist between the variables and least squares 
regression analysis was employed to estimate the slopes of the lines which were 
equal to the factor Cp in equation 4.6. The permeability constant Kp was hence 
calculated from Cp using equation 4.8 and the values of 52 were subsequently 
calculated from equation 4.4, using Kp as an estimate of the upper bound of DK. 
These values are shown in table 4.2. It can be seen that b1 only varies 
significantly from 1.00 for formulation 3C, and it was therefore concluded that 
this formulation was the only example amongst the four matrix formulations 
investigated through which uniform pressure diffusion at approximately 1 atmosphere 
pressure, occurred in the transition region between free-molecule and continuum 
diffusion.
Formulation C cm4 s-1 r2 K cm2 s"1 6 i
3A 3.26 x 1 0 '3 0.9994 0.886 0.99
3B 4.64 x 10” 3 0.9991 1.35 1.00
3C 3.31 x 10"5 0.9996 8.90 x 10-3 0.88
3D 4.51 x 10"3 0.9997 2.61 1.00
Table 4.2 Slope C of V(0) -  V(t) versus time plot from pressure decay experiments, 
permeability coefficient K and for formulations 3A -  3D
4.4.4 Calculation of Tortuosity Factors from Diffusion Data and Comparison with 
Tortuosity Factors Calculated from Drug Release Data
The factor q was calculated from equation 4.1 using the published value for
the true diffusion coefficient of helium in air of 0.691 cm2 s_1 (222). The 
tortuosity Le/L  was calculated from q using equation 3.22. Mean values for 
tortuosity for each formulation were calculated and these are shown in table 4.3 
with the tortuosity values calculated from the drug release data (section
3.3.2.3). It can be seen that the tortuosity values obtained from the diffusion
experiments were an order of magnitude lower than those obtained from drug release
data, and can all be considered to be physically realistic i.e. greater than 1 and 
less than approximately 10, a range which as discussed above (section 1.4.5.2.1) 
could be considered reasonable. These results would appear to be evidence to
support the hypothesis that tortuosity values obtained from drug release data were 
inaccurately high indicators of the true tortuosity of the pore structure of the 
matrices and that an artefact which the Higuchi equation was unable to account for 
such as slow or incomplete wetting caused them to be increased to such high values.
However, in the Higuchi equation, the true diffusion coefficient of the drug 
solute molecules in bulk solution is modified by the inclusion of the porosity and 
tortuosity terms, which is exactly the same model used to modify the diffusion 
coefficient of one gaseous species in another in equation 4.1. Hence the factor q 
is equivalent to the tortuosity factor x, and therefore t is also equal to the 
square of the true tortuosity Le/L. If it was assumed that x = Le/I_  when actually 
i  = (Le/L)2, this would lead to the assumption of an incorrectly low figure for the 
physically realistic upper bound of x. For example, if the upper bound of Le/L  is 
taken as 10, then the upper bound of x and hence q becomes 100. The values of x 
obtained from drug release data were therefore all square-rooted in order to obtain 
Le/L  values, which were then compared to the equivalent values obtained from the 
diffusion experiments. The figures obtained are shown in table 4.3. It can be seen 
that the values for Le/L  obtained from the diffusion experiments are comparable 
with the modified square root of x values obtained from the drug release 
experiments. It was therefore concluded that the modified tortuosity values 
determined from drug release data, were confirmed by the diffusion experiments as
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physically realistic estimates of the tortuosity of the pore structure of the 
matrices. It was also concluded that slow or incomplete wetting did not limit drug 
release rates from HVO-based matrices.
Mean Parameter Formulation
(± 95% C.I.) 3A 3B 3C 3D
Corrected e /q  
ratio x 10"3
13.5 (0.258) 2.95 (1.20) 2.52 (0.671) 20.5 (1.75)
q 21.2 (3.52) 78.1 (29.5) 70.6 (16.9) 11.5 (0.998)
t from Drug 
Release Studies
32.1 (3.9) 55.4 (4.5) 45.6 (6.9) 12.2 (2.4)
Le/L 4.58 (0.408) 8.70 (1.70) 8.36 (1.21) 3.38 (0.188)
/x  from Drug 5.67 (2.0) 7.44 (2.1) 6.75 (2.6) 3.49 (1.6)
Release Studies
Table 4.3 Mean corrected e /q  ratio, q, and Le/L  determined from diffusion tube 
experiments and x and /x  from drug release studies
These conclusions indicated that the Higuchi equation ought to be modified by
having the tortuosity term squared. In the work concerned with the original 
validation of the Higuchi equation (163 -  167) it was found that tortuosity values 
up to approximately 10 with one value of 18 were obtained from drug release data 
from polyethylene and polyvinyl chloride matrices. This would indicate that the 
actual tortuosity factors of these matrices would be less than 4.25, which is less 
than the figures obtained from HVO-based matrices. A tentative explanation for 
these differences can be tendered by considering the method of preparation of the 
matrices. The polyethylene and polyvinyl chloride were compressed with heating, 
which might be expected to produce a less tortuous pore structure than direct 
compression of the HVO-based matrices, which included dicalcium phosphate
dihydrate, an excipient which is known to undergo brittle fracture during
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compaction.
The ability of the diffusion method to determine tortuosity factors 
independently of drug release data indicated that this technique might be usefully 
employed to determine tortuosity factors during formulation of porous matrices for 
the delivery of drugs at desired rates. It may also be possible to use it to 
determine whether any relationship existed between tortuosity and formulation 
variables such as drug and excipient concentration or particle size, or compaction 
pressure. This might enable the effects of formulation variables on tortuosity and 
hence drug release rate to be predicted, making further formulation a simpler 
process.
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Chapter 5
Investigation of the Feasibility of Production of Hemispherical, Zero-order Drug 
Releasing HVO-based Matrices for Oral Use
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5.1 Theory
When matrix devices from which drug release is diffusion controlled are used 
clinically they suffer from the potentially significant disadvantage that the 
amount of drug released is proportional to the square-root of time and hence drug 
release rate constantly decreases during the period of delivery. Zero-order 
kinetics would result in a drug release profile which would be more desirable i.e. 
drug release rate would always be constant since the amount of drug released would 
be a linear function of time. One means of altering the characteristic release 
profile of drug loaded matrices is to alter the geometry of the device. Several 
such geometrical shapes have been proposed and they have been shown to release drug 
with approximately zero-order kinetics. Diagrams of these devices are shown in 
figure 5.1. A device with hemispherical geometry (type 1, figure 5.1) has been 
described (223, 224). A matrix is coated completely with a water-impermeable 
barrier and a small hemispherical cavity is made in the centre of the planar 
surface of the device, exposing the matrix material. As drug is released, the 
section of the device depleted of drug becomes hemispherical in shape and 
constantly increasing in radius. This concomitantly increases the area of drug 
available for diffusion and thus compensates for the increase in diffusion distance 
to the exposed surface. Drug is therefore released at a constant rate. In release 
from a cyiindrically shaped matrix, or from a single planar surface of a matrix, it 
is the increase in diffusion distance without a corresponding increase in area 
which is responsible for the constantly decreasing release rate. Devices with other 
geometries which operate on the same principle include a cylindrical device (type
2, figure 5.1) which is coated with a water-impermeable barrier and which has a
narrow circular central hole drilled laterally through the device (225). Another 
type of device (226) consists of a wedge-shaped section of a circular cylinder 
(type 3, figure 5.1), which is coated with a water-impermeable barrier except on 
the narrow end of the "wedge", which is exposed to dissolution medium. A related
device (227) (type 4, figure 5.1), consists of an inwardly tapered disc which is







Figure 5.1 Geometrical configuration of zero-order drug releasing matrix devices 
(Hatched areas indicate water -  impermeable barriers)
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coated with a water-impermeable barrier, except for a circular shaped portion in 
the centre of disc, from which drug release occurs. A further device reported (228)
(type 5, figure 5.1) consists of an array of sections of cones, the exact 
geometrical shape being described as a frustrum of a cone. The frustra are enclosed 
in a water-impermeable slab with a water-Impermeable backing, with the narrow ends 
of the frustra exposed to dissolution medium.
The composition and methods of preparation of the matrices used in the devices 
described varied and only the cylindrical device with the drilled hole was produced 
by tableting. It was found with this system that drug release over periods which 
were useful for oral devices could be obtained without including any matrix-forming 
material in the tablets. Drug was hence able to be blended with just a soluble 
inert diluent and tableted using direct compression technology. This system was 
therefore of potential clinical use, because it had the advantage that it could be 
prepared with conventional tableting and coating technology, with the one extra 
step required being the drilling of the hole. It was found though, that the system 
was not suitable for highly water-soluble drugs, which were released too rapidly.
Since drug release from all the types of device described is affected by the 
surface area of the core exposed to dissolution medium it was considered that a 
device which might be useful for delivering highly water-soluble drugs with zero- 
order kinetics would be the hemispherical system. It was considered that the 
exposed matrix surface area would be small and easily adjusted and secondly that 
this shape would be the simplest of those described to produce, both in terms of 
the feasibility of the production of the devices by direct-compression tableting, 
and the opening of the cavity in the coat. As described for the cylindrical system, 
if a device with the desired zero-order drug release profile could be produced 
more simply than is presently possible, and mostly by using conventional production 
technology, this would potentially be a clinically useful system.
An equation describing drug release from hemispherical matrices was derived by 
Rhine et al (223) and takes the following form :-
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Q = 2nCsDai {R/(R -  a^J-t equation 5.1
where a  ^ = radius of the cavity
R =  radial distance to the interface between dissolved and dispersed 
drug within the matrix
Note 1: the diffusion coefficient D is that of the drug in the matrix, and for a 
porous matrix will become the diffusion coefficient of the drug in the release 
medium multiplied by the porosity/tortuosity factor g / t as in equation 1.24.
Note 2: The equation only applies if the radius of the device is at least three 
times that of the radius of the cavity a ,.
Examination of this equation indicates that drug release rates could be
modified by altering drug solubility, porosity, tortuosity, and the radius of the
cavity.
It was therefore decided to investigate the production of hemispherical shaped 
drug delivery devices by tableting, evaluate suitable methods of coating and assess 
the effect of various formulation factors on drug release profiles.
5.2 Materials
Chlorpheniramine maleate: micronised, Lot 39MI, was supplied by Schutz and 
Co., D -2000, Hamburg 11, F.R.G.
Camauba Wax: GLR grade, Lot 9862950F, BDH Chemicals 
Ethylcellulose: viscosity grade -  14 cP at 25° C in 80 : 20 toluene : ethanol 
by weight, Lot 5105962H, BDH Chemicals
Polyvinyl pyrrolidone: K -9 0  grade, sample, was supplied by Midland
Dykem Chemicals, Leicester, U.K.
Toluene: Analar grade, lot 5762780B, BDH Chemicals
Industrial methylated spirit: GPR grade, Lot 5066400H, BDH Chemicals
Diethyl phthalate: Lot 6336680, BDH Chemicals
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Dichloromethane: HPLC grade, Lot T2306, Fisons Scientific Apparatus,
Loughborough, U.K.
Lactose Ph. Eur.: Direct compression grade -  "Tablettose", Lot 227773, was 
supplied by Meggle, D -8090 Wasseburg, F.R.G.
Ethylcellulose coating suspension: "Ethocel AQ", Lot MM880622, was supplied by 
Colorcon, Orpington, U.K.
Colloidal silicon dioxide: 'Aerosil 200", Lot 0494 was supplied by Degussa 
AG, D -6000, Frankfurt 1, F.R.G.
5.3 Methods
5.3.1 Assay of Chlorpheniramine Maleate Using UV Spectrophotometry
A model drug which was highly water-soluble and which preferably could be 
assayed by UV spectrophotometry was required for this study. Chlorpheniramine 
maleate (CHL) was selected, having a water solubility at 20 °C  of approximately 1 
part in 4 parts water (202) and a maximum UV absorbance at a wavelength of 
approximately 265 nm (202). The following procedures were carried out as described
above (section 2.2.6.1). A series of aqueous solutions of increasing
chlorpheniramine maleate concentration in the range 5 -  140 mg dm-3  was prepared; 
the wavelength of maximum absorption was determined and the absorbance of the 
solutions was measured at this wavelength. Excipient solutions were also prepared 
as described above (section 2.2.1.2) and any UV absorbance was determined.
5.3.2 Preparation of Hemispherical Matrices using Tableting
The target mass of all tablets prepared in this part of the study was 350 mg.
The matrix tablets produced for the initial studies were prepared as described
above (sections 2.2.1.1 and 3.2.1.2). Compaction was carried out manually using
12.7 mm diameter, flat-faced punches to produce tablets with a diametral crushing 
strength in the range 59 -  78 N according to the following formulation: -




CHL 40% /  HVO 40% /  MCC 19% /  MS 1%
Note 1: Information relating to the composition of all formulations used in this 
chapter is given in table 5.1 at the end of the chapter.
Tablets were also prepared as described above using a 12.7 mm diameter flat— 
faced lower punch and a 12.7 mm diameter deep concave upper punch according to the 
following formulations 5B -  5E.
Formulation Composition
5B CHL 40% /  HVO 30% /  SDL 29% /  MS 1%
5C CHL 40% /  HVO 10% /  SDL 49% /  MS 1%
5D CHL 40% /  HVO 5% /  SDL 54% /  MS 1%
5E CHL 40% /  HVO 2.5% /  SDL 56.5% /  MS 1%
An upper punch of 10 mm diameter having a hemispherical radius of curvature 
and a flat-faced lower punch were also used to prepare tablets from formulations 
5B -  5E and from formulations 5F and 5G :-
Formulation Composition
5F CHL 40% /  SDL 59% /  MS 1%
5G CHL 40% /  SDL 60%
A problem which occurred during the process of pan-coating of hemispherical
tablets with sprayed ethylcellulose films, which is described below (section 
5.3.3.2), was that tablets of several of the formulations described split along the 
plane where the hemispherical portion of the tablet met the small cylindrical 
portion. This was considered to be due to inadequate mechanical strength and for
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this reason granulations of powder mixes of further formulations were prepared in 
an attempt to improve the compactibillty of powder mixes. Formulations 5H -  5M were 
prepared using a polymeric binder (polyvinyl pyrrolidone-K90 grade (PVP)) dissolved 
in the granulating fluid and the drug content was reduced from 40% to 29.4% :-
Formulation Composition
5H CHL 29.4% /  HVO 29.4% /  SDL 38.7% /  PVP 2% /  MS 0.5%
51 CHL 29.4% /  HVO 19.6% /  SDL 48.5% /  PVP 2% /  MS 0.5%
5J CHL 29.4% /  HVO 9.8% /  SDL 58.3% /  PVP 2% /  MS 0.5%
5K CHL 29.4% /  HVO 4.9% /  SDL 63.2% /  PVP 2% /  MS 0.5%
5L CHL 29.4% /  HVO 2.5% /  SDL 65.6% /  PVP 2% /  MS 0.5%
5M CHL 29.4% /  SDL 68.1% /  PVP 2% /  MS 0.5%
The granules were prepared using a pestle and mortar and the wet granules were 
screened through a 20 mesh sieve followed by tray-drying in a fan oven at 35°C for 
12 hours. The dried granules were re-screened through a 22 mesh sieve and 
subsequently mixed with magnesium stearate at a concentration of 0.5% w /w  for 3 
minutes, using a cube blender as described above (section 2.2.1.1). Tablets of 
formulations 5H -  5M were prepared as described above except that they were 
prepared to approximately the same initial porosity. This was achieved in the 
following manner.
The true densities of CHL and PVP were determined using helium -  air 
comparison pycnometry as described above (section 3.2.1.1). The dimensions of a 
hemispherical tablet were determined using a micrometer to measure the thickness of 
the whole tablet, and digitally-reading calipers (Model 600 -  880, RS Components) to 
measure the thickness of the small cylindrical portion. The volume of the 
cylindrical portion was calculated as described above (section 2.2.7.2). The 
remaining portion of the tablet was not a complete hemisphere because the rim of
the upper punch which had hemispherical curvature had a finite thickness, and
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therefore only allowed tablets to be produced which had the shape of part of a 
hemisphere. The shape of the punch and the actual tablet shape produced are shown
c
in figure 5.2. The volume V of the partial hemisphere portions of tablets was 
determined using the following equation: -
V = nH2{r -  (H /3)} .equation 5.2
where H = distance from the centre of the planar surface to the furthest
point on the curved surface 
r = radius of curvature of the partial hemisphere portion of the 
tablet
Having determined the total volume occupied by the tablets, the porosity was 
calculated using equation 3.2. Tablets of formulation 5H were prepared to a high 
diametral crushing strength in the range 157 -  176 N (16 -  18 KPond). A mean
porosity of 10 tablets was determined as described immediately above and tablets of 
further formulations were prepared to a similar porosity by adjusting compaction 
pressure accordingly.
5.3.3 Coating of Hemispherical Tablets
In order to achieve a water-impermeable barrier around the tablets, except for 
the opening through which drug release would occur, two methods of tablet coating 
were employed. In initial studies, the tablets were dip-coated using molten wax.
The second method used pan-coating to apply either organic solutions or aqueous
suspensions of ethylcellulose by spraying onto tablet cores.
5.3.3.1 Dip-Coating of Tablets in Molten Camauba Wax
Initial studies were carried out using tablets prepared from formulations 5B -  
5E having one deep concave and one flat surface, and hemispherical tablets prepared
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A. Cross-section of tablet
H mm









Figure 5.2 Cross-sections of tablet machine punch having hemispherical curvature
and the shape of a tablet produced therefrom
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from formulations 5F and 5G. These tablets were dip-coated in molten carnauba wax 
using the following technique. The tip of a needle mounted on a wooden handle was 
heated in a bunsen flame and inserted into the centre of the planar face of a 
tablet to a depth just sufficient to allow the needle to be picked up with the 
tablet attached. The tablet was then dipped five times into in an evaporating dish 
on a heating mantle containing the molten wax which had been allowed to cool to 
just above its melting point. This procedure caused a solid wax coat to be 
progressively built up on the tablet surface. The mounted needle was then removed, 
leaving a hole in the coat This was used as a guide to make a larger hole in the 
coat using an appropriate bit in a high speed drill mounted perpendicularly on a 
drill stand. In the case of the 12.7 mm diameter tablets the hole diameter was 
4.0 mm and with the 10 mm diameter tablets, 3.2, 4.0, 4.8 or 5.6 mm according to 
the experiment. The tablet was held in place manually and the hole was drilled 
through the coat until the tablet surface was reached.
The permeability of the coat to water was tested on six tablets which had not 
had holes drilled in them. The small hole left by removal of the mounted needle was 
sealed with a drop of molten carnauba wax. The tablets were then subjected to 
dissolution testing as described above (section 2.2.6.3) for 24 hours to determine 
whether any drug was released.
5.3.3.2 Organic and Aqueous Rim -Coating of Tablets with Ethylcellulose
The batch of tablets of formulations 5B -  5G prepared with the 10 mm diameter 
hemispherical upper punch was coated with a film coat of ethylcellulose applied by 
spray-coating in a brass coating pan. Ethylcellulose film -coats have been used to 
control drug release from tablets and microspheres, and factors affecting drug 
release rates were found to be the thickness of the coat, and the percentage of 
water soluble additives in the coat (101, 102). Hence If no water-soluble additives 
are included and a thick enough coat is applied, a water-impermeable barrier should 
be formed. In order to obtain such a barrier, it was considered that a percentage
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gain in tablet mass of at least 15% was required. This was estimated from previous 
work (201) which had established that drug release occurred through coats of a 
thickness resulting from an increase in mass of up to 12%. The following coating 
solution was used and was prepared by dissolving the ethylcellulose in the mixed 
organic solvents and then adding the plasticiser diethyl phthalate:-
Material Amount
Ethylcellulose 4 g
Diethyl phthalate 1 g
Dichloromethane 57 g
Industrial methylated spirit 38 g
In order to reduce the likelihood of the "twinning" of hemispherical tablets 
i.e. the adhesion of the planar faces of two tablets with coating solution, the 
solvent of which then evaporates leaving the tablets held together with a film of
coating material, the tablets were coated along with other tablet cores. These had
convex faces to prevent twinning, did not contain drug and were prepared in the 
following manner. 5 kg of powder mix was prepared according to the formulation 
described immediately below by blending the lactose and the microcrystalline 
cellulose in a laboratory blender (Model KM/502, Kenwood, Havant, U.K.) for 15




Microcrystalline cellulose 297.5 g
Magnesium stearate 5.0 g
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Tablets were produced volumetrically using 9 mm diameter shallow concave 
tooling fitted to a rotary tablet machine (Model B, Manesty Machines), with a 
diametral crushing strength in the range 98 -  118 N (10 -  12 kPond).
Hemispherical tablets of formulations 5B -  5G were identified with 
combinations of coloured dots applied to the hemispherical surfaces with felt— 
tipped pens. A total tablet load of approximately 3 kg was coated in a b^ass 
coating pan of approximately 10 dm3 capacity with the coating solution sprayed onto 
them via a peristaltic pump (Model Minipuls 2, Gilson, 95400 Villiers Le Bel, 
France) and using a spray head (Model L910, Binks Bullows, London, U.K.) attached 
to a compressed air source. Coating solution and air flow rates were adjusted to 
give a suitable spray pattern. This was ascertained by holding a piece of paper 
approximately 20 cm from the nozzle of the spray head and adjusting the pump speed 
and air flow rate until a circular pattern of approximately 10 cm diameter was 
produced from which coating liquid did not run. Solvent evaporation was aided by 
employing a domestic hairdryer. The even coating of the tablets was aided by taping 
two intersecting pieces of rubber tubing of diameter 5 mm onto the inner surface of 
the pan, which facilitated tumbling of tablet cores during coating.
This system proved satisfactory at producing the desired type of coat, 
(section 5.4.3.2 below), but suffered from the disadvantages that it required a 
large total amount of tablets and large quantities of coating material in order to 
coat a small number of hemispheres. Coating with ethylcellulose also necessitated 
the use of organic solvents, whose toxicity and potential flammability were 
undesirable in a laboratory environment. A smaller version of the coating equipment 
was therefore constructed and a water-based coating formulation of ethylcellulose 
obtained. A small coating pan was constructed from the lower part of a fla t- 
bottomed flask having two pieces of square perspex with dimensions indicated in 
figure 5.3 glued to its base. A screw of length 40 mm was driven perpendicularly 
through the centre of one of the pieces of perspex so that it protruded from the 
opposite surface, and the other piece of perspex was glued to the side opposite to









Figure 5.3 Small scale coating pan
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the protruding screw. This effectively fixed the position of the screw in the 
perspex and provided a means of attaching it to a variable drive motor (Model 
KQ/506, Citenco Ltd., Boreham Wood, U.K.). The motor and bowl assembly was clamped
into a suitable position and the motor speed adjusted to rotate the bowl
at 15 rev min-1 .
Coating suspension was pumped to a spray-head using a peristaltic pump. The 
spray-head was clamped into a suitable position and the spray pattern was adjusted 
in the manner described immediately above. Drying air was provided by a domestic 
hair-dryer, in this case used on the low heat setting. Trials established that a
r
suitable load for the pan was approximately 100 tablet core hemispheres in a total 
mass of 250 g of tablet cores. This load ratio minimised the occurrence of twinning 
of the planar faces of hemispheres. The coating suspension was prepared using the 
following formula by dispersing the colloidal silica in the ethylcellulose 
suspension (Ethocel AQ) by gentle stirring using a magnetic stirrer and then 
diluting to volume with water:-
Material Quantity
Ethylcellulose coating suspension (Ethocel AQ) 100 g
Colloidal silicon dioxide 1.25 g
Distilled water 135 cm3
The coating process was carried out until the hemispheres showed an increase 
in mass of at least 15%, in comparison with the uncoated cores. It was found that 
the most reproducible method of opening a hole in the film coat through which drug 
release could occur was to use a circular cork borer of the appropriate size 
(diameter 3.2 mm). Using this, it was possible to cut out and remove a disc-shaped 
section of the coat without damaging the tablet surface. Circular apertures were 
produced in this manner in the centre of the planar faces of the hemispherical 
tablets. This technique did not produce a hemispherical cavity in the planar
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surfaces, but it was considered that a simple and reproducible method of producing 
such a cavity was not available, and that such a technique would only be worth 
developing if the lack of a such a cavity was found to have a significantly 
detrimental effect on zero-order drug release kinetics.
As described above (section 5.3.3.1) with the wax-coated tablets, tablets 
without a hole were subjected to dissolution testing to ascertain whether drug was 
released through the intact coat.
5.3.4 Determination of Drug Release Characteristics of Hemispherical Tablets
Drug release rates were determined as described above (section 2.2.6.3). It 
was found that when tablets were first placed in dissolution fluid, an air bubble 
sometimes lodged on the tablet surface in the hole In the coat. This occurred with 
both wax and ethylcellulose coated tablets and air bubbles were removed by 
aspiration using a pasteur pipette.
5.4 Results and Discussion
5.4.1 Assay of Chlorpheniramine Maleate Using UV Spectrophotometry '
The wavelength of maximum absorbance of chlorpheniramine maleate (CHL) in 
aqueous solution was found to be 261 nm. The absorbance data obtained was plotted 
against concentration, and is shown in figure 5.4. It was considered that a linear 
relationship existed between concentration and absorbance and least squares 
regression analysis was used to estimate the relationship between the variables. It 
yielded the following parameters:-
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Figure 5.4 Calibration curve of UV absorbance at 261 nm versus concentration of
chlorpheniramine maleate
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The results were considered to show that the assay was appropriate for 
analyses in the concentration range measured. No significant difference in 
absorbance was noted between any of the excipient solutions prepared and a blank of 
distilled water and it was concluded that any dissolved excipient did not interfere 
with the assay.
5.4.2 Preparation of Hemispherical Matrices using Tableting
Mean values for the true densities of CHL and PVP were found to be 1.30 g cm"3 
(C. V. =  1.82%, n =  3) and 1.18 g cm-3  (C. V. = 2.53%, n = 3) respectively, using 
helium -air comparison pycnometry. The mean porosities of tablets of formulations 
5H -  5M are given in table 5.2.







Table 5.2 Mean porosity and 95% confidence interval for tablets prepared from
formulations 5H -  5M
5.4.3 Coating of Hemispherical Tablets
5.4.3.1 Dip-Coating of Tablets in Molten Camauba Wax
No drug release was found to occur from the tablets completely coated with wax 
which were subjected to dissolution testing. This confirmed that the wax coat was
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impermeable to water and continuous.
A disadvantage of wax coating which was found, apart from the need to coat 
each tablet individually, was the irreproducibility of both the thickness of the 
coat applied, and the depth to which the hole through the coat could be drilled,
The drilling process also sometimes caused part of the coat immediately adjacent to 
the hole to split away from the tablet, due to the brittleness of the solid wax.
These factors caused significant variability in the drug release data which was 
obtained (section 5.4.4 below). It was for these reasons, in addition to the fact 
that coating by this method could not be easily employed in large scale production, 
that film-coating with ethylcellulose was also studied.
S.4.3.2 Organic and Aqueous Film-Coating of Tablets with Ethylcellulose
No drug release was found to occur from tablets completely coated with 
ethylcellulose which were subjected to dissolution testing. This confirmed that a 
gain in mass of 15% was sufficient to render the coat continuous and impermeable to 
water over 24 hours, when applied to tablets of the size and shape used. This 
method of coating and the method of opening an aperture in the coat with a cork 
borer was found to produce devices from which the drug release rates were less 
variable than from the tablets dip-coated with carnauba wax.
5.4.4 Determination of Drug Release Characteristics of Hemispherical Tablets
In order to ascertain the period over which CHL would be released from an H VO - 
based matrix, tablets of formulation 5A were subjected to dissolution testing. The 
drug release profile obtained Is shown in figure 5.5, and the tablets were found to 
have released approximately 90% of their drug content after 8 hours. It was 
considered that coated hemispheres of this formulation might release drug -too 
slowly for potential oral use and thus the HVO concentration was reduced in the 
first formulation from which hemispheres were produced. Coated tablets of 
formulation 5B were hence subjected to dissolution testing and uncoated hemispheres
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Figure 5.5 Drug release profile for formulation 5A (table 5.1)
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were also subjected to dissolution testing for comparison. The release profiles 
obtained are shown in figure 5.6. It can be seen that the uncoated tablet shows a 
rapid non-linear release profile, but that the coated tablet releases drug with an 
initially slightly | decreasing rate over approximately 10 hours, then a constant 
zero-order phase. Least squares regression on the linear phase of release was 
performed and the results are given in table 5.3 at the end of the chapter. This 
shape of release profile is characteristic of a hemispherical matrix (224), but it 
is interesting to note that the tablets from which it was derived were not truly 
hemispherical in shape. They had been produced with a punch having deep concave 
curvature, not hemispherical curvature. They also had a small cylindrical portion 
(figure 5.2). This indicated that true hemispherical curvature appeared not to be 
an absolute requirement for zero-order release characteristics.
Since the coated tablets of formulation 3B had only released approximately ,25% 
of their drug content over 23 hours, it was decided to investigate the effect of 
further reducing the HVO content of tablets, in order to attempt to attain complete 
drug release over a shorter time. Formulations containing 10%, 5%, and 2.5% HVO 
(formulations 5C -  5E) were therefore prepared as described above (section 5.3.2) 
and subjected to dissolution testing. The drug release profiles exhibited by 
tablets of these formulations together with the formulation containing 30% HVO are 
shown in figure 5.7.
Examination of these plots indicated that HVO proportion appeared not to have 
a consistent effect on drug release rate, with the formulation containing 10% HVO 
exhibiting a faster drug release rate than the formulation containing 5% HVO. The 
large 95% confidence interval bars, which overlap for all the four formulations, 
indicate that it is not possible to distinguish statistically between the drug 
release rates exhibited by any of these formulations. The slopes of the linear, 
zero-order portions of the release profiles are given in table 5.3.
Since the inclusion of only 2.5% HVO in a formulation resulted in a drug 
release rate which was not significantly different from a formulation containing
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Figure 5.7 Effect of hydrogenated vegetable oil concentration on drug release
profile from wax-coated hemispheres
Key: A = 2.5% HVO
+  = 5% HVO
•  = 10% HVO
■ = 30% HVO
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30% HVO, this indicated that the formation of a porous matrix structure was not 
necessary for prolonged zero-order release characteristics. It was decided to 
investigate the effect on drug release rate of removing HVO completely from a
formulation and also the effect of not including magnesium stearate in a
formulation. This was because the proportions of HVO which appeared to prolong drug 
release were low enough to be considered as only having a lubricant effect, and 
since magnesium stearate was also a lubricant, its presence may have affected drug 
release rate. At this point of the study, a tablet machine punch with hemispherical 
curvature had been obtained and tablets of formulation 5G and 5H were prepared 
using it They were subjected to dissolution testing and the drug release profiles 
obtained are shown in figure 5.8.
The drug release profiles obtained indicated that the exclusion of HVO from a 
formulation did not result in a marked increase in release rate compared to
formulations containing HVO. The shape of the release profile was altered, with an
initial lag period rather than a burst phase observed. The exclusion of magnesium 
stearate from a formulation resulted in a slight increase in release rate, but the 
variability in the data indicated that no statistically significant difference 
could be distinguished between the two release profiles. The shape of the steady-  
state portions of the release curves indicated that zero-order drug release was 
exhibited by the truly hemispherical tablets, as well as those which were prepared 
having deep convex curvature. The slopes of the zero-order phases of drug release 
are given in table 5.3.
The results obtained indicated that the system was capable of releasing drug 
with predominantly zero-order kinetics, but that the period of drug release was too 
long to be of potential clinical use. In an attempt to increase drug release rate 
from hemispherical tablets, the effect of increasing hole size was examined. 
Tablets of the formulation containing no HVO (5G) were prepared with holes of 4.0,
4.8 and 5.6 mm diameter and subjected to dissolution testing. The drug release 
profiles obtained are shown in figure 5.9, with the profile for the tablets with




















24.00.0 4.0 8.0 12.0 16.0 20.0
Time (hr)
Figure 5.8 Effect of magnesium stearate on drug release profile of wax -  coated 
hemispheres not containing hydrogenated vegetable oil
Key: □ = 0% magnesium stearate
O = 1% magnesium stearate
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Figure 5.9 Effect of delivery hole diameter on drug release profile from wax- 
coated hemispheres of formulation 5G (table 5.1)
Key: O = 3.2 mm
A = 4.0 mm 
□ = 4.8 mm
O = 5.6 mm
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3.2 mm diameter holes also shown for comparison.
Examination of these plots indicated that increasing hole size resulted in an 
increased drug release rate. The 95% confidence intervals indicated that no
statistically significant difference could be distinguished between tablets with 
holes of 3.2, 4.0 and 4.8 mm, but that tablets with a 5.6 mm diameter hole released 
drug at a significantly greater rate than tablets with each of the three smaller 
holes. The shape of the release profiles indicated that after a lag period, drug 
release still conformed to approximately zero-order kinetics. One of the original 
requirements for the hemispherical matrix system was that the hole in the coat was 
no greater in diameter than one-third of the diameter of the hemisphere. The holes 
of diameter greater than 3.2 mm were greater than one-third of the diameter of: the 
hemispheres, and the results indicated that with hemispheres not containing matrix-  
forming material, hole diameter could be increased beyond this limit without
altering the zero-order release characteristics. The slopes of the linear phases of 
the drug release profiles are given in table 5.3.
It was considered that the inconsistency and variability in the results 
obtained were due to the method of coating and of drilling the hole in the coat, 
which resulted in the disadvantages described above (section 5.4.3.1). For these 
reasons, it was decided to investigate the method of spray-coating with
ethylcellulose films. This technique would be more likely to deposit a coat of 
reproducible thickness and hence the holes would be of reproducible dimensions.
Tablets of formulations 5B -  5G were prepared and coated with ethylcellulose 
as described above. As mentioned in section 5.3.2 above, a problem which occurred 
during the film-coating process was that tablets of some of the formulations split 
into two pieces, and unfortunately only enough intact tablets from formulations 5B 
and 5C were recovered on which to perform dissolution studies. The drug release 
profiles obtained are shown in figure 5.10. These profiles showed that the
formulation containing 30% HVO released drug with the characteristic pattern of a 
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Figure 5.10 Drug release profiles of ethylcellulose -  coated hemispheres of
formulations 5B and 5C (table 5.1)
Key: □ = formulation 5B
A = formulation 5C
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gradually increasing release rate. It was considered that this was due to small 
radial cracks surrounding the hole which had appeared in the coat on the planar 
surface of tablets of this formulation. This suggested that the coat was not 
adequately plasticised, and constituted a further reason to replace the organic -  
based ethylcellulose coating solution with the water-based suspension, which 
produced a less brittle coat.
In order to further investigate the effect on drug release profile of HVO 
content, tablets from other formulations (5H -  5M) were prepared using granulated 
powder mixes of drug and excipients in order to increase the mechanical strength of 
tablets and increase the probability of their surviving the film-coating procedure.
It was found that tablets from all the formulations produced using powder mixes 
which had been granulated were sufficiently strong to withstand the coating process 
and they were therefore subjected to dissolution testing. The dissolution profiles 
obtained for tablets from these formulations are shown in figure 5.11. Examination 
of these data confirmed that increasing HVO content resulted in decreasing release 
rate. A decrease in HVO content from 29.4% to 19.6% and from 19.6% to 9.8% was 
found to only slightly increase drug release rate. However, there was a 
comparatively large increase in release rate when HVO content was decreased from 
9.8% to 4.9% and from 4.9% to 2.5%, although a smaller increase in release rate was 
found when HVO content was reduced from 2.5% to 0%. Wide variability in drug 
release rate was found between tablets of the same formulation of both the 
formulation containing 2.5% HVO and the one containing no HVO. In comparison, 
excellent reproducibility was found between drug release rates of individual 
tablets from formulations containing 29.4%, 19.6%, and 9.8% HVO, with the tablets 
from the formulation containing 4.9% HVO showing a variability in drug release rate 
intermediate between the two extremes.
Apart from the formulation which did not contain HVO, whose drug release 
profile was slightly sigmoidal in shape, the shapes of the drug release profiles 
showed that the tablets delivered drug with the predominantly zero-order profile
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Figure 5.11 Effect of hydrogenated vegetable oil concentration on drug release 
profile from ethylcellulose -  coated hemispheres
Key: O = 0% HVO
A = 2.5% HVO 
□ = 4.9% HVO 
O = 9.8% HVO 
■ =19.6% HVO 
▲ =29.4% HVO
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characteristic of a hemispherical matrix, even when there was apparently 
insufficient HVO in a tablet to form a porous matrix. The slopes of the linear 
phases of the release profiles are given in table 5.3.
In an attempt to elucidate the mechanism by which drug was released with zero - 
order kinetics from hemispherical tablets containing low concentrations of HVO, 
tablets from formulations 5H -  5M were recovered after dissolution testing had been 
performed and were immediately cut into two sections along a diameter of the planar 
faces. This enabled visual examination of any material remaining within the coat 
With the tablets of the formulations containing 19.6%, 9.8% and 4.9% HVO, it was 
found that a hemispherical portion of the tablet had been removed, and the 
remaining material appeared to have taken up water and could best be described as 
being a thick slurry. The very bottom of the tablets of the formulation containing 
29.4% HVO appeared dry and the remainder of the space within the coat of tablets 
was still completely filled with material. The amount of slurry remaining appeared 
to increase with increasing HVO content, which would be expected since HVO is 
insoluble. No material was found to be remaining within the coat of tablets of the 
formulations containing 2.5% HVO and containing no HVO.
It was considered that these observations, and the drug release data which was 
obtained, could be explained in the following manner. In tablets prepared from a 
formulation containing 29.4% HVO a porous matrix would be expected to form on 
compaction and would remain within the coat during the drug release process 
allowing drug to diffuse through water-filled pores to the opening in the coat As 
the proportion of HVO decreased in a formulation, the amount of insoluble material 
present decreased to a level insufficient to form a continuous porous matrix. The 
amount of water entering the tablet was not sufficient to dissolve the soluble 
components of the tablet, and hence a thick suspension or slurry was formed. This 
can be deduced from a knowledge of the volumes of the tablets which were determined 
during the porosity measurements. A typical tablet volume was found to be 
approximately 0.275 cm3 and since each tablet contained a nominal CHL content of
140 mg, (aqueous solubility approximately 250 mg cm-3 ), this mass of drug would 
require 0.56 cm3 water to completely dissolve. The presence of the soluble 
excipient (approximate aqueous solubility 200 mg cm-3  (229)), would effectively 
further reduce the amount of water available to dissolve drug. This suspension 
would effectively act as a form of porous matrix, with drug solute molecules having 
to diffuse around suspended particles of HVO and undissolved drug and soluble 
excipient After some drug and excipient had dissolved and diffused out of the 
device through the hole in the coat, there would be sufficient water present to 
dissolve all the drug and excipient which would diffuse out around the remaining 
suspended HVO particles. As the HVO concentration was reduced further, to 4.9% and 
2.5%, drug release would become controlled increasingly by the dissolution rate of 
drug and excipient within the device, rather than diffusion through a suspension.
Zero-order kinetics were maintained because the concave surface area of the 
dissolving compact increased with time, compensating for the increased diffusional 
distance which drug solute molecules must traverse through the unstirred solvent 
layer within the coat In a formulation containing entirely soluble components, 
e.g. formulation 5M, drug release was considered to be controlled by the intrinsic 
dissolution rate of the drug and excipient, and the subsequent diffusion of solute 
molecules through the static solvent layer within the hemisphere.
It therefore appeared that the rate -  controlling mechanism of drug release 
changed with decreasing HVO content from an entirely diffusion controlled system, 
to a system where intrinsic dissolution rate was a significant factor governing 
drug release. It is not possible to determine unequivocally from the drug release 
data at what, if any, concentration of HVO, dissolution rate becomes the rate- 
controlling factor in drug release. However it may be hypothesised that the large 
increase in drug release rate which was found when HVO concentration was decreased 
from 9.8% to 2.5%, occurred because the rate of drug release changed from being 
diffusion controlled to dissolution controlled.
The drug release data obtained showed that this method of impermeable coating
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of tablets was capable of delivering highly water-soluble drugs for periods 
suitable for oral use with predominantly zero-order kinetics. Drug release rates 
could be altered by choice and proportion of soluble and insoluble excipients, and 
hole dimensions. Providing a formulation could be found which exhibited the 
required drug release rate, it would be possible, if tablets could be prepared with 
sufficient mechanical strength to withstand the film -coating process, to prepare 
hemispherical tablets using direct compression technology. If a reproducible method 
of opening a hole in the tablet coat could be adapted to a production process, the 
system would represent a reasonably simple means of producing oral drug delivery 
devices which released drug with zero-order kinetics, using established excipients 
and production processes. The initial data which was obtained from tablets which 
were not truly hemispherical in shape, also indicated that hemispherical geometry 
appeared not to be an absolute requirement for zero-order drug release, possibly 
making tablet production simpler.
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Formulation Composition
5A CHL 40% /  HVO 40% /  MCC 19% /  MS 1%
5B CHL 40% /  HVO 30% /  SDL 29% /  MS 1%
5C CHL 40% /  HVO 10% /  SDL 49% /  MS 1%
5D CHL 40% /  HVO 5% /  SDL 54% /  MS 1%
5E CHL 40% /  HVO 2.5% /  SDL 56.5% /  MS 1%
5F CHL 40% /  SDL 59% /  MS 1%
5G CHL 40% /  SDL 60%
5H CHL 29.4% /  HVO 29.4% SDL 38.7% /  PVP 2% /  MS 0.5%
51 CHL 29.4% /  HVO 19.6% /  SDL 48.5% /  PVP 2% MS 0.5%
5J CHL 29.4% /  HVO 9.8% /  SDL 58.3% /  PVP 2% /  MS 0.5%
5K CHL 29.4% /  HVO 4.9% /  SDL 63.2% /  PVP 2% /  MS 0.5%
5L CHL 29.4% /  HVO 2.5% /  SDL 65.6% /  PVP 2% /  MS 0.5%
5M CHL 29.4% /  SDL 68.1% /  PVP 2% /  MS 0.5%
Table 5.1 Composition of tablet formulations prepared in Chapter 5 
Key: CHL = chlorpheniramine maleate
HVO = hydrogenated vegetable oil 
MCC = microcrystalline cellulose 
SDL = spray-dried hydrous lactose 
MS = magnesium stearate 
PVP = polyvinyl pyrrolidone
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Formulation Slope % hr-1  Intercept % r2
5B 0.823 6.27 0.9997
5C 1.16 6.54 0.9999
5D 0.912 4.34 0.9999
5E 1.26 1.89 0.9993
5F 1.96 -1 1 .0 0.9998
5G 1.81 -5 .7 6 0.9992
5H 0.902 1.82 0.9990
51 1.05 1.95 0.9998
5J 1.14 2.97 0.9991
5K 2.14 9.33 0.9995
5L 16.9 -1 1 .8 0.9989
Table 5.3 Slopes, intercepts and correlation coefficients obtained using least 
squares regression analysis of linear portions of drug release profiles of tablets
prepared from formulations 5B -  5L
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Conclusions
Direct compression of powder mixes of hydrogenated vegetable oil with drug and 
inert excipients was found to produce tablets from which drug release was sustained
A
for periods of several hours. Drug release rates were found to be affected by drug 
loading, type of inert excipient, concentration of microcrystalline cellulose, 
drug solubility and hydrogenated vegetable oil particle size. It was found that the 
rate-controlling mechanism in drug release from HVO-based tabets was diffusion, 
with drug release conforming to the Higuchi square-root of time kinetic model. It 
was concluded that drug release occurred through water-filled tortuous pores within 
a tablet matrix. Differences in drug release rate observed between different 
formulations were postulated to be due to differences in porosity and tortuosity 
between the tablets prepared from different formulations. Drug release into 
dissolution medium of acidic pH was found to be unchanged compared to drug release 
into water, but a small decrease in drug release rate was found when drug release 
studies were performed in medium of alkaline pH.
Tortuosity factors determined according to the Higuchi equation from drug 
release data from single planar faces of hydrogenated vegetable oil-based matrices 
were found to be in the range 32 -  55, compared to 12 for a polyvinyl chloride 
matrix. Drug release rates from hydrogenated vegetable oil-based matrices In 
surfactant solution were found to be not significantly different from release rates 
in water, and it was concluded that slow or incomplete wetting was not a factor 
affecting release rates. A permeametry technique based on the application of the 
Carman -  Kozeny equation to air flow under pressure through matrices which had been 
leached of drug was used to determine matrix tortuosity factors, but tortuosity 
factors of less than 1 were obtained. Since tortuosity factors must by definition 
be greater than or equal to 1, this indicated that the results were meaningless. 
Mercury porosimetry of matrices which had been leached of drug showed that a wide 
pore size distribution existed within the matrices, and this was concluded to 
account for the failure of the Carman -  Kozeny equation in this case.
An experiment based on the application of Graham’s law of gaseous
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interdiffusion was used to determine the effective diffusion coefficient of helium 
in air through matrices which had been leached of drug. Tortuosity factors 
calculated from this data were found to be greater than 1, but approximately one 
order of magnitude lower than tortuosity factors calculated from drug release data.
a
However, when the tortuosity factors obtained from drug release data were square -  
rooted, in the same manner as those obtained from the diffusion data, the 
tortuosity factors became comparable. It was concluded that the tortuosity factor 
in the Higuchi equation should be square -  rooted in order to give a realistic 
indication of the nature of the pore structure within a matrix. The diffusion 
technique was concluded to be a valid method of the determination of tortuosity 
factors, independently of drug release data.
Drug release from hemispherical, hydrogenated vegetable oil-based matrix 
tablets coated with a water-impermeable barrier and with a delivery orifice in the 
centre of the planar face was investigated, and it was found that zero-order drug 
release could be obtained. However, release rate of a highly water-soluble drug 
was found to be too slow for potential oral use. Coat thickness and delivery 
orifice dimensions were found to be factors which affected the reproducibility of 
drug release data, and a pan-coating system involving the spraying of aqueous 
suspensions of ethylcellulose was found to give a coat of reproducible thickness in  ^
which suitable delivery orifices could be made. The effect of reduction of 
hydrogenated vegetable oil content on drug release profile was investigated and 
increased drug release rates were obtained. Small increases in release rate were 
found on reduction of hydrogenated vegetable oil concentration from 29.4% to 19.6% 
and to 9.8%, but a larger increase was found on further reduction to 4.9%. A 
further large increase was found on reduction to 2.5%, and a smaller increase when 
hydrogenated vegetable oil was excluded completely. A combined 
diffusion/dissolution model was proposed to explain the drug release behaviour, and 
it was hypothesised that the rate -  controlling mechanism changed progressively from 
diffusion to dissolution with decreasing hydrogenated vegetable oil concentration.
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Appendix 1
10 FACTOR =1
20 ON ERROR GOTO 130
30 REM AUTO DISSOL
40 REM SAB(0,X)=TIME,SAB(1 -  6,X) = REPS 1 -  6,SAB(7,X) = MEAN,SAB(8,X) = STD DEV,SAB 






100 FL% = 1 
110 PROCKEY





170 DEF PROCMENU 
180 CLS
190 PRINTfO -  CALIBRATE/ZERO"’
200 PRINT"f1 -  CONTINUE WITH RUN"’
210 PRINTf2 -  PRINTOUT RESULTS"’
220 PRINT"f3 -  SAVE DATA ON DISC"’
230 PRINTf4 -  START ANOTHER RUN"’
240 PRINT"f5 -  FINISHED"’
250 ENDPROC
260 DEF PROCKEY
270 IF IN K E Y (-33) = -  1 PROCCAUB
280 IF IN K E Y (-114)= -1  PROCRUN
290 IF IN K E Y (-115)= -1  PROCPRINT
300 IF IN K E Y (-116)= -1  PROCSAVE
310 IF IN K EY(-21)= -1  FL% = 3
320 IF INKEY( - 117)= -1  PROCEND
330 ENDPROC
340 FL% = 1
350 DEF PROCRUN
360 CLS
370 INPUT'ENTER NUMBER OF REPS "K%
380 INPUT'ENTER RUN TIME h 'TM
390 INPUT'ENTER SAMPLE FREQUENCY (NO. OF SAMPLES PER HOUR "JJ%
400 PRINT'ENTER TOTAL AMOUNT IN TABLET"




450 J% = (J J%*TM) +1
460 PRINT'TO START DATA COLLECTION RUN PRESS SPACE"
470 @%=&20306
480 IF GET < > 3 2  THEN 480
490 FOR N% = 1 TO J%
500 SAB(0,N%) = (TM/(J% -1  )*(N% -1 ))
510 l% = 0
520 PROCWAIT
530 FOR l% = 1 TO K%
540 IF l% = 1 THEN 560





590 SAB(I%,N%) = ((AV%*2.82E -  5) + 0.019) *A1 
600 IF N% = 1 THEN Z(I%) = SAB(I%,N%)
610 SAB(I%,N%) = SAB(I%,N%) -  Z(l%)
620 IF SAB(I%,N%) < .02 THEN SAB(I%,N%) = 0.0184 






690 @% = 10
700 IF PR1% = 1 THEN 720 
710 VDU2
720 FOR N% = 1 TO J%






790 FOR l% = 1 TO K%
800 FOR N% = 1 TO J%
810 SAB(I%,N%) = SAB(I%,N%) -  0.0184
820 SAB(I%,N%) = SAB(I%,N%)/0.0212:REM CONC IN1000





880 FL% = 2
890 ENDPROC
900 DEF PROCPRINT
910 IF PR%=1 THEN 930
920 VDU2
930 Tl% = 2
940 FL% = 2




990 FOR l% =1 TO 6 
1000 PRINT" REP ";l%;
1010 NEXT
1020 PRINT" MEAN SD SE"
1030 PRINT"AM.TAB ";
1040 @% = &20206 
1050 FOR l% = 1 TO 9 
1060 PRINT SAB(l%,0)" ";
1070 NEXT 
1080 PRINT
1090 FOR N% = 1 TO J%
1100 PRINT'
1110 FOR l% =0 TO 9 
1120 PRINT SAB(I%,N%)"





1170 IF SK% = 1 THEN 1200
1180 PRINT'T50 = 'T50
1190 PRINTT90 = 'T90




1240 FOR l% = 0 TO 10
1250 FOR N% = 0 TO 25






1320 SK% = 0
1330 VDU15
1340 PRINTWILL YOU HAVE A PRINTER AT THE END ? Y /N ”
1350 Z% = GET
1360 IF Z% >90 THEN Z% = Z % -3 2
1370 IF Z%< >78 AND Z % < > 89  THEN 1350
1380 IF Z% = 78 PR% = 1
1390 IF Z% = 89 PR% = 0
1400 PRINT'DO YOU HAVE A PRINTER DURING THE RUN ? Y/N'
1410 Z% = GET
1420 IF Z% >90 THEN Z% = Z % -32
1430 IF Z% < > 78 AND Z % <>89  THEN 1410
1440 IF Z% = 78 PR1% = 1
1450 IF Z% = 89 PR1% = 0
1460 *FX15,1
1470 INPUT"SET REQUIRED ABSORBANCE .5 OR 1 OR 2 "A1





1530 FOR N% =0 TO J%
1540 FOR l% = 1 TO K%
1550 SAB(7,N%) = SAB(7,N%) + SAB(I%,N%)
1560 NEXT
1570 SAB(7,N%) = SAB(7,N%)/K%
1580 NEXT
1590 FOR N% = 1 TO J%
1600 FOR l% = 1 TO K%
1610 SAB(8,N%) = SAB(8,N%) + ((SAB(I%,N%) -  SAB(7,N%)) 2)
1620 NEXT
1630 SAB(8,N%) = SQR(SAB(8,N%)/(K% -1 ))




1680 INPUT'ENTER SAMPLE CODE "SC$
1690 INPUT'ENTER DESCRIPTION (MAX 80 CHRS) "DESC$
1700 ENDPROC
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1710 DEF PROCT
1720 C50% = 0:C90% = 0
1730 T50= -  1:T90= -1
1740 FOR N% = 1 TO J% -1
1750 IF SAB(7,N%) > = 50 THEN 1780
1760 C50% = N% +1
1770 GOTO 1800
1780 IF SAB(7,N%)> =90 THEN 1800 
1790 C90% = N% + 1 
1800 NEXT
1810 IF C50% = 0 THEN T50 = 0
1820 IF T50 = 0 THEN 1870
1830 P50D = SAB(7,C50%) -  SAB(7,(C50% -  1))
1840 P50 = (SAB(7,C50%) -  50)/P50D 
1850 TI50 =  SAB(0,C50%) -  SAB(0,(C50% -1 ))
1860 T50 = SAB(0,C50%) -  (P50*TI50)
1870 IF C90% = 0 THEN T90 = 0
1880 IF T90 = 0 THEN 1930
1890 P90D = SAB(7,C90%) -  SAB(7,(C90% -  1))
1900 P90 = (SAB(7,C90%) -  90)/P90D 
1910 TI90 = SAB(0,C90%) -  SAB(0,(C90% -1 ))
1920 T90 = SAB(0,C90%) -  (P90*TI90)
1930 ENDPROC 
1940 DEF PROCSAVE 
1950 FL% = 2
1960 INPUT"ENTER FILENAME"FLNM$
1970 FLNML$=LEFT$(FLNM$,7)
1980 X% = OPENIN(FLNML$)
1990 IF X% = 0 THEN 2120 
2000 CLOSE# X%
2010 PRINTTILENAME ALREADY IN USE"
2020 PRINT'RENAME FILE ? Y/N"
2030 Z% = GET
2040 IF Z% >90 THEN Z% = Z % -32  
2050 IF Z% = 89 THEN 1960 
2060 IF Z% < > 78 THEN 2030
2070 PRINT'THIS OPTION OVERWRITES THE FILE OK ? Y/N" 
2080 Z% = GET
2090 IF Z% >90 THEN Z% = Z % -32  
2100 IF Z% = 78 THEN 1960 




2150 PRINT# X%,SC$,DESC$,K%,J%,T50,T90 
2160 FOR l% = 0 TO 10 







2240 IF l% = 0 AND N% = 1 THEN 2260
2250 IF ?&FC00 = 254 THEN 2250
2260 IF IN K E Y (-113)= -1  THEN FG% = 1
2270 IF FG% = 1 THEN 2290
2280 IF ?&FC00 = 255 THEN 2260




2320 AV% = 0
2330 TT%=TIME
2340 FOR M% = 1 TO 100
2350 AV%= AV%+ ADVAL(2)
2360 IF TIME<TT% + 5 THEN 2360
2370 TT%=TIME
2380 NEXT




2430 PRINT"ABSORBANCE ON SPEC SHOULD BE "A1 
2440 PRINT'DWELL TIME MUST BE AT LEAST 10 SECONDS" 
2450 PRINTTRESS SPACE TO CONTINUE "
2460 IF GET < > 32 THEN 2460 
2470 FOR L% = 1 TO 6 
2480 PROCWAIT 
2490 IF FG% = 1 THEN 2550 
2500 PROCAV
2510 IF FG% = 1 THEN 2550 
2520 @% = &20306




2570 IF FG% = 1 THEN 2590
2580 GOTO 2470
2590 @ %=10
2600 FL% = 2





2660 FL% = 4 
2670 ENDPROC
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